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1.0 Introduction to Arthritis 
 
1.0.1 Prelimary Statistics 
Arthritis is defined as any limb, joint or spine condition associated with inflammation or 
structural change 1. Symptoms of arthritis in general include pain, swelling, warmth and 
restricted movement of the joint 2. 
There are in excess of 200 types of arthritic disease but the two most common forms are 
osteoarthritis (OA) and rheumatoid arthritis (RA) 1.  Other forms of the disease include 
gout, pseudogout (PS), psoriatic arthritis, Reiter’s syndrome, colitic arthritis and Behçet’s 
syndrome.   
A common misconception held by many is the association of arthritis solely with old age.  
Juvenile idiopathic arthritis (JIA) occurs in one in every thousand children in the UK.  
This particular disease varies on a geographical basis e.g. 0.7 per 1000 in USA to 4 per 
1000 in Australia 3.  Figures released by Arthritis Ireland 4 reveal that currently; 
1. One in six people in Ireland i.e. three quarters of a million men and women, suffer 
from some form of arthritis.   
2. 1,000 of these are children.  
3.  34% of women and 23% of men are affected by arthritis in Ireland.   
4.  Over 30% of GP visits are arthritis related.   
5.  18% of arthritis patients are less than 55 years old.   
6.  It is estimated that the cost of arthritis to the state due to lost working hours is €1.6 
billion per annum.   
7.  The majority of arthritis patients suffer from OA.  
8.  40,000 people suffer from RA. 70% of these are women.  
 
Further statistical data show that in Europe, a joint is replaced every 1.5 minutes due to 
OA.  In the USA a total of around 500,000 joint replacements are performed each year 5.  
Table 1.1 highlights that the number of individuals suffering form osteoarthritis (OA) 
and rheumatoid arthritis (RA) is steadily increasing on a global scale and it has been 
postulated that this is due to increasing population longevity.  However, it is also 
believed that obesity is a major risk factor for developing OA and Allman-Farinelli et al. 
  6 
6
 suggest that there will be an epidemic of obesity-related OA in the general population, 
particularly among the 45-54 age-group in the coming years.  Significantly, even though 
RA accounts for a small number of cases relative to OA (less than one for every 10), its 
mechanism of disease and potential cures are better understood.  This is due in part to the 
fact that RA attracts more scientific and public attention than OA 5.     
 
Country 2002 2007 2012
United States 13.2 14.4 15.5
Europe 14.5 15.2 15.8
Japan 6.6 6.9 7.2
Total OA Cases 34.3 36.5 38.6
Total RA Cases 2.8 3.1 3.4
Osteoarthritis Epidemiology
 
Table 1.1: Number (in millions) of people already diagnosed with OA and a projected 
figure for 2012. Included for comparison are the corresponding figures for RA. Data 
taken from Arthritis Ireland website 4 
  
 
1.0.2 Osteoarthritis (OA) 
As mentioned, OA is the most common form of arthritis and is characterised by the 
progressive degeneration of articular cartilage 7. It is also defined as “a loss of 
homeostasis in the maintenance of healthy articular cartilage” 8.  The American College 
of Rheumatology define OA as a “heterogeneous group of conditions that leads to joint 
symptoms and signs which are associated with defective integrity of articular cartilage, 
in addition to related changes in the underlying bone at the joint margins” 9.  A 
schematic representation of a normal versus an osteoarthritic knee may be seen in Figure 
1.1 10.  It is clear from this that OA does not have a single pathology and indeed, clinical 
heterogeneity is a feature of OA. 
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Figure 1.1: Schematic diagram of contrasting a normal knee versus an osteoarthritic 
knee. This illustrates that OA is a multi-symptomatic and complex disease. The 
schematic diagram was sourced from 10 
 
An important and notable point in the definition given above is that OA is a 
multifactorial disease, i.e. there is no one, unique attributable cause for the onset of OA 
in any particular individual.  Coupled to this is the fact that not only are the initiating 
factors of the disease poorly understood, but so also are the relative contributions of each 
to joint damage in individual patients at specific stages of disease 11.  By extension, this 
could mean that there is unlikely to be any single species that may be hypothesised to be 
the cause of this disease and thus the render the causative agent in turn to become a 
therapeutic target.  Therefore, to gain a firm understanding of the pathophysicological 
causes of OA, it has come to be recognised that a multidisciplinary approach is required.  
Indeed, it is argued 12 that pooling knowledge obtained from recent advances in 
phosphoproteomics (the analysis of phosphorylated proteins), glycoproteomics (the 
analysis of glycosylated proteins), glycomics (the analysis of sugars), lipidomics (the 
analysis of lipids) and degradomics (the analysis of protein degradation products) is the 
way forward.  
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1.0.3 Cartilage Composition 
 
It is interesting to note that in the embryo, cartilage initially develops along the same 
pathway as bone 13.   However, at the onset of endochrondral bone formation, cartilage 
development diverges and becomes an independent entity. Cartilage is a layered 
structure consisting mainly of cartilage cells (chondrocytes), cartilage tissue (the Extra 
Cellular Matrix - ECM) and a collagen network. A schematic diagram of articular 
cartilage may be seen in Figure 1.2. 
 
 
Figure 1.2: Schematic representation of articular cartilage showing four main zones; 
superficial (SZ), middle (MZ), deep (DZ) and calcified cartilage matrix (CZ) plus the 
underlying subchondral bone (SB). The figure shows that each zone differs in cell 
morphology (left), collagen fibre organisation (middle) and ECM molecular 
composition. Figure from Wilson et al. 14  
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Surprisingly, cartilage has relatively few chondrocytes with only 5% of cartilage 
consisting of cells.  The remaining 95% consists of the ECM, which is a cell-free matrix. 
This scarcity of cells may explain why cartilage cannot regenerate by means of cell 
turnover. Effectively, each cell is a completely independent entity and only gains 
information through mechanical forces and molecular mediators e.g. cytokines and 
growth factors. Structurally, approximately 5% of the wet weight of cartilage is 
composed of highly-sulphated proteoglycans.  The two major proteoglycans are 
aggrecan and the glucuronic acid polymer, hyaluron 15. The aggrecan entities, however, 
do not exist in isolation but instead, they bind in their hundreds to a central hyaluronic 
acid (HA) filament.  HA is a polysaccharide composed of repeating units of glucuronic 
acid and N-acetyl glucosamine.  Its monomer structure may be seen in Figure 1.3. 
 
 
Figure 1.3: A monomer unit of the polysaccharide hyaluronic acid (HA). The two 
subunits glucuronic acid and N-acetyl-glucosamine are also labelled. 
 
Hyaluronic Acid is the component of synovial fluid that imparts viscosity and gives the 
joint fluid an “egg-like” appearance and consistency. It is believed that the size of the HA 
entity decreases while its actual abundance increases with age 16 and with the onset of 
arthritic diseases17. This decrease in size is attributed to degradation and is thought to 
involve the action of hyaluronidases or free radicals. The increase in the volume of HA 
produced is offset by a dilution of the synovial fluid.  A study completed by Lenormand 
et al. 18 concluded that HA can complex with proteins at various conditions of pH, ionic 
strength and protein over HA ratios.  Therefore, an analysis of synovial fluid necessarily 
involves the hydrolysis of HA by hyaluronidase (HAase).  Furthermore, the high 
viscosity of synovial fluid due to HA is problematic when it comes to instrumental 
analysis.  
  10 
Proteoglycans are located between the collagen fibres in fixed locations.  An interesting 
feature of these is that they are only 40 – 60% hydrated.  This is due to the restrictive 
network of collagen network fibres i.e. there is a swelling pressure generated 15.  As a 
result, this imparts a degree of stiffness to the cartilage.  However in OA, proteolytic 
enzymes degrade both the proteoglycans (aggrecanases) and collagen (collagenases)19, 20.  
Though the entire process is quite complex, the net manifestation is eventual cartilage 
degradation. 
Horton et al. 21 propose that chondrocyte apoptosis is more prevalent in OA.  They 
further advance that chondrocyte cloning is evident and this may be interpreted as a 
localised attempt at cartilage repair and regeneration.  Poole and colleagues believe there 
is evidence of increased chondrocyte synthetic activity in early OA 22.  They interpret 
this as an attempt by the chondrocytes to regenerate the matrix components e.g. 
collagens and aggrecans.  This attempt at repair by the chondrocytes manifests itself in 
the appearance of fibres, matrix depletion, cell clusters and above all, as changes in the 
quantity, distribution and/or composition of matrix proteins 23.  Therefore, the 
simultaneous but opposing processes of cartilage degradation and cartilage repair are at 
work in the very early stages of OA.  Abramson 11 also supports this theory, stating that 
the chondrocyte undergoes a series of complex changes, including hypertrophy (an 
increase in volume), proliferation, catabolic alterations and finally, death.  Eventually, as 
the disease and/or ageing process progresses, the catabolic processes overcome their 
anabolic counterparts.  Sarzi-Puttini et al. 9 concur that the degradation of the ECM 
exceeds its synthesis and this leads to a decrease in the amount of cartilage matrix and 
eventually, to the complete erosion of the cartilage thus exposing the underlying bone.  
Eventually a stage is reached where once the cartilage is severely degraded, the 
chondrocyte is unable to replicate the very complex collagen network structure and total 
cartilage destruction is certain. 
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1.0.4 Osteoarthritis – Diagnosis and Prognosis 
 
OA has been described as the “silent plague” of the 21st century 24.  It is a degenerative 
disease and a consequence of many factors including natural age-related changes, genetic 
predisposition and abnormal biomechanical forces that alter metabolic processes and 
destruction of articular cartilage 25.  Not only is the cartilage affected but also the entire 
joint structure, including the synovial membrane, bone, ligaments and the periarticular 
muscles.  In spite of the compelling statistical data presented above relating to its 
prevelance, there is currently no prevention or cure for OA.  Though the American 
College of Rheumatism has published criteria for the diagnosis and classification of OA, 
these are not convenient for the early detection of the disease 26.  It is also stated that 
evaluation of OA progression is equally uncertain, and lacks coherent, standardised 
criteria.  For the most part, the seriousness and progression of the disease are evaluated 
based on the pain experienced by the patient at the time.  Cushnaghan 27 states that the 
cardinal symptom of OA is pain, which occurs with joint use and is only relieved by rest.  
It is usually aching in character and it is often difficult to locate the site of origin.  
Rheumatologists ascertain the severity of the disease by employing the 
Kellgren/Lawrence scoring system to knee joint x-rays.  However, it has also been shown 
that some patients who experience moderate to severe pain may actually have very little 
bone damage (by radiography) and only a third of patients with x-ray evidence of OA 
complain of pain at the relevant site 9. The author goes on to state that not only is there 
“no gold standard diagnostic test for OA”, but also current radiographic diagnosis may 
be non-specific. This renders the early detection of OA extremely difficult as the 
progression of the disease is already underway before intervention can be affected should 
a cure be eventually found.  Moreover, to date there is no specific diagnostic laboratory-
detectable abnormality in primary OA 9 
The natural aging process also frustrates any attempted OA diagnosis 28.  Major 
components of the ECM e.g. type II collagen and proteoglycans, undergo structural and 
compositional changes during the natural aging process.  Gobezie et al. 29 offer a number 
of reasons for the difficulties in developing diagnostic and treatment solutions for OA 
(Figure 1.4). 
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Figure 1.4: Confounding factors in the development of diagnostic and treatment 
solutions for OA. 
 
Coupled to these difficulties is the realisation that cartilage deterioration is non-uniform 
in terms of disease progression with time as there are intermittent episodes of 
inflammatory attacks and remission periods.  Regan et al 30 support this hypothesis by 
claiming that radiographic evidence often occurs late after significant loss of cartilage 
has already taken place.  Indeed, by the time OA is positively diagnosed, the 
deterioration of cartilage has reached the point of no return and the patient is already 
undergoing symptomatic treatment with anti-inflammatory drugs or analgesics 12.  
Though the early detection of OA is problematic and intervention is limited to pain 
relief, the prognosis is all too clear. Should the symptoms not be effectively controlled, 
the suffering patients’ fate is likely to be total joint failure leading to eventual joint 
replacement 31. 
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1.0.5 Traditional methodologies for OA diagnosis 
 
In 1985, Fawthrop et al. 32 undertook an investigation to identify particulate matter in 
synovial fluid (SF).  In particular, they sought to examine the specificity and sensitivity 
of routine techniques available at the time in order to differentiate between normal and 
pathological SF.  The authors noted that prior to this, other work had been done 
employing light microscopy for the identification of urate (in gout), pyrophosphate and 
cholesterol crystals.  They were however, unaware of any previous study of normal, 
healthy fluid for these crystals.  Their findings revealed that crystals were present in some 
normal fluids from young patients with no clinical evidence of joint disease, which cast 
doubts on the specificity of the technique.  Moreover, the alizarin red assay used to detect 
hydroxyapatite particles also lacked specificity as particles in normal fluid were also 
stained.  The effects of exercise and the levels of lactate were also examined in this study.  
It was concluded that all the techniques examined, lacked disease specificity.  Finally, it 
was recommended to interpret synovial fluid microscopy with caution. 
More recently however, Yavorskyy et al. 33 countered this assertion by stating that basic 
calcium phosphate crystals are unique to OA and may represent a therapeutic target.  
Rosenthal 34 supports this claim and found that 60% of synovial fluids from patients with 
severe OA contain calcium pyrophosphate (CPPD) or basic calcium phosphate crystals.  
Sinz et al. 35 also expressed reservations concerning the ability of current routine clinical 
tests on synovial fluid to offer a precise description of particular disease states.  These 
tests include measurement of synovial fluid transparency, viscosity, glucose and protein 
concentrations as well as the quantity and morphology of any cells present.  Though the 
synovial fluid from RA patients has been found to be increased in volume, cloudy from 
suspended cells, less viscous than normal SF and liable to clot on standing (due to higher 
fibrinogen content), the fluid from OA patients retains normal colour, clarity and high 
viscosity with an only increase in volume 17. 
Joint imaging with conventional radiography, arthroscopy and magnetic resonance 
imaging (MRI) are also routinely used to monitor pathologic changes in the osteoarthritic 
joint.  These methods are the current diagnostic tools.  The severity of OA is assessed by 
measuring cartilage thickness and evaluating osteophytes and any ulceration of the 
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cartilage surface.  However, it is believed that these methods fail to provide a sensitive 
assessment of disease progression 36.   
It would appear then, that the more traditional diagnostic methodologies are limited in 
terms of early disease diagnosis, disease specificity and monitoring disease progression.  
Even with the availability of these limited methods, the primary manifestation of OA is 
the presence of pain, despite the poor correlation between level of pain and severity of 
OA.   However, breakthroughs and developments in molecular and cell biology in the 
latter part of the 20th century have increased our understanding of many diseases e.g. 
cancer 37.  Specifically, disruption to cellular networks is now believed to be the 
consequence of genetic changes and/or environmental factors.  These changes are 
manifested through altered mRNA transcriptions and subsequent modifications to protein 
profiles.  In addition, the up or down regulation of other molecules that have a role in 
metabolic processes e.g. reactive oxygen species, cytokines, proteases and enzyme 
inhibitors are also useful biomarker candidates 38.  Thus, the phenomenon of body fluid 
proteomics, peptideomics, glycomics, metabolomics and the search for disease 
biomarkers has begun in earnest.   
 
 
1.0.6 Biomarker classification and a system approach to biomarker discovery 
 
In 2001 the Biomarker’s Definitions Working Group defined a biomarker as a 
“characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes or pharmacological responses to therapeutic intervention” 39. 
Bauer et al. 40 sought to classify osteoarthritis biomarkers in particular, on the basis of 
function. The BIPED classification scheme was introduced in 2006.   A single biomarker 
may be classified in one or more of the following categories; 
Burden of disease; Investigative; Prognostic; Efficacy of intervention; Diagnostic 
Burden of disease biomarkers ascertain the severity or extent of the disease at a particular 
point in time.  This determination can be in just a single joint or a group of joints 
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simultaneously.  The authors stress that this classification has nothing to do with the 
economic or social “burden” of the disease. 
Investigative biomarkers are the least precisely defined class.  In brief, they are markers 
where the relationship to various normal and abnormal parameters of cartilage turnover 
has not yet been established. They are listed in this category to stimulate further research. 
The main feature of a prognostic marker is to predict the future onset of OA among 
“healthy” individuals or the progression of OA among those already with the disease.  
This generally requires a longitudinal study in order to track the levels of a particular 
marker over time. 
Efficacy of intervention markers may be measured prior to therapy to predict treatment 
efficacy, or may be measured more than once to assess short-term changes that occur as a 
result of pharmacologic or other interventions.  Finally, diagnostic makers are usually 
employed in a dichotomous manner - diseased or non-diseased, OA or RA etc.   
In the last decade it has been recognised that a “systems biology” approach towards 
elucidating the cause of a disease is required 41.  This has generally been defined as a 
broad study of the components of biological processes e.g. proteins, reactive oxygen 
species, glycosylation entities and nucleic acids (e.g. ribonucleic acid; RNA).  The study 
of these various components is believed to lead to a greater and deeper understanding of 
the dynamic biological processes at the cellular and tissue levels. It is widely accepted 
that this systems methodology will eventually lead to the identification of the most 
important moieties that differentiate between health and disease and could become 
primary targets for therapeutic intervention.  
1.0.7 Body fluids as a source of OA biomarkers 
Over recent years a number of review papers have been published 42 37 relating to human 
bodyfluid analysis in the search for protein biomarkers.  They outline the unique features 
and challenges in the analysis of each particular biofluid as well as the applications of 
each to human disease biomarker discovery.  An extensive list was reviewed and 
included:  plasma/serum, urine, cerebrospinal fluid, saliva, bronchoalveolar lavage fluid, 
synovial fluid, nipple aspirate, tears fluid and amniotic fluid.  All research papers studied 
related to the search for biomarkers for arthritis in general and OA in particular, 
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discussed the analysis of just three of these biofluids i.e. serum/plasma, urine and 
synovial fluid.   
The scope of this project is limited to the analysis of synovial fluid.  Therefore, a detailed 
description of the composition and sample treatment of serum/plasma and urine will not 
be discussed here.  However, confining research to one biofluid i.e. synovial fluid is not 
without some merit.  Indeed, Gibson et al.17 advise caution against the simultaneous 
analysis of synovial fluid and plasma/serum stating that at present, there is no evidence of 
any correlation between the two fluids.  It is now believed 43 that what are termed 
“proximal fluids” of which synovial fluid is a good example, increase the probability of 
finding new biomarker molecules for OA.  The reasoning behind this is that blood, 
though readily obtained, may contain potential disease biomarkers at such low 
concentrations due to dilution effects, that detection may be difficult.  Felson et al. 44 also 
expressed concern about OA biomarkers derived from blood or urine.  Their reasoning 
was as follows:  A cartilage degradation marker is released into the synovial fluid where 
it is potentially diluted by a large volume of SF.  It then travels through the synovial 
membrane at a rate dependant on a concentration gradient between synovial fluid and 
blood.  Leaving the joint cavity, the biomarker may be metabolised by synovial cells, 
lymph nodes etc. with the result that the epitopes that originally identified it are altered, 
and any assays that were developed to detect it, are no longer effective.  Finally further 
dilution and metabolism will take place in the kidney.  Yamagiwa et al. 45 agreed, stating 
that ECM proteins, ECM degradation products, proteins from the synovium, ligament, 
meniscus, joint capsule and bone, all accumulate in the synovial fluid.  Though there is 
protein exchange between synovial fluid and the systemic circulation, it is known that the 
protein concentration in the former is approximately three and a half times that of the 
latter.  This may be seen in Table 1.2.   
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Protein Molecular
Weight (kDa) Normal OA RA Normal OA RA
Hyaluronan 2x106 3.2 1.5 0.17-2.0
Fibrinogen 340 0.15-2.10 0.25-0.55 3 7.0
Albumin 69 12.0 - 20.0 11.0-34.0 8.0-35.0 32.7 26.0 29.2-44.0
Haptoglobin 100 0.1 0.2 0.9-4.0 1.8 2 2.4-6.0
IgG 156 4.0-30.0 10.3-11.0 4.0-12.0 11.0-20.1
Total Protein 19 40.0-68.0 38.0-84.0 67.7 70.0
Synovial Fluid Serum/Plasma
 
Table 1.2: Comparison in protein concentration between SF and serum/plasma. All 
concentrations are in mg/mL.  In addition a comparison between healthy and arthritic 
synovial is made.  The molecular weight of each protein is included.  This data was taken 
from Gibson et al.17 
A further merit to synovial fluid analysis is that information relevant to the specific joint 
may be obtained. Therefore biofluids in direct contact with the diseased site may contain 
interesting and potentially useful biomarkers at a concentration that renders detection 
possible.  Sarzi-Puttini 9 concluded that the use of serum markers for diagnostic and 
prognostic purposes remains investigational.  In a recent review 46 it was stated, that 
although serum and urine biomarkers for diagnosis and prognosis have been found, none 
of them can yet be used in clinical practice because of large inter-patient variations.  
However, the same author did concede that synovial fluid analysis may be impractical for 
large-scale clinical diagnosis and monitoring.  Courtney et al. 47 state that aspiration of 
synovial fluid from a joint can quickly relieve severe pain by reducing intra-articular 
pressure and therefore the aspiration of synovial fluid from the joint is routinely 
employed at the clinic.  For proteomic analysis in particular, it was stated that the high 
abundance of hyaluronan is extremely problematic for biomarker detection and so this 
anionic macromolecule needs to be removed prior to analysis.  A further and not 
insignificant confounding factor with the analysis of synovial fluid is the difficulty in 
securing normal or healthy samples.  Therefore, any biofluid being mined for diagnostic, 
prognostic markers with a view to therapeutic targeting is not without some inherent 
challenges.  
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1.0.8 Properties of Synovial Fluid (SF) 
Synovial fluid is a viscous liquid that lubricates the joints of the body.  Its physical 
characteristics are similar to egg white in being clear yellow, transparent and highly 
viscous due to the high content of hyaluronic acid which is synthesised locally within the 
joint.  One of its functions is to provide a cushion around the joint cartilage in order to 
reduce friction.  It has a coefficient of friction of 0.002 – which is about 25 times less 
than steel on ice or that of an artificial joint replacement 48.   Normal healthy knee joints 
contain a small amount of synovial fluid, approximately 0.5mL whereas other joints 
contain a few drops 47.  A photograph of normal, healthy synovial fluid can be seen in 
Figure 1.5.    
 
 
 
 
             
 
 
Figure 1.5:  Synovial fluid aspirated from a normal, healthy knee.  Note the small volume 
of the clear, slightly yellow viscous fluid. Photograph taken from Courtney et al. 47 
SF is not a static pool within the joint.  A dynamic situation exists, whereby the synovial 
lining of the joint cavity (see Figure 1) continually absorbs and replenishes joint fluid 49.  
Fluid turnover is governed by three elements – the synovial capillary system, the synovial 
interstitium and the lymphatic drainage system.  Normal, healthy synovium contains a 
row of capillaries approximately 30µm below the surface.  These capillaries in turn, 
possess fenestrations (membranes with a high permeability to water), often on the side of 
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the joint cavity that are the sites of synovial fluid formation and nutrient supply 50-52.  SF 
is a plasma dialysate whereby plasma undergoes a filtration process by this capillary 
network embedded in the synovial membrane.  This is the second function of synovial 
fluid and serves to facilitate the transport of essential nutrients to the cartilage.  At the 
sub-synovium-synovium border there is a network of terminal lymph vessels which 
drains away fluid, macromolecules, and particles that leave the joint cavity 53.   Generally 
speaking, the onset of inflammatory conditions changes the appearance from a clear to a 
cloudy, cell packed fluid.  A contrast between the appearance of non-inflammatory and 
inflammatory SF may be seen in Figure 1.6. 
   
 
 
 
 
 
 
 
 
 
Figure 1.6:  A comparison in the appearance between non-inflammatory (left) and 
inflammatory SF.  Note the increase in volume compared to normal SF in Figure 4.  Also 
the cloudy appearance is evident in inflammatory SF.  Picture taken from Courtney et al. 
47
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Finally, Figure 1.7 shows an example of SF that was inadvertently contaminated with 
blood during aspiration.  Blood contaminated samples were omitted from all studies in 
this project. 
 
  
 
 
 
 
 
 
Figure 1.7:  A specimen of blood tinged SF.  Picture taken from Courtney et al. 47 
 
 
1.0.9 Overarching project aim 
As discussed above, osteoarthritis is an extremely complex and heterogeneous pathology.  
In this project it is hoped to apply a suite of techniques to the characterisation of both 
whole synovial fluid and the micro/nano-vesicular sub- component.   
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2.0 Introduction 
2.0.1 Proteomics 
Proteomics is a relatively new and exciting field of study that has enabled the discovery 
of biomarkers for disease and has helped the elucidation and understanding of disease 
mechanisms. Proteomics has been defined as “the study of the set of proteins expressed 
by a tissue or cell, and the changes in protein expression patterns in health and disease 
or in different environments.” 1.  It is also believed that proteomic studies offer a more 
useful insight than the previous genomic RNA systems studies. The reasons for this 
include the fact that RNA levels do not accurately predict protein levels and/or post-
translational modifications of proteins which are often an indicator of their biological 
activities.  It is further hypothesised that protein expression profiles of diseased tissue or 
biological fluids can effectively function as a disease “fingerprint” that reflects the onset 
or progression of a particular pathologic disease.  Body fluids are now being 
conceptualised as “windows into health and disease” and there are aspirations that these 
fluids may be mined for markers that ascertain the onset of disease, the monitoring of 
disease progression and drug efficacy in various conditions 2. 
 
2.0.2 Proteomic Methodologies 
Traditional proteome analysis generally commences with 2D polyacrylamide gel 
electrophoresis (2D-PAGE) separation of proteins. Spots or bands of interest are then 
excised from the gel and digested by an enzyme with particular cleavage specificity and 
the resulting peptide mixture is introduced into a mass spectrometer (MS).  For each 
mixture, the data obtained for the peptide masses, protein molecular mass, cleavage 
specificity and isoelectric point are all compared with data in a protein sequence 
database, and the output is the identity of the proteins selected on a “best match” basis.  
The confidence of identification is increased with the increasing selection of more 
peptides from the same protein(s) in MS analysis. An advantage of this methodology is 
that the researcher can effectively hand pick spots of interest (including those not highly 
expressed) for further investigation 3.  The strengths of the 2-D PAGE technique include 
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its ability to separate and quantify thousands of intact proteins in a single run 4.  
Quantification is a relatively new step forward in this technique and is achieved through 
multi-colour fluorescent labeling techniques analogous to those used in mRNA analysis. 
The 2D-PAGE proteomic analysis of biological fluids is recognised as a slow and labour 
intensive protocol due to the 2D gel electrophoresis and enzymatic digestion steps.  These 
shortcomings in 2D PAGE have prompted an upsurge in the development of gel-free 
approaches and quantification 5.  Though 2D PAGE is a powerful and widely employed 
technique, some of the limitations of the technique cited include labor-intensive 
preparation procedures (often requiring hours or days for a single analysis) and stringent 
demands on reproducibility of experimental procedures and reagents in order to effect the 
high reproducibility required in any proteomic study.  Shi et al. 6 stated that though there 
are recent improvement in 2D-PAGE techniques, reproducibility was still an issue.  This 
view was also taken up by Bodzon-Kulalowska et al. 7 in their review paper who stated 
that reproducibility of protein patterns between laboratories is difficult to achieve due to 
protocol variations, artifacts and technology.  There are also technical difficulties with 
on-line coupling to MS.  Further, classical Coomassie-stained gels display at most four 
orders of magnitude in protein concentration 4.  Finally, proteins with a molecular mass 
of less than approximately (~) 20kDa, highly acidic or basic proteins and hydrophobic 
(membrane) proteins are not well resolved by gel electrophoresis 8.  This potentially leads 
to the loss of important biological information 9.  Gygi et al. 8 estimate that more than 
half of all proteins in the yeast proteome are not detectable by 2D-PAGE analysis.   
An increasingly attractive alternative to 2D-PAGE is high performance liquid 
chromatography (HPLC).  This is due to its high resolving power, high reproducibility 
and its on-line compatibility with electrospray MS.  In addition, there is a broad range of 
mobile and stationary phase combinations available.  In recent years a number of HPLC 
methods have appeared for the analysis of both peptides and intact proteins.  Another 
major benefit of chromatographic techniques in a proteomic study, is the range of modes 
available e.g. reversed-phase, ion chromatography, affinity chromatography and size 
exclusion.  These have been employed either alone or in combination with each other.  
When two or more different, orthogonal modes of chromatography are employed (e.g. 2D 
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or 3D LC), then superior resolution may be achieved.  Relative to the 2D-PAGE 
approach, sample handling and preparation are minimal.  Furthermore, automation is 
possible and this results in a high sample throughput, thus making it ideal for a clinical 
laboratory. It is also known that because of the high resolving power of LC, ion 
suppression effects in MS can be reduced or even eliminated.  In short, chromatography 
in proteomics can provide high resolution, high speed, good sensitivity and specific 
separation of very complex matrices i.e. biological fluids.  Finally, this kind of separation 
facilitates on-line MS detection and quantification. 
 
2.0.3 A critique of “Top-Down” versus “Bottom-Up” or “Shotgun” Approach 
Bottom-up (or shotgun) proteomics generally refers to the enzymatic digestion of intact 
proteins into a peptide mix that is injected into a MS for protein elucidation and 
identification. This approach is undoubtedly the most widely used approach in proteomic 
literature today.  Peptides possess greater solubility, are stable in a wider range of 
solvents and are therefore easier to separate than proteins 10.  There are however, some 
limitations associated with this approach.  The peptide database mapping may be 
compromised due to insufficient search specificity, incomplete digestion, sample 
impurities, post-translational modifications and/or database sequence errors 11. Following 
enzymatic digestion, the sample is rendered more complex with certainly thousands and 
possibly millions of peptides in solution.  Tang et al. 10 advise that bottom-up approaches 
provide very limited “true” molecular information of intact proteins, in particular proteins 
that have undergone post-translational modifications.  As a significant portion of disease 
biomarkers maybe among the very low abundant proteins, peptides of these interesting, 
low abundant species may be masked by those of the high abundant, ubiquitous proteins 
e.g. albumin.  Intact protein analysis offers the advantage of the detection of post-
translational modifications and it is possible that a top-down approach has the potential to 
enhance biomarker discovery research.  Analysis of intact proteins by HPLC is however 
technically challenging and problematic.  Difficulties experienced include carryover, 
multiple peak formation (splitting) and broad, poorly shaped peaks 12.  The reasons for 
these difficulties include, slow intra-pore diffusion times, unresolved structural micro-
  30 
heterogeneities and conformational isomers and finally secondary interactions with the 
stationary phase.  To offset the effects of broad peaks, longer gradients are required 
which results in longer run times. Also, though the analysis of intact proteins has the 
potential to offer useful molecular level information, the process currently requires the 
use of Fourier transform ion cyclotron resonance (FTICR)-MS/MS for obtaining protein 
sequencing measurements 13.  Finally, positive protein identification is currently limited 
by the relative scarcity of bioinformatic tools to date to analyse intact protein data. 
Though these challenges may appear formidable, there is still merit to analysing whole, 
intact proteins via HPLC.  On or off-line digestion of the resolved or even partially 
resolved eluted proteins, would greatly facilitate protein identification through peptide 
mass mapping.  In this case, instead of performing enzyme digestion on the whole sample 
at once, fractions of interest could be collected and each aliquot digested separately 
before MS analysis.  This method eliminates the relatively lengthy 2D-PAGE approach.  
Because there are significantly less peptides in each fraction, this approach may greatly 
increase the chances of securing correct identification of a protein in addition to a 
reduced chance of missing low abundant and potentially interesting species.  The peak 
resolution could be further improved by removal of high abundant proteins prior to 
HPLC analysis. 
Gillette et al. 14 published a review paper outlining the merits (and also the precautions) 
of pattern profiling in proteomic biomarker discovery.  More specifically, they critiqued 
pattern profiles generated by MS as a reliable, legitimate and reproducible mode of 
analysis in the search for markers of disease.  Two platforms are currently available for 
biomarker discovery; 1) pattern profiling and 2) protein identification.  They reminded us 
that there is a broad consensus view that heterogeneity and complexity of the individual, 
environment and disease, imply that individual markers are rarely sufficient for 
establishing a diagnosis or prognosis.  On the contrary, panels of biomarkers are typically 
required.  This may be particularly true for a complex and heterogeneous pathology like 
OA.  The author also commented on the time consuming nature of protein identification.  
Everley and co-workers 15 characterised the Clostridium species through the analysis of 
intact proteins employing LC/MS without identifying the individual proteins.  They 
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justified this approach by claiming that reproducible biomarkers candidates had been 
observed allowing for characterisation at the strain level without actually knowing the 
identity of the proteins involved.  Again they noted that the sequencing of intact proteins 
on a chromatographic time scale is extremely challenging and was not attempted. 
Therefore, acknowledging the aforementioned difficulties with intact protein analysis – in 
particular the scarcity of algorithms for identifying intact proteins by MS – pattern 
profiling of intact proteins in SF may be instructive and informative.  A thorough search 
of the literature showed that this work has not been attempted before.  It was therefore the 
objective of the present study to separate intact, native SF proteins via reverse phase 
HPLC and then to compare the chromatographic and/or MS profiles generated for each of 
the various arthritic pathologies in the hope that this leads to a protein footprint that is 
indicative of a particular joint pathology.  Knowing that no one single agent is wholly 
responsible for the onset of OA, establishing a footprint that characterises a particular 
arthritic pathology may merit further study.  
 
2.0.4 Putative OA biomarkers found to date 
A literature survey was carried out in order to ascertain what OA biomarkers have been 
discovered to date and what methodologies were used.  Table 1 displays the findings of 
various research groups in the search for protein biomarkers that differentiates OA from 
the various controls and/or other arthritic pathologies.  Inspection of Table 2.3 reveals a 
wide variety in the type and number of biomarkers found and the methodologies used.  
De Ceuninck et al. 16 advised caution concerning the application of proteomic techniques 
to OA in particular as it is not straightforward due to the inherent complexity of the 
disease, and they reiterated that the progression of OA is slow with sporadic episodes of 
inflammation and remission.  This may be interpreted as a reminder that a single sample 
from a patient is just a snap-shot of the disease at a particular moment in time.  
Furthermore they advised that although serum and urine biomarkers for diagnosis and 
prognosis have been proposed, it is said that none of them can be used in actual clinical 
practice because of large inter-individual variation.  
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Year Biofluid Biomarker 
Concentration 
change in OA 
relative to RA or 
Control 
Mode of Analysis Reference 
1993 
Plasma & 
Synovial 
Fluid 
Substance-P No change HPLC & RIA 17
 
2002 
Plasma & 
Synovial 
Fluid 
(i) Calgranulin B 
(MRP14)                   
(ii) Serum amyloid 
A 
(i) Not observed in 
OA                 (ii) Not 
observed in OA 
2-DE/MALDI-TOF 
MS 
18
  
2003 
Synovial 
Fluid                 
(4 OA 
samples) 
Haptoglobin 
18 spots increased 5-
fold between any two 
samples and 9 spots 
increased 100-fold 
between any two 
samples 
2D-PAGE 19
 
2006 Synovial Fluid   
(i) Superoxide 
dismutase                 
(ii) Catalase             
(iii) glutathione 
reductase                
(iv) glutathione-S-
transferase         
(v)Malondialdehyde                           
(vi) Viscosity 
Enzyme activities 
were elevated in the 
OA group relative to 
the control group.                                           
Glutathione 
reductase activity 
higher in secondary 
OA group.                 
Viscosity lower in OA 
group. 
Various kinetic
methods.  Viscosity 
measured on a 
viscometer 
20
 
2006 Cartilage 100 proteins Identified 
Carilage 
Characterisation 
1-D-SDS PAGE 
MS/MS 
21
 
2007 Articular Cartilage 59 proteins 
Differentially 
expressed relative to 
control 
SDS-PAGE/ 
nanoHPLC/  MS-MS 
22
 
2007 Blood & Urine 
(i) Epitopes of type 
II collagen (C2C, 
C1, C2)                          
(ii) Aggrecan 846 
epitope (CS846)             
(iii) Cartilage 
Oligomeric Matrix 
Protein (COMP) 
COMP levels indicate 
cartilage loss.  
Upregulated in OA. 
ELISA 23
 
2007 Urine 
C-termina cross-
linked telopeptide 
of type II collagen 
CTX-II 
Up-regulated in OA Not specified 24
 
2007 
Synovial 
Fluid             
(1 control & 
1 
postmortem 
sample) 
40 proteins 
identified 16 unique to OA 
Reverse Phase 
nano-HPLC/ MS 
25
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2007 Synovial Fluid 
135 proteins 
identified 
18 proteins 
differentially 
expressed between 
OA and control - 3 
down-regulated in 
OA & 15 up-
regulated. 
1D-PAGE/ MS/MS 26
 
2008 Serum 16 proteins identified 
15 proteins up-
regulated and 1 
down-regulated in 
OA 
Rolling circle 
amplification 
27
 
2008 Synovial Fluid 
(i) Extra-cellular 
superoxide 
dismutase (EC-
SOD)                   
(ii) Ascorbate               
(iii) Urate                                  
(iv) Glutathione 
(GSH)                           
(v) Total Nitrates                        
(vi) Cytokines IL-6 
& TGF-β 
(i) Decrease in late 
OA samples                          
(ii) Decrease in late 
OA samples                            
(iii) No difference                            
(iv) Decrease in late 
OA samples                                   
(v) No difference                                 
(vi) No difference 
(i) ELISA               (ii) 
HPLC        (iii) HPLC        
(iv) Colorimetric 
Assay            (v) 
Greiss Assay                     
(vi) ELISA 
28
 
2009 Serum Il-6 Up-regulated in OA ELISA 29
 
2010 
Serum & 
Synovial 
Fluid 
(i) S100A8                  
(ii) S100A12                 
(iii) S100A9 
10 fold higher in RA 
SELDI-TOF MS      
Western Blot     
ELISA 
30
 
2011 
Serum & 
Synovial 
Fluid 
(i) V65 vitronectin 
fragment                        
(ii) C3f peptide                  
(iii)Unknown 
protein @ m/z 
3762                     
(iv) Connective 
tissue-activating 
peptide III protein 
(i) Increase in OA 
patients relative to 
control (both fluids)                  
(ii) Increased in OA 
patients relative to 
control                                     
(iii) Increased in OA 
patients relative to 
control and RA 
patients                (iv) 
Decreased in OA 
relative to control 
patients 
SELDI-TOF MS      31
 
Table 2.1: A list of proposed biomarkers for OA found in a variety of biological fluids.  
Also shown is their relative abundance to other arthritic diseases or control samples.  
Finally, the analytical techniques employed are shown.  
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2.0.5 Protein dynamic range in SF  
Though the protein concentration of serum and plasma is relatively high (tens of mg/mL), 
99% of the protein content is comprised of just 22 individual proteins e.g. albumin, IgG, 
fibrinogen and transferrin 32.  Albumin accounts for about 50% of the total protein 
concentration in blood.  Though plasma proteins can enter the SF by passive diffusion -
indeed SF is considered a dialysate of blood plasma – concentrations of larger proteins 
remain substantially less in SF than in plasma, 30% less in fact 33.  However, it is not 
correct to suggest that all proteins found in SF originated in the blood.  Recent 
developments have shown that many of the constituents of SF present in disease e.g. 
cytokines, proteases and various antibodies, are produced locally in the joint 34 .   
Albumin is the most abundant protein in SF, accounting for about 64% of the total 
protein load in normal SF.  As mentioned already, the protein composition of SF is 
dominated by a relatively small group of proteins.  Indeed, the dynamic range between 
potentially clinically useful proteins and the high abundant proteins may differ by a factor 
of 1010 in both SF 34 and plasma 32. For example, albumin and the high abundant proteins 
are found in the mg/mL range, while a protein like the cytokine TNFα is present in the 
pg/mL range.  Removal of the high abundant proteins would increase the sample loading 
capacity and hence improve the detection sensitivity of low abundant proteins 35.     
 
2.0.6 Methods employed for removal of the most abundant proteins 
In order to increase the chances of unearthing potentially insightful pattern profiles, it is 
now believed that the high abundant proteins should be removed from the matrix prior to 
any separation, whether by 2D-PAGE, chromatography, capillary electrophoresis or any 
other mode of analysis.  It must be stressed that removal of the high abundant proteins is 
by no means a suggestion that they are uninteresting or an unfortunate inconvenience that 
must be overcome in order to reach the lower abundant species.  It is known that the 
immunoglobins and albumin can act as carrier molecules by binding to other peptides and 
proteins.  Indeed “albuminomics” has become a useful offshoot of depletion strategies, 
  35 
where research has been conducted on the albumin fraction in order to investigate the 
entities that attach to this carrier molecule 36.  Moritz et al. 37 also found that abundant 
plasma proteins act as sponges for low molecular weight peptides.  Examples of 
interesting potential biomarkers that have been found to associate with albumin and so 
have the potential to be removed during albumin depletion are peptides, C-reactive 
protein, cystatin, apolipoprotein CIII, lumican and angiotensinogen 38.  A more prudent 
strategy would be to analyse both the low and high abundant fractions as not only the 
lower abundant proteins, but also the proteins that are specifically or non-specifically 
removed may be analysed 4.  The author in this case discovered that 129 proteins were 
identified in the high abundant protein fraction.  After identifying 40 of these proteins, it 
was discovered that 26 proteins were common to both the high and low abundant 
fractions, thus underlining the importance of keeping and analysing all fractions.  
Several approaches exist for the removal of the most abundant proteins in biofluids.  
Some of the methods available to the researcher include, the removal of human serum 
albumin (HSA) by immunoaffinity columns based on HAS-specific antibodies 39, 
isoelectric trapping using albumin as a marker 40, peptide affinity chromatography 41, 
Cibacron Blue (CB) to remove albumin 42 and ultrafiltration 43.  More recently, 
immunoaffinity columns and cartridges have been developed for the removal of multiple 
abundant proteins 44 45 46.  Non-specific depletion of plasma proteins can also be 
accomplished by rivanol (2-ethoxy-6,9-diamino acridine, ammonium sulphate and 
caprylic acid 37.  Limitations of the CB method mentioned above include binding to the 
binding sites of proteins other than albumin 47.  Zolotarjova et al. 42 performed a study 
where the objective was to compare CB and IgG immunoaffinity methodologies for the 
removal of the must abundant protein, HSA, from serum.  Their findings revealed that 
not only were other non-targeted proteins inadvertently removed, but that a significant 
amount of HSA was found in the depleted fraction.  This compounds the difficulty in 
identifying very low abundant proteins, as these species are now placed in an even more 
concentrated solution of serum albumin which in turn increases the difficulty in 
identifying and quantifying these proteins of interest.   On the other hand, the IgG system 
was observed to have no albumin, transferrin, alpha-1-antitrypsin or haptoglobin present 
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in the flow-through fraction.  It was confirmed by ELISA assays that the depletion of the 
target proteins was typically greater than 98%.  An immunoaffinity column was used by 
Liu et al 45 for the proteomic analysis of plasma.  The author did note some non-specific 
binding to the column.  
 
2.0.7 Project Aim 
For this project it was decided to employ an affinity column consisting of avian IgY 
antibodies, in order to remove twelve high abundant proteins – albumin, IgG, α1-
antitrypsin, IgA, IgM, transferrin, haptoglobin, α1-acid glycoprotein (orosomucoid), α2-
macroglobin, HDL (apolipoproteins AI & AII) and fibronectin – from synovial fluid in a 
single step prior to reverse-phase high performance liquid chromatography (RP-HPLC) 
and/or capillary electrophoresis (CE).  All fractions were analysed i.e. the non-bound, the 
non-specific binding and the bound fractions.  On achieving a good separation in all 
fractions, peaks of interest would be characterised by LC-MS or CE-MS.  
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2.1 Materials and Methods 
2.1.1 Reagents and materials 
HPLC grade methanol (MeOH), Isopropyl alcohol (IPA) and water were purchased from 
Sigma Aldrich. 
HPLC grade acetonitrile was obtained from Sigma or Fisher Scientific. 
 
Reagent grade trifluoroacetic acid, formic acid (98%), acetic acid (99-100%) was 
obtained from Sigma for use as ion-pairing reagents. 
 
Sodium Dodecyl Sulphate (≥99.0%) was purchased from Fluka. 
 
Sodium Tetraborate was obtained from Sigma. 
   
Peptide standards, protein standards, bovine serum albumin (BSA), human serum 
albumin (HSA), hyaluronidase from bovine testes were purchased from Sigma. 
 
Triethylamine, urea, dimethylformamide & tetrahydrofuran were obtained from Sigma 
and used for column regeneration. 
 
 A Beckman Coulter ProteomeLab IgY-12 High Capacity Partitioning Kit was obtained 
from Phenomenex. 
 
Amicon Ultra centrifugal filter units with a 3kDa cut-off were obtained from Millipore. 
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2.1.2 HPLC Instrumentation 
A Waters HPLC modular system was used and comprised of the following: 
 1) 600E Powerline multisolvent delivery system with 100µL heads 
 2) 600E system controller 
 3) 717plus autosampler 
 4) 486 UV absorbance detector 
 5) 474 Fluorescence detector. 
 The instrument was controlled by Empower software. 
 
 
2.1.3 Capillary Electrophoresis Instrumentation 
Capillary electrophoresis (CE) was carried out using an Agilent H-P3D CE Instrument 
with a UV-Vis diode array detector.  
The instrument was controlled by HP Chemstation software. 
 
A roll of fused silica polyimide coated capillary was purchased from Composite Metal 
Services.  The capillary for analysis was prepared as follows; a length of capillary, 
48.6cm long was cut from the roll.  A detection window was made by burning the 
polyimide coating 40cm from one end.  Polyimide was also removed from both ends of 
the capillary to prevent capillary blockage.   
 
 
2.1.4 Miscellaneous equipment     
A Hettich Mikro120 centrifuge was used in the immunoaffinity protocol in order separate 
non-bound proteins from targeted, bound proteins. 
A Gilson GV Lab vortex mixer was used mix sample and standard solutions. 
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2.1.5 Peptide Standard Preparation 
The purchased five-peptide mixture (0.5mg of each peptide) was prepared by weighing 
out the compound mixture and diluting in water to a final concentration of (0.1mg/mL of 
each peptide).  The mixture was stored in aliquots at -20ºC.  The five peptides were:       
1) Gly-Phe 
2) Val-Tyr-Val 
3) Met Enkephalin 
4) Angiotensin  
5) Leu-Enkephalin.  
 
2.1.6 Protein Standard Preparation 
A four protein mixture was prepared (1mg/mL of each protein) by weighing out the 
compound mixture and diluting in water. The mixture was stored in aliquots at -20ºC.  
The four proteins were: 
1) Ribonuclease A (13.7kDa, pI 8.63) 
2) Cytochrome C (12kDa, pI 10.0-10.5) 
3) Holotransferrin (77kDa, pI 5.0-6.0)  
4) Apomyglobin (17kDa, pI 7).  
 
HSA and BSA standards were prepared by weighing out the appropriate quantity of each 
protein and diluting in water.  
 
2.1.7 Synovial fluid preparation 
 
Synovial fluid samples were obtained by informed consent from patients attending the 
Rheumatology Department of the Mater Hospital in Dublin.  Samples were aspirated 
from the patient and placed in plastic sample containers containing 1mM EDTA and 
centrifuged at 2500g for 20 minutes to remove cells and cellular debris and then stored in 
aliquots at -80ºC.  Only one freeze/thaw cycle was permitted. 
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In order to reduce the high viscosity of SF, each sample was treated with hyaluronidase 
from bovine testes (1mg hyaluronidase dissolved in 1mL phosphate buffer. 250mL added 
to each sample and incubated overnight at 37ºC). 
 
 
2.1.8 Removal of high abundant proteins from synovial fluid 
  
A Beckman Coulter Proteome Lab IgY-12 High Capacity Proteome Partitioning kit was 
purchased from Phenomenex.  The kit consisted of two affinity columns containing beads 
(60µm polymeric microbeads) coated with avian antibody (IgY)-antigens for the 12 
targeted proteins and three buffers to be used for sample loading, washing, eluting and 
regenerating the column.  The buffer composition was: 
• 10x Dilution Buffer: Tris buffered saline (100mM Tris-HCl, pH 7.4, 1.5M NaCl). 
This was used for sample dilution, washing and equilibrating the column. 
• 1M Stripping Buffer: (1M glycine-HCl, pH 2.5). This was used for eluting the 
bound proteins from the column. 
• 1M Neutralisation Buffer: (1M Tris-HCl, pH 8.0).  This was used for neutralising 
column and also the eluted, bound proteins. 
The manufacturer’s instructions were followed throughout.  
The immunodepletion process is outlined in Figure 2.1.  
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Figure 2.1: A schematic work flow diagram of the immunoaffinity process  
2.1.9 HPLC Conditions 
RP-HPLC columns: Phenomenex Jupiter C18 300Å (150 x 3.0mm, 5µm)  
                                 Phenomenex Jupiter C4 300Å (150 x 4.5mm, 5µm).  
                                 No guard column was used. 
A linear gradient elution was performed with two mobile phases; Mobile Phase A: 0.01% 
(v/v) aqueous TFA and Mobile Phase B: 0.01% (v/v) TFA in acetonitrile/water (60/40).  
The gradient elution was 100% mobile phase A to 100% mobile phase B over 80 
minutes.  
UV detection wavelength: 220nm 
Fluorescence detection wavelength: λex 280nm, λem 360nm 
Injection volume: 50µL 
Flow rate: 0.8mL/min 
All mobile phases were vacumn filtered through 0.45µM filters and then sonicated in a 
water bath for 5 minutes before use. 
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2.1.10 Capillary Electrophoresis 
All new capillaries were conditioned by first washing through with 0.1M NaOH for 
10mins followed by distilled water for 5mins and finally with the background electrolyte 
(BGE) for 10mins.  Between runs, the capillary was rinsed with 0.1M NaOH, distilled 
water, 0.1M HCl, distilled water and BGE for 5mins each.  The BGE consisted of 10mM 
sodium tetraborate and 60mM sodium dodecylsulphate (SDS), pH 9.   
The column was maintained at 25ºC. 
Operating voltage was 15kV 
 Detection wavelength: 200nm, 220nm, 235nm and 280nm 
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2.2 Results 
2.2.1 Standard peptide analysis with C18 column 
A five peptide standard (0.1mg/mL of each peptide) was injected in order to establish 
retention times, peak shape and check the suitability of the system.  Mobile phase was 
prepared as outlined by 48. Briefly, mobile phase A was composed of 0.1% (v/v) formic 
acid and mobile phase B was 0.1% (v/v) formic acid in acetonitrile /water (60/40).  A 
sample chromatogram can be seen in Figure 2.2.  The peaks are identified from the 
supplier’s datasheet.  
 
 
 
 
 
 
 
 
 
 
Figure 2.2: A five peptide standard mix (0.1mg/mL of each); 1=Gly-Phe, 2= Val-Tyr-
Val, 3= Met Enkephalin, 4= Angiotensin II, 5 Leu-Enkepalin.  Detection wavelength 
220nm. The column was a Phenomenex Jupiter C18 300Å (150 x 3.0mm, 5µm).  
 
 
2.2.2 Standard protein analysis with C18 column 
A four protein standard was then prepared and run under the same operating conditions as 
the peptide analysis.  However, the quality of the separation was extremely poor, with 
broad, tailing peaks. 
As a result of the poor chromatography obtained for the standard proteins, the formic acid 
was removed from the mobile phase.  However, this made the chromatography worse.  
Acetic acid was then tried but again peak shape was problematic.  Trifluoroacetic acid 
(TFA) is another wellknown ion pairing agent used in RP-HPLC.  However, TFA is 
deemed unsuitable if the HPLC is to be coupled to electrospray MS 49, which was the 
ultimate aspiration of this study.  This is because TFA forms very strong ion pairs with 
analytes that can not be easily broken apart in the conditions used in the electrospray 
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chamber which would hinder ionisation of the sample.  Huber and Premstaller 50 
compared the performance of acetic acid, formic acid and TFA for the analysis of 
proteins with molecular masses ranging from 14kDa to 80kDa.  They found a 35 to 160- 
fold improvement in sensitivity when formic acid was used instead of TFA.  However, 
Wang and colleagues 13 also conducted a study of ion pairing reagents and concluded 
TFA was the best choice for the HPLC analysis of intact proteins with MS.  This was 
further supported by Corradini et al. 51  who studied TFA, formic acid and acetic acid for 
the analysis of membrane proteins by RP-HPLC-ESI-MS.  Despite the fact that both 
formic acid and acetic acid showed less signal suppression than TFA, these acids resulted 
in poorer quality chromatography.  The authors therefore, recommended TFA at a 
concentration of 0.05% (v/v) as the most suitable mobile phase additive.  In this 
experiment 0.01% (v/v) trifluoroacetic acid (TFA) was added to each mobile phase and 
the chromatography dramatically improved (Figure 2.3). 
 
 
 
 
 
 
 
Figure 2.3: Chromatograms of a 4 protein standard mixture and chromatographic 
conditions as in Figure 2.1 with the exception that the formic acid was replaced by 
0.01%(v/v) TFA. The upper and lower chromatograms are for UV-Vis and fluorescence 
detection respectively. The column employed was a Phenomenex Jupiter C18 300Å (150 x 
3.0mm, 5µm)   
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2.2.3 Immunodepletion of the 12 most abundant proteins  
A “proof of concept” study was undertaken in order to assess the ability of the 
immunoaffinity column to extract albumin from samples. A human serum albumin 
(HSA) standard was prepared at approximately 15mg/mL- comparable to the 
concentration of albumin found in SF 34.  In addition, a bovine serum albumin (BSA) 
standard was also prepared at the same concentration for comparison.  Each standard was 
analysed employing the immunoaffinity protocol supplied by the manufacturer, in order 
to assess the specificity of the method.  All fractions was collected and analysed.   
As expected, the immunoaffinity separation was specific for HSA as there was no protein 
peak found in either the “flow-through” or the non-specifically bound fractions.  This 
demonstrates that the HSA present in SF will be fully removed thus potentially 
uncovering lower abundance proteins that may otherwise have been masked by the 
dominant HSA peak.  However, the presence of some BSA in the bound fraction 
demonstrated that the immunoaffinity column may non-specifically remove proteins from 
the SF i.e. remove proteins other than the 12 listed by the manufacturer.  A possible 
reason for this could be that BSA shares similar amino acid sequences as HSA, and these 
epitopes may be recognised by the HSA antibodies attached to the beads.  Therefore, 
saving and analysing all three fractions would appear to be a prudent course of action. 
2.2.4 Assessment of the effect of removing high abundant proteins on non-targeted 
proteins 
Although the high abundant proteins, particularly albumin, will mask less abundant 
proteins with similar elution times, depletion columns may also bind proteins in a non-
specific manner 52.  Whether bound directly to the column or indirectly through binding 
to a carrier protein e.g. albumin, lower abundant proteins may be inadvertently discarded.  
Albumin is a known carrier protein and an offshoot to proteomics – termed albuminomics 
– has emerged.  It was decided to perform a study in order to determine if any of the four 
standard proteins would be non-specifically removed either by direct adhesion to the 
column or possibly through attachment to albumin.  A mixture of HSA (20mg/mL) and 
the four protein standard mixture, (1mg/mL of each) was prepared and the mixture 
underwent the immunoaffinity protocol.  The resulting chromatographs representing 
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analysis prior to and after employing the immunoaffinity protocol, are shown in Figures 
2.4, 2.5 & 2.6. 
 
 
 
 
 
 
 
 
 
Figure 2.4: Chromatograms depicting a mixture of four commercial, standard 
proteins(1mg/mL of each) plus HSA (20mg/mL) prior to the immunodepletion protocol. 
The upper chromatogram results from UV detection while the bottom chromatogram 
represents fluorescence detection. The column employed was a Phenomenex Jupiter C18 
300Å (150 x 3.0mm, 5µm) 
It can be seen from Figure 2.4 that the HSA peak eluted at the same retention time as one 
of the standard proteins and decreased the resolution of another.   
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Figure 2.5: Chromatograms depicting the flow-through (FT) fraction for a mixture of 
four commercial, standard proteins(1mg/mL of each) plus HSA (20mg/mL) after the 
immunodepletion protocol was employed. The upper chromatogram results from UV 
detection while the lower chromatogram represenst fluorescence detection. The column 
employed was a Phenomenex Jupiter C18 300Å (150 x 3.0mm, 5µm) 
 
 
 
 
 
 
 
Figure 2.6: Chromatograms depicting the flow-through (FT) fraction for a mixture of 
four commercial, standard proteins(1mg/mL of each) plus HSA (20mg/mL) after the 
immunodepletion protocol was employed. The upper chromatogram results from UV 
detection while the lower chromatogram represenst fluorescence detection. The column 
employed was a Phenomenex Jupiter C18 300Å (150 x 3.0mm, 5µm) 
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Comparing Figures 2.5 and 2.6 it can be appreciated that removal of albumin via 
immunodepletion resulted in the almost complete removal of the standard proteins that 
eluted at a similar retention time.  Figure 2.6 confirmed albumin as the principal 
component of the bound fraction. 
2.2.5 Analysis of synovial fluid prior to immunodepletion on C18 column 
Prior to applying the immunodepletion procedure, it was decided to analyse one synovial 
fluid sample (1:25 dilution) in order to ascertain if proteins could be detected.  Figure 2.7 
shows that peaks are clearly evident and that both UV and fluorescence modes of 
detection are complimentary, with each chromatogram displaying peaks that are not 
evident in the other.   
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Figure 2.7: Chromatograms for the analysis of a synovial fluid sample (1 in 25 dilution). 
The figure displays two modes of detection-UV (upper) and fluorescence (lower).   
Chromatography conditions were the same as those for the standard protein runs. 
 
2.2.6 Analysis of whole synovial fluid representing four different pathologies prior 
to immunodepletion 
Four SF samples were chosen – each representing a different arthritic pathology – and 
analysed as before.  The fluorescence chromatograms are displayed in Figure 2.8. 
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Gout 
Figure 2.8:  Fluorescence detection chromatograms representing four arthritic diseases 
– OA, RA, CPPD and Gout.  The chromatography conditions were as before.  
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2.2.7 Analysis of synovial fluid after immunodepletion on C18 column 
A SF sample was treated with dilution buffer (1:25 dilution) and the immunoaffinity 
protocol was employed, as described in the materials and methods section.  All fractions 
were retained and analysed.  However rather surprisingly, no protein peaks were evident 
in the chromatograms.  Other SF samples were treated in the same way and analysed with 
the same.   Increased injection volumes were tried in the hope that the sensitivity would 
increase, in addition to a number of changes to the mobile phase composition.   Various 
alterations to the sample dilution stage were also tried.  The manufacturer’s standard 
operating procedure requires a 1:25 dilution of the sample with buffer.  Various smaller 
dilution factors were also investigated.  However, this resulted in some of the targeted 
proteins being found in the FT fraction.  The most likely explanation for this is that all the 
antibody binding sites were saturated so that the excess proteins were eluted from the 
column with the first “wash-through”. 
2.2.8 Analysis of synovial fluid by 2D-PAGE 
A sample of SF was sent to a colleague to confirm the protein complexity by 2D-PAGE.  
Approximately equal amounts of protein were loaded onto the gel as were loaded onto 
the HPLC.  A complex proteome was confirmed (Figure 2.9).  The protein complexity is 
comparable with that of plasma. 
  
 
 
  
 
  Figure 2.9:  A 2D-PAGE image of a synovial fluid sample (right).  For comparison 
purposes a 2D-PAGE image of plasma taken from SwissProt is also displayed (left). 
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2.2.9 Analysis of non-bound fraction employing a monolith capillary 
A sample of the non-bound fraction containing the targeted, lower abundant proteins was 
sent to a protein separation specialist in Dionex (UK) Ltd to establish if proteins could be 
detected.  Separation was performed on a monolith capillary employing UV detection.  
The resulting chromatogram is displayed in Figure 2.10. 
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Figure 2.10:  Chromatogram of a “non-bound” fraction following immunodepletion of 
the 12 most abundant proteins. Rather than employing a C18 reverse phase column, a 
capillary monolith column used.  The sample was anlaysed in Dionex (UK) Ltd in order 
to establish if there was protein present in this fraction and that these proteins could be 
detected by UV detection . 
 
2.2.10 Synovial fluid sample analysis with immunodepletion on a C4 column 
Having proposed earlier that each arthritic pathology may have its own unique protein 
signature pattern, it was decided to select a number of samples of a single disease type in 
order investigate proteins that may be characteristic of that particular disease and 
determine inter-patient variability.  Four OA samples were taken and the “non-bound” 
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fractions of each, following immunodepletion, were analysed on a C4 column.  The 
chromatograms of the non-bound fraction of each can be seen in Figure 2.11.  
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Figure 2.11: Chromatograms of the non-bound fraction obtained after the 
immunoaffinity depletion of four OA samples. Separation was performed on a                                 
Phenomenex Jupiter C4 300Å (150 x 4.5mm, 5µm) column.  The mobile phase and 
chromatographic conditions were as in the materials and methods section. 
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2.2.11 Standard peptide analysis by CE 
The same peptide mix that was used in the HPLC experiment was employed here.  
Following a good deal of method development a successful separation was obtained 
(Figure 2.12). 
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Figure 2.12: Electropherogram of a standard five-peptide mixture.  The applied voltage 
was 25kV and the background electrolyte consisted of 10mM sodium tetraborate 
containing 60ppm SDS.    
 
2.2.12 Standard protein analysis by CE 
A mixture of four protein standards was run employing the same operating conditions. A 
sample electropherogram can be seen in Figure 2.13. 
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Figure 2.13:  Electropherogram of a four model-protein mixture.  The applied voltage 
was 25kV and the background electrolyte consisted of 10mM sodium tetraborate 
containing 60ppm SDS. Detection was at 280nm employing UV.      
 
2.2.13 Analysis of synovial fluid by CE   
A SF sample was filtered through a 3kDa spin filter in order to assess the low molecular 
weight protein/peptide/ion fraction and the high molecular weight protein fraction.  An 
example of the low and high molecular weight fractions of a SF sample can be seen in 
Figure 2.14.   
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Figure 2.14:  Electropherograms for the low molecular weight (<3kDa upper) and high 
molecular weight (>3kDa lower) fractions of a synovial fluid sample after filtration 
through a 3kDa “cut-off” filter.   
 
2.2.14 Reproducibility of CE separations 
To date, CE is not regarded as a routine tool in proteomics research due to the tendency 
of proteins to strongly adsorb onto the capillary wall which causes serious peak tailing, 
low efficiency and poor reproducibility and recovery 53.  It is said that in order to make 
CE as a proteomic technique more acceptable for routine analysis, improving the 
reproducibility in terms of peak migration time and peak area is still a major issue 54.  
Capillary blockage with proteins, even over short sample sets, is another limitation.  To 
determine if any of these issues were likely to be problematic here, a synovial fluid 
sample was prepared and five successive injections were performed.  Three of resulting 
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electropherograms are displayed in Figure 2.15.  Following the third run, the current 
dropped to zero and no separation took place. 
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Figure 2.13: Electropherograms for successive injections of the same synovial fluid 
sample. The applied voltage was 25kV and the background electrolyte consisted of 10mM 
sodium tetraborate containing 60ppm SDS. Detection was at 280nm employing UV.      
 
  58 
2.3 Discussion 
2.3.1 Analysis of intact proteins in SF by HPLC 
A good separation was obtained for the five standard peptide mixture (Figure 2.2).  A 
small impurity was noted at peak number 4. 
On substituting TFA for formic acid in the mobile phase, the resolution and peak shape of 
the four standard protein mixture improved dramatically.  It is interesting to note in 
Figure 2.3 that the peak at 25mins is virtually absent in the fluorescence chromatogram.  
Only three of the twenty amino acids are naturally capable of fluorescence – tryptophan, 
tyrosine and phenylalanine – due to the fact that these are the only amino acids to possess 
aromatic side chains.  Tryptophan is the most sensitive UV-absorbing amino acid, 
followed by tyrosine, while phenylalanine is the least 55. The fluorescence of tryptophan 
is about ten times that of tyrosine, while that of phenylalanine is negligible due to its low 
absorbtivity and quantum efficiency.  However, unlike absorption measurements, the 
fluorescence of proteins is not linearly proportional to the number of aromatic residues 55.  
This would imply that more that one mode of detection is beneficial in complex sample 
analysis. 
On assessing the specificity of the immunoaffinity it was found that some BSA remained 
in the bound fraction.  This may be the effect of non-specific binding to the beads.  It was 
concluded that the analysis of both bound and unbound fractions is necessary. 
Figures 2.4, 2.5 & 2.6 demonstrate the effect of removing a high abundant protein like 
albumin from other less abundant proteins.  The first point to note here is that all the HSA 
(retention time ~ 63 minutes) was successfully removed (Figure 2.5).  However, 
comparing Figure 2.4 and 2.5, it may be argued that some of standard proteins close in 
retention time to HSA (protein standard number 4 ~ 65 minutes) were also removed.  A 
possible explanation for this phenomenon, is that these proteins either remained non-
specifically bound on the beads, or were attached to albumin.  Gundry et al. 56 in their 
study of an albumin-enriched fraction of human serum, found 35 proteins, of which 24 
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were intact, were associated with albumin and included both known high and low 
abundance proteins.  This confirms the necessity to analyse all fractions. 
This importance of more that one mode of detection was again highlighted in the analysis 
of synovial fluid prior to immunodepletion (Figure 2.7).  Here it is clear that both UV-Vis 
and fluorescence detection yield chromatograms with entirely different features.  Both 
modes of detection display unique information.  This could be extremely important for 
any ‘pattern recognition’ experiment where positive identification by MS may not be 
feasible or even required. 
Encouraged by these initial results, it was decided to analyse whole synovial fluid 
representing a number of arthritic pathologies – OA, RA, CPPD and Gout.  Inspection of 
Figure 2.8 clearly highlights striking differences between each of the four pathologies in 
the 0 – 35 minute window.  The gout sample has a markedly different protein profile to 
the other three diseases. The OA sample also displays unique features at retention times 
of 20 and 25 minutes.  Collection of fractions at these times and analysis by MS may 
prove fruitful.  However, from 35 minutes on, a large and relatively featureless ‘mass’ is 
evident.  It is hypothesised that a highly complex series of proteins are eluting here.  In 
order to confirm this, a colleague performed a 2D-PAGE analysis of synovial fluid 
(Figure 2.9).  This revealed that synovial fluid is plasma-like in terms of protein 
complexity and established that in order to unearth lower abundant species, removal of 
high abundant protein is necessary. 
Following immunodepletion of the most abundant proteins, all fractions were analysed.  
Disappointingly, no peaks were observed in the HPLC chromatograms.  Suspecting a 
sensitivity issue, the injection volumes were increased.  In addition, changes to the 
sample dilution stage were also implemented.  The manufacturer’s standard operating 
procedure recommends a 1:25 dilution of the sample with buffer.  Various smaller 
dilution factors were investigated.  However, this resulted in some of the targeted 
proteins being found in the non-bound fraction.  A possible explanation for this is that all 
the antibody binding sites were occupied so that the excess proteins were eluted from the 
column with the first wash-through.   
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Two possible reasons for this lack of chromatographic information were postulated; 
1. The interesting peaks found in Figure 2.8 were captured on the immunoaffinity 
column and that the protein concentration of the unbound fraction is so low as to 
be undetected by both modes of detection.  This would signify insufficient 
sensitivity. 
2. There was protein adhesion to the head of the C18 column. 
To test the insufficient sensitivity hypothesis, a sample of the unbound fraction was sent 
to Dionex (UK) Ltd. for analysis by HPLC employing a capillary monolith column and 
UV detection.  A sample chromatogram may be seen in Figure 2.10.  There are clearly 
peaks evident, thus nullifying the lack of sensitivity hypothesis.  
Another reason for the scarcity of peaks in the chromatograms may be that the C18 
column is too hydrophobic and that there is a build up of proteinaceous matter on the 
head of the column.  Therefore a C4 column was procured and the experiments repeated.    
Figure 2.11 displays the chromatograms of the “non-bound” fractions from four different 
OA patients and peaks are evident.  The C4 is less hydrophobic and exhibits less affinity 
for proteins.  On close inspection of the four chromatograms in Figure 2.11, it can be 
seen that patient samples 3 and 4 are remarkably similar with some inter-patient 
variability within 0-10 minutes and 36-40 minutes.  There are a number of peaks that 
share the same retention times.  Other peaks are upregulated e.g. the peak at 56 minutes 
in sample 1. 
These initial studies we deemed encouraging and the next phase of the project was to 
dramatically increase the sample cohort and generate a large volume of data on all the 
various disease subtypes in order to afford a meaningful comparison that would highlight 
both similarities and differences in the pattern profiles.  The final stage was to identify 
particular proteins of interest by mass spectrometry. 
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2.3.2 Column Issues 
As more SF samples were injected, the backpressure of the HPLC system steadily 
increased.  Checking through the instrument logs revealed that when the C4 column was 
first installed, the back pressure was around 500psi.  After a number repeated injections 
with SF, the backpressure was over 3500psi.  Various column cleaning/regenerating 
protocols were sought and tried.  Back-flushing with all of these made no impact on 
column regeneration.  Dowell et al. 3suggested that due to the inherent complexity of 
their structures, proteins exhibit very unpredictable interactions with the stationary phase 
in the column.  The primary mode of separation in RP-HPLC is due to the partitioning 
effect, whereby analytes constantly partition themselves between the stationary and 
mobile phases as they progress down the column.  By contract, proteins stick to the 
stationary phase due to hydrophobic interactions – the greater the number of exposed 
hydrophobic residues, the stronger the adhesion to the column.  Wang et al. 13 compared 
C4 and C18 columns for protein separations using the same model proteins that were used 
in this experiment and concluded that they experienced protein loss due to hydrophobic 
interactions with the C18 column.  No such loss was found with the C4 column.  This 
study would appear to challenge that assertion when complex biological samples are 
being analysed.  It would appear that the separation of intact proteins in a complex 
biological matrix such as SF could not be achieved by RP-HPLC without regular 
replacement of expensive columns.  This was disappointing as there was great potential 
for intact protein pattern profiling in SF. 
2.3.3 Analysis of intact proteins in SF by Capillary Electrophoresis (CE) 
It was then decided to continue this area of research by CE.  SF analysis by CE to date 
has been largely being carried by Grimshaw and co-workers57-59 .  These three studies 
involved the quantitative analysis of hyaluronic acid in SF, a qualitative comparison 
between control, OA and RA samples for non-protein moieties e.g. uric acid, and finally 
the identification of α1- acid glycoprotein.  These components of interest were positively 
identified through a series of spiking experiments. Inspection of the electropherograms 
generated in these studies, show these analytes eluted first, followed by a large protein 
mass.  No further work on this broad protein peak was carried out.  The authors 
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acknowledged that attaining reproducible migration times was extremely difficult during 
the electrophoresis of SF samples.  They attribute protein adhesion to the capillary wall 
as the primary reason for this.  In order to minimise protein adhesion, sodium 
dodecylsulphate (SDS) was included in a high pH phosphate background electrolyte 
(BGE) and micellar electro kinetic capillary chromatography (MECC) was employed as 
the mode of separation.  SDS is a cationic surfactant that forms micelles, with which the 
proteins interact and thus effect a separation.  However, a major drawback with the use of 
surfactants and other additives to the BGE is that coupling to mass spectrometry is not 
possible 60.  The technical difficulties of coupling CE to MS for proteome analysis remain 
a challenge 61 . 
As a starting point, Grinshaws’s work was repeated and similar electropherograms were 
obtained.  However as the separation of the protein agglomerate was the principal aim of 
this project, a new CE method was required.  As in the HPLC experiment, standard 
model peptides and proteins were used for method development.  Satisfactory resolution 
and peak shape were obtained (Figures 2.12 and 2.13).  
Prior to performing the immunodepletion protocol and then analysing bound and 
unbound fractions, SF was subdivided based on molecular weight.  Samples were filtered 
through a 3kDa filter and both molecular weight categories were separately analysed.  
Figure 2.14 displays the electropherograms for each fraction.  As can be seen, for the 
<3kDa subset, good separation was obtained and the potential for pattern profiling 
between pathologies is evident.  The >3kDa fraction would require further method 
optimization before useful information could be extracted.   
However, prior to expending time and resources on this, it was deemed prudent to assess 
the reproducibility of CE in separating biological fluids.  To date, CE is not regarded as a 
routine tool in proteomics research due to the tendency of proteins to strongly adsorb 
onto the capillary wall which caused serious peak tailing, low efficiency and poor 
reproducibility and recovery 53.  It is said that in order to make CE as a proteomic 
technique more acceptable for routine analysis, improving the reproducibility in terms of 
peak migration time and peak area is still a major issue 54.  Capillary blockage with 
  63 
proteins, even over short sample sets, is another limitation.  To determine if any of these 
short-comings are likely to become an issue here, a synovial fluid sample was prepared 
and five successive injections were performed.  The electropherograms are displayed in 
Figure 2.15.  Examination of the electropherograms shows that the migration times are 
getting shorter with each successive run.  More importantly though, is that this was a five 
injection run.  After the third injection the current dropped from approximately 80µA to 
zero.  Therefore no electrophoretic separation was possible.  Up until that point, single 
injections were performed with relatively simple model proteins and peptides.  On 
turning to complex matrices like SF, it was likely that protein adhesion to the capillary 
wall became a significant issue.  In a quite detailed study of protein attachment onto silica 
surfaces, Stutz 62  distinguishes between two classes of proteins, which he termed “hard” 
and “soft”.  Hard proteins, such as cytochrome C and ribonuclease A, have a rigid 
structure and undergo little or no conformational change at the capillary interface.  On the 
contrary, what he termed soft proteins e.g. HSA, BSA, Hb and IgG, are prone to 
unfolding once attached to the capillary surface.  As the proteins unfold, there are more 
positively charged sites available to electro-statically attach to the negatively charged 
capillary wall.  As the number of attachment sites increase, it becomes ever increasingly 
more difficult to remove the proteinaceous matter from the capillary inner wall.  This 
exasperates the problem because the adsorption of further proteins is influenced by the 
proteins already adsorbed onto the capillary wall.  Soon the proteins interact with each 
other forming what are termed “protein clusters” and “multilayer formations”. 
It is interesting to note that all the literature encountered in this study employed the use of 
model proteins to demonstrate the benefits of various buffers, wall coatings etc.  Indeed, 
the two “hard” proteins cited by Stutz, i.e. cytochrome C and ribonuclease A, were two 
of the four model proteins employed in this study.  These were used in many different 
studies over relatively long time periods with no adverse consequences.  However, on the 
analysis of SF samples which contain a high content of what Stutz termed “soft” 
proteins, capillary deterioration occurred after a small number of injections were 
performed.      
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2.4 Conclusions       
The aim of this project was to mine the proteome of synovial fluid for potential 
biomarkers of OA.  This necessitated the targeted removal of the 12 most abundant 
proteins and analysis of the remaining depleted fraction.  Biomarker discovery would 
be achieved by comparing the intact protein profiles of the various arthritic diseases 
and noting interesting differences.  Identification of promising moieties would then be 
carried out by MS.  The merit to this study would be to offset some of the limitations 
inherent in traditional proteomic methodologies e.g. gel electrophoresis and bottom-
up, shotgun proteomics, in terms of lengthy sample preparation times and the 
potential to overlook very low abundant, interesting species.  
The HPLC study displayed real potential in the differential characterisation of SF.  
Notable differences were observed between various disease states, and collection and 
identification of peaks of interest could be achieved.  Disappointingly though, the 
potentially high attrition rate of columns was cost prohibitive.  Investigation into the 
use of capillary monolith columns for intact protein analysis should merit further 
investigation. 
Interesting separations were also achieved with CE.  However reproducibility and 
extremely short capillary lifetimes were an issue and rendered this mode of analysis 
unattractive.  In addition CE-MS is still in its infancy and there was little chance in 
taking advantage of this technique for this project. 
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Chapter 3 
 
Isolation and characterisation of microvesicles in 
synovial fluid  
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3.0 Introduction 
3.0.1 Microvesicle nomenclature 
 
A relatively recent and interesting line of research into small vesicles s from most cell 
types, has contributed to an increase in understanding in signalling and molecular transfer 
mechanisms between cells 1.  Cell-to-cell communication is required to ensure a 
coordinated functionality among different cell types within the tissue.  Modes of 
communication include (i) secretion of soluble species e.g. cytokines and hormones 2, (ii) 
cell-to-cell interaction via adhesion molecules which enable ligand-receptor mediated 
exchange of surface molecules e.g. the activation of T cells by antigen-presenting cells 
i.e. immunological synapse and (iii) the exchange of both membrane and cytosolic 
components (including organelles) via nanotubules 3, 4. In addition to these 
communication lines, cells may transfer information via membrane-bound fragments 
which are generically termed microvesicles (MVs).  MVs have been known to exist for 
quite some time.  However, their role in cell-to-cell communication was not initially 
realised.  It was thought that they were simple inert cell debris or plasma membrane 
turnover 5 or even artefacts 6.  It was De Broe et al. 7 who first suggested that these 
plasma membrane fragments result from a specific, biological process and also, that the 
enzyme composition of the vesicle membrane maintained the same ratio as that of the 
parent cell. 
Subsequently, it was realised that the term microvesicle does not represent one, unique 
homogeneous entity.  Indeed, the nomenclature in the field of membrane-bound small 
fragments remains controversial and confused.  Terms such as microvesicle, 
microparticles (MPs), exosomes, ectosomes, shedding vesicles and even apoptotic blebs 
are often used interchangeably in the literature.  In their review paper, Simpson et al. 8 
observe that these entities share many similarities.  For example, exosomes, apoptotic 
blebs and MPs exhibit the same membrane topology, i.e. the cytosolic side of the lipid 
bilayer is inside the vesicle while the luminal portion of the membrane is exposed with 
bound phosphatidylserine.  The authors state that in the case of MPs and MVs, the variety 
of isolation schemes employed, and a lack of biochemical and biophysical validation 
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protocols leads one to ask if these vesicles represent discreet entities with specialised 
functions or are merely different sizes of the same thing.  Further, the term MVs is often 
used to describe different species of vesicle, while at other times as a generic term for 
MPs and exosomes, thus using the terms interchangeably.  Sadallah et al. 9 make no 
distinction between ectosomes and shedding vesicles.  Johnstone 10 cites some examples 
of studies which produced conflicting results in the analysis of vesicles derived from 
tumour cells.  It was concluded that a lack of information and a precise definition of 
terms may lie at the core of the discrepancy in the literature.  The author further adds that 
a single cell may produce different populations of vesicles and that most investigators 
have harvested these as if they represented a single population of identical vesicles.  
Cocucci et al. 6 define a number of terms which may be useful in clarifying all 
subsequent discussion in this project, and is produced in Table 3.1. 
 
 
        
 
 
 
 
 
 
Table 3.1: A list of various micro/nano vesicles and their definitions as proposed by 6   
With a defined vocabulary in place, a more detailed examination of micro/nano vesicles 
will follow.  Regardless the vesicle type or its origin, there are but two distinct processes 
of vesicle release from cells.  In broad terms these are; 
Micro/Nano Vesicle Terminology
Ectosome: term used to indicate shedding vesicles of neutrophils and 
monocytes.
Endosome: small vesicle accumulated within MVBs and discharged upon their
exocytosis.
Enlargesome: a non-secretory exocytic vesicle.
Endosomal sorting complexes required for transport (ESCRETs):
multimolecular systems involved in the sorting of MVB vesicles.
Exosome: a vesicle contained in MVBs.
Microparticle: term used to define shedding vesicles of platelets and 
monocytes.
Microvesicle: term used to indicate exosomes and shedding vesicles together.
Multivesicular bodies (MVBs): intracellular organelles of the endosomal 
system that contain exosomes.  MVBs can fuse with the plasma membrane, 
releasing exosomes from the cell.
Shedding vesicle: a vesicle that buds directly from the plasma membrane into 
the extracellular space.
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1. Vesicles that are derived from the endosomal pathway which following 
subsequent fusion with the plasma membrane, are exocytosed as exosomes 11 . 
2. Vesicles that originate by direct budding of the cell plasma membrane 6.  
3.0.2 Microvesicle variety 
 
A concern in the study of MVs lies in distinguishing one vesicle type from another.  As 
mentioned above, the terminology and vocabulary employed does not enjoy universal 
agreement.  Vesicle populations recovered from either cell incubation media or biofluids 
are inevitably of mixed origin.  Théry et al.12 provide a very useful table summarising the 
physicochemical characteristics of different types of secreted vesicle.  This is shown in 
Table 3.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.2:A summary of the physicochemical properties of secreted vesicles.  Various 
differences and similarities are evident. ND=not determined. TNFRI=Tumour necrosis 
factor receptor 1.   Information adapted from 12. 
Feature Exosomes Microvesicles Ectosomes Membrane 
Particles
Exosome-like 
Vesicles
Apoptopic
Vesicles
Size 50-100nm 100-1,000nm 50-200nm 50-80nm 20-50nm 50-500nm
Density in 
Sucrose 1.13-1.19g/mL ND ND
1.04-
1.07g/mL 1.1g/mL 1.16-1.28g/mL
Appearance by 
electron 
microscopy
Cup shape
Irregular shape 
and electron-
dense
Bilamellar and 
round Round
Irregular 
shape Heterogeneous
Sedimentation 100,000g 10,000g 160,000-200,000g 100,000-200,000g 175,000g
1,200g, 
10,000g or 
100,000g
Lipid 
Composition
Enriched in:      
Cholesterol, 
Sphingomyelin
, Ceramide
Contains lipid 
rafts; exposes 
phosphatidyls
erine
Exposes 
Phosphatidyl
serine
Enriched in:      
Cholesterol, 
Diacylglycerol
exposes 
phosphatidylserine
ND
Do not 
contain lipid 
rafts
ND
Main protein 
markers
Tetraspanins
(CD63 & 
CD9)         
Alix
Tsg101
Integrins, 
selectins and 
CD40 ligand
CR1 and 
proteolytic
enzymes; no CD63
CD133; no 
CD63 TNFRI Histones
Intracellular 
origin
Internal 
compartments 
(endosomes)
Plasma 
membrane Plasma membrane
Plasma 
membrane
Internal 
compartments ND
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The author however, cautions that all vesicle preparations are heterogeneous with 
different protocols allowing enrichment of one type over another.  Also, it was stressed 
that electron microscopy is only an indication of vesicle type and should not be employed 
to define vesicle types.  Cocucci et al. 6 advise that presently the most promising studies 
are those based on immunoprecipitation, using antibodies against antigens exposed at the 
vesicle surface.  Recently Lee et al. 13 listed differentially expressed markers between 
ectosomes and exosomes.  A modified list can be seen in Table 3.3. 
Marker Function
Tissue factor (TF) Coagulation and angiogenesis
Flotillin-1 Lipid raft molecule
PSGL1 P selectin glycoprotein ligand 1 - cell adhesion
β1 integrin Cell adhesion molecule
IL-1β Cytokine involved in inflammation
MMP2 Matrix metalloproteinase involved in degradation of ECM
MMP9 Matrix metalloproteinase involved in degradation of ECM
EMMPRIN ECM metalloproteinase inducer
ARF6 Remodelling of membrane lipids and actin
MUC1 Mucin associated with pathogen protection
CB1 Cannabinoid G protein coupled receptor
Lineage Markers CD61; glycophorin A; CD66e; CD14; CD62e
CD9 Tetraspanin - cell surface glycoprotein
CD37 Tetraspanin - cell surface glycoprotein
CD63 Tetraspanin - cell surface glycoprotein
CS81 Tetraspanin - cell surface glycoprotein
CD106 Tetraspanin - cell surface glycoprotein
Tspan8 Tetraspanin - cell surface glycoprotein
HSP70 Heat shock protein
HSP90 Heat shock protein
Caveolin-1 Scaffolding protein of lipid rafts
Rab-5a GTPase involves in endocytosis
Rab-5b GTPase involves in endocytosis
PLP Proteolipid protein
Alix Protein involved in late endocytosis
TSAP6 P53 transcriptional target involved in exocytosis
Tsg101 Protein involved in ubiquitination-dependent endocytosis
MHC ClassI/II Immune recognition/regulation
Flotillin-1 Lipid raft molecule
Ectosome/ Shedding Vesicle
Exosomes
 
Table 3.3: Molecular markers believed to be associated with ectosomes/shedding 
vesicles and exosomes 
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Recently, György et al. 14 published a paper cautioning against interfering species in the 
isolation of MVs.  It was claimed that after comprehensive characterisation of MVs by 
electron microscopy, atomic force microscopy, dynamic light scattering and flow 
cytometry, protein complexes, especially insoluble immune complexes (IC) overlap in 
biophysical properties (size, light scattering and sedimentation) with MVs.  The effect of 
this overlap is that purification and quantification of MVs is compromised as both ICs 
and free immunoglobulins may co-precipitate in the pellet.  This is especially true in the 
case where ICs are common, including autoimmune diseases, hematologic disorders, 
infections and cancer.  They conclude that “Results obtained without MP-IC 
discrimination should be interpreted cautiously.  This is also underlined by a previous 
work in which RA SF MPs were reported to carry IgG, IgM, complement components, 
serum amyloid P and C-reactive protein”.  A study by Mayr et al. 15 on microparticles, 
found that immunoglobulins were not surface labelled with the fluorescent tag CyDyes 
and suggested that these species might be entrapped within the vesicles.  In light of these 
findings it may be important to establish the origin of any immunoglobulins present.  Are 
they (i) free species within the matrix, (ii) associated on the microvesicle surface or (iii) 
entrapped within the vesicle?  Could it be that they are present in all three locations? 
 
Other potential “contaminants” in any MV-isolation protocol are high-density 
lipoproteins (HDLs).  This is because due to considerable overlapping density ranges, 
HDLs will be potentially present if MV isolation is based on differential centrifugation or 
any variation thereof.  From above, exosomes have a density range between 1.13-
1.19g/mL, while HDLs fall within the 1.063-1.210g/mL range 16.     
 
MVs are therefore, an assorted population of membrane-bound entities that differ in 
cellular origin, size and cargo composition and are shed in both physiological and 
pathological conditions 9.  Ratajczak and co-workers 17 state that MVs are released by 
cells upon activation by soluble agonists, by physical or chemical stress e.g. oxidative 
stress and hypoxia and also by shear stress.  
It now follows to describe the biogenesis of the vesicles produced by these pathways. 
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3.0.3 Microvesicle Biogenesis 
3.0.3.1 Exosomes - Microvesicles derived from the endosomal pathway 
 
Exosomes are saucer-shaped vesicles, 30-100nm in diameter and are bound by a lipid 
bilayer 18.  In general, these vesicles have a density ranging from 1.13g/mL (for B cell 
derived) to 1.19g/mL (for intestinal derived) 19.  They are released into the extracellular 
matrix (ECM) upon fusion of multivesicular bodies (MVBs) with the cell surface.  MVBs 
contain intralumenal vesicles (ILVs) that are released during exocytosis.  These released 
or exocytosed ILVs are then termed exosomes.  To date knowledge on the assembly 
mechanism of exosomes is still not complete 1.  However, what is known for certain is 
that exosomes are a product of the endosomal pathway. 
 
Electrographs displaying the exocytosis of exosomes may be seen in Figure 3.1.  In 
Figure 3.1a the MVBs from the endosomal pathway carrying ILVs can be seen 
approaching the cellular membrane.   Following fusion of the MVB with the plasma 
membrane, The ILVs undergo exocytosis and are released into the ECM as exosomes 
(Figure 3.1B).   
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Figure 3.1: Colloidal gold electron micrographs of maturing sheep reticulocyte 
exosomes at two different times.  In (A) 18 hours post incubation with transferrin 
receptor mAb.  The black arrow indicates the point of contact of the MVB with the 
plasma membrane. After 36 hours(B) the MVB cargo is shed into the ECM as exosomes.  
Picture taken from8  
 
3.0.3.2 Biogenesis of exosomes 
 
Exosomes originate from the cell surface and their role is to ferry unneeded, damaged or 
dangerous plasma membrane protein cargo - either internalised from the cell membrane 
or through the Golgi network - to the lysosome for destruction 20 21 or to the cell surface 
for release as exosomes.  Johnstone et al. 22 initially coined the term exosome for vesicles 
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produced by intracellular budding in the endosome while Harding et al. 23 first proposed 
a model for the secretion of entrapped vesicles within the endosome at the cell surface.  
This model was confirmed by Pan et al. 24.  Using immunoelectron microscopy, both 
groups studied the fate of an internalised anti-transferrin receptor antibody in 
reticulocytes.  They also provided a chronological sequence of events culminating in the 
release of exosomes at the cell surface.  This may be seen in Figure 3.2. 
 
 
Figure 3.2:  The chronological pathway for the formation of exosomes as proposed by 
Harding 23 and Pan 24.  The pathway followed by internalised anti-transferrin-receptor 
antibody is outlined.  Invagination or internal budding of the late endosome to for a MVB 
can be seen before final release to the ECM as exosomes. Image taken from 25  
 
 
An overall schematic representation of the endocytic pathway outlining the fate of 
proteins can be seen in Figure 3.3. 
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Figure 3.3: A schematic diagram of the endosomal pathway.  Proteins (in red) are 
entrapped inside the endosome.  From there two destination routes are possible – 
destruction by fusion with a lysosome or exocytosis via fusion with the plasma membrane 
as exosomes. Diagram is taken from 26. 
 
 
From Figure 3.3 it may be seen that proteins which are delivered to the endosome 
become engulfed in vesicles which are generated by internal budding or invagination of 
the endosomal membrane to form ILVs.  This MVB is then destined to fuse with the 
lysosome or with the plasma membrane.  It is still not known how a decision at the 
cellular level is made determining which of the two routes the MVB embarks upon.     
 
Though the presence of MVBs is now widely accepted, there are still significant gaps in 
the understanding of MVB biogenesis, in particular the budding or invagination 
mechanism and the protein cargo selection process 27. 
 
Relating to the sorting of cargo, Katzmann et al. 28 proposed that protein sorting into 
MVBs involves monoubiquitination of endosomal proteins, while van Niel et al. 29 in 
their study of dendritic cells suggested that oligoubiquitination may also be a sorting 
mechanism for trafficking proteins into MVBs.  It was proposed that oligoubiquitination 
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increases the cargo sorting efficiency.  Finally, other studies 30, 31 provide evidence that 
proteins need not be ubiquitin labelled for inclusion in the MVB. 
Hurley et al. 32 outline four membrane budding models which may be seen labelled A-D 
in Figure 3.4. 
 
 
Figure 3.4: Modes of endosomal membrane budding within the cell. Four separate 
mechanisms are known to exist, labelled A ,B, C and D.   Diagram taken from 32 
 
3.0.3.2.1 ESCRT Dependant Membrane Budding 
A key promoter for protein inclusion in MVBs is the hetero-oligomeric protein complex, 
endosomal sorting complex required for transport (ESCRT) 27.  ESCRT-0, -I, -II and –III 
are believed to recognise ubiquitinated proteins and ensure their inclusion in MVBs.  It is 
believed that once the cargo is delivered to the vesicle, the ESCRT complex dissociates 
from the membrane and is recycled for further cargo transport.  Interestingly, Simpson et 
al. 8 include the ESCRT-I,-II and -III complexes in their list of proteins possessed by all 
exosomes.  This conflicting data again highlights a lack of consensus within this current 
area of research. 
The endosomal pathway is believed to begin with the presence of the lipid, 
phosphatidylinositol 3-phosphate (Pl(3)P) plus ubiquitin-labelled species on the surface 
  82 
of the early endosome.  This may be seen in the pathway labelled B in Figure 3.4.  The 
Pl(3)P plus the ubiquitinated cargo form a docking site on the endosomal surface for the 
ESCRT complexes.  The membrane budding process is quite complex and the fine detail 
is still not fully understood.  Briefly ESCRT-0, which contains five ubiquitin-binding 
domains, binds to ubiquitinated cargo on the endosomal surface 32.  This initiates the 
recruitment of ESCRT –I, -II and –III 33, 34.  The ESCRT–I and –II complexes are 
believed to drive the budding process while the ESCRT-III unit cleaves the bud neck and 
so completes the formation of the ILV.  It is hypothesised that as the ESCRT complexes 
are localised at the bud neck, budding proceeds away from the cytosol without the 
ESCRT complex being included in the ILV.  Again, this would appear to conflict with 
Simpson et al. 8 who found ESCRT moieties engulfed within exosomes. 
 
3.0.3.2.2 Lipid Lysobisphosphatidic Acid (LBPA) Dependant Membrane Budding 
 
Matsuo et al. 35 proposed an alternative invagination model specific to the late endosomal 
pathway.  They note that the late endosome contains approximately 15% LBPA and 
declare that this lipid is not present anywhere else in the cell.  The authors conclude that 
LBPA is involved in the trafficking of proteins and lipids through late endosomes.  
Furthermore, they proposed that LBPA in conjunction with the Alix protein in an acid 
environment also produces ILVs.  Alix is one of the proteins that are part of the 
endosomal machinery responsible for sorting proteins along the endocytic/degradative 
pathway 27.  This model is also ESCRT-dependent.  Their studies have also shown that 
the absence of either LBPA or Alix disrupts the production of ILVs.  This process is 
labelled A in Figure 3.4. 
 
3.0.3.2.3 ESCRT and Ubiquitin Independent Membrane Budding 
 
MVBs are also formed within lysosome-related organelles e.g. melanosomes, without 
requiring the ESCRT complex or ubiquitin labelling.  Raposo et al. 36  studied the sorting 
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of the glycoprotein Pmel17 into ILVs in an ESCRT-independent reaction.  This can be 
seen as pathway C in Figure 3.4. 
3.0.3.2.4 Spingomyelinase Dependent Membrane Budding 
 
Trajkovic et al. 37 discovered a further ESCRT-independent budding mechanism.  Here, 
ILVs are produced by the hydrolysis of sphingomyelin by shingomyelinase to produce 
ceramide.  However, it is not clear which properties of ceramide favour the budding 
mechanism.  What is known though, is that exosomes produced by this mechanism are 
highly enriched in the tetraspanin CD63.  CD63 is an exosomal marker (Tables 3.2 and 
3.3) and will be used to confirm the presence of exosomes.   This mechanism is shown as 
pathway D in Figure 3.4. 
 
3.0.3.3 Biogenesis of ectosomes or shedding vesicles 
 
Vesicles released directly from the cell surface are termed ectosomes or shedding 
microvesicles 6.  Stein and Luzio 38 first coined the term ‘ectocytosis’ for the release of 
vesicles from the cell membrane,  though these microparticles were first reported by Wolf 
et al. in 1967 39.  It was noticed that human plasma platelets shed particles that were 
small, membrane-coated vesicles.  Hence the term “platelet dust” was coined.  Further 
studies demonstrated that like the cells from which they were derived, these particles 
have a role in clotting and are not inert.  Subsequently it was discovered that 
microparticles can be released from multiple cell types e.g. macrophages, monocytes, B 
and T cells, neutrophils, erythrocytes, endothelial cells, vascular smooth muscle cells, 
epithelial cells and tumour cell lines 40.    
The cell membrane is composed of a lipid bilayer.  However, each of the two leaves is 
quite different in terms of lipid composition i.e. there is lipid heterogeneity.  The inner 
(cytosolic) membrane contains phosphatidylserine (PS) and phosphatidylethanolamine 
(PE), while the outer leaf is enriched in phosphatidylcholine and sphingomyelin.  This 
asymmetric lipid composition of the cell membrane is maintained and controlled by three 
enzymes – flippase, floppase and scramblase 41.  In response to cell stimulation there is a 
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sustained increase in Ca2+ concentration in the cytoplasm and this is thought to lead to a 
breakdown in the asymmetric lipid composition of the outer membrane 42.  A notable 
feature of this remodelling is the surface exposure of the inner PS moiety.  This is 
followed by MP release into the ECM by a Ca2+-dependent proteolysis of the cellular 
membrane. These released vesicles are termed ectosomes or shedding vesicles.  A 
schematic diagram of such vesicles may be seen in Figure 3.5.  This representation does 
not display all the cargo species present in these vesicles.   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: A schematic representation of an ectosome/shedding vesicle released from 
the outer membrane of a stimulated cell. Different classes of protein and lipid effectors 
are displayed.   Diagram taken from 42  
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Sadallah et al. 9 in their recent review, state that although the shedding process is the 
same in all cell types, the stimuli inducing the formation of ectosomes can differ from 
one cell type to another.  They go on to list vesicle-release triggers for various cells. 
3.0.4 Vesicle cargo composition 
3.0.4.1 Exosome cargo composition 
 
The membrane and internal composition of MVs depends on (i) the original cell type and 
(ii) the mechanism of MV release 1.  In the case of exosomes, the cargo is believed to 
consist of entities found in the cytoplasm and in the plasma membrane.  They do not 
contain proteins belonging to the nucleus, mitochondria, Golgi or ER 43.  A review of the 
protein composition of exosomes classified by protein function and their location was 
provided by Schorey et al. 19.  A schematic summary is reproduced in Figure 3.6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6:  A schematic diagram of an exosome displaying protein composition by 
name, function (in red) and location (i.e. membrane bound or soluble). Diagram taken 
from 19  
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Simpson et al. 8 in their recent review provide two tables listing proteins found in 
exosomes.  In the first table (reproduced here to aid discussion, as Table 3.4) is a list of 
proteins reported to be found in all exosomes studied to date, while the second table 
provides a list of cell-type specific exosome proteins.  Included in this list are some 
biofluids, though synovial fluid is not included.  
 
Protein Category Description 
1 Antigen-presentation HLA class 1 histocompatability antigen 
  
 
2 Cell Adhesion Lactadherin 
  Thrombospondin-1 
  Integrins 
  Claudin-1 
  
 
3 Cell structure and motility Actins 
  α-Actinin-4 
  Cofilin-1 
  Erzin 
  Moesin 
  Myosin 
  Radixin 
  Tublins 
  
 
4 Heat shock proteins & chaperones Heat shock cognate 71kDa protein 
  Heat shock protein hsp90β 
  T-complex protein 1 
  
 
5 Metabolic enzymes α-Enolase 
  Fatty acid synthase 
  Glyceraldehyde-3-phosphate dehydrogenase 
  Phosphoglycerate kinase 1 
  Phosphoglycerate mutase 1 
  Pyruvate kinase isozymes M1/M2 
  
 
6 MVB biogenesis Alix 
  ESCRT I complex 
  Tumour susceptibility gene 101 protein 
  Vacuolar sorting protein 28 
  Vacuolar sorting-associated protein 37 
  ESCRT II complex 
  Vacuolar sorting-associated protein 25 
  Vacuolar sorting-associated protein 36 
  Vacuolar sorting protein SNF8 
  ESCRT III complex 
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  Charged MVB proteins 
  
 
7 Signaling proteins 14-3-3 Proteins 
  GTPase Hras 
  Rho GDP-dissociation inhibitor 1 
  
Rho-related GTP-binding protein RhoC 
precurser 
  Ras-related protein Rap-1b 
  Ras-related protein Rap-2b 
  Ras-related protein R-Ras2 
  Ras GTPase-activating-like protein IQGAP1 
  Syntenin-1 
  Transforming protein RhoA 
  
Guanine nucleotide-binding protein (G 
proteins) 
  
 
8 Tetraspanins CD9 antigen 
  CD63 antigen 
  CD81 antigen 
  CD82 antigen 
  
 
9 
Transcription and protein 
synthesis Histones 
  Ribosomal proteins 
  Ubiquitin 
  Elongation factor 1-α 1 
  
 
10 Trafficking and membrane fusion Annexins 
  ADP-ribosylation factor 
  AP-2 complex subunit α-1 
  AP-2 complex subunit β-1 
  Clatherin heavy chain 1 
  Rab GDP dissociation inhibitor β 
  Synaptosomal-associated protein 23 
  Syntaxin-3 
Table 3.4: List of proteins commonly found in all exosomes studied to date. Adapted from 
8
 
 
3.0.4.2 Ectosome/Shedding vesicle cargo composition 
 
Vesicles originating from the plasma membrane are now thought to contain some unique 
proteins and like exosomes, their cargo content reflects their cellular origin.  Figure 3.5 
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displays the protein and lipid classes that are thought to comprise ectosomal cargo.  For 
example, β1 integrin is concentrated in the membrane of all shedding vesicles 
investigated to date, while vesicles shed from tumors and neutrophils are enriched with 
metalloproteinases and other proteolytic enzymes 6.  The latter are believed to function in 
the digestion of the ECM necessary for the progress of inflammation and caner growth.  
Del Conde et al. 44 discovered that the vesicles shed from platelets also contain various 
integrins necessary for coagulation e.g. the glycoproteins GPIb and GPIIb-IIIa.   
 
3.0.5 Microvesicle function 
 
It has already been mentioned that cellular vesicle release is one mode of communication 
between cells.  Figure 3.7 outlines the mechanisms involved in vesicle-mediated cell-to-
cell communication. 
 
 
 
 
 
 
 
 
Figure 3.7: Four mechanisms by which microvesicles can interact with target cells.  
Diagram is taken from 5 – MVs act as (a) signaling complexes, (b) receptor transferors, 
(c) delivery agents and (d) mediators in the transfer of genetic information between cells.  
Camussi et al. 5 provide detailed examples of each mechanism.  In brief, MV function 
may influence the activity of target cells in four ways; 
(a) Act as signaling complexes by directly stimulating target cells – e.g. in 
coagulation and clotting factors 
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(b) Act as receptor transferors between cells – e.g. (i) antigen presentation to T-cells, 
(ii) promotion of pro-adhesion properties through the transfer of CD41, (iii) removal 
of harmful molecules such as Fas or complement attack complexes and (iv) spreading 
infective agents such as HIV type I 
(c) Act as delivery agents of proteins between cells – e.g. apoptosis induction 
molecules such as caspase-1 or the delivery of molecules that contribute to the 
destruction of certain infective agents e.g. prions.  In addition, they act as vehicles for 
soluble (e.g. IL-1β) and insoluble (e.g. membrane antigens, transmembrane receptors 
and transmembrane ligands) proteins.    
(d) Act as mediators in the transfer or shuttling of genetic information between cells – 
e.g. mRNA from tumour cells to monocytes or microRNAs (regulators of protein 
translation)  
In the last year Lee et al. 13 stress the importance of intercellular communication via MVs 
to processes such as cell polarity, cell differentiation (e.g. from reticulocytes to mature 
red cells by the removal of transferrin), migration, chemotherapy resistance, 
immunoregulation, inflammation, coagulation, angiogenesis and cancer metastasis.  In 
their study of cancer metastasis Hendrix et al. 45  postulate that MVs provide a platform 
for the controlled assembly of multimolecular complexes with a pre–programmed 
composition of proteins, lipids and nucleic acids.  These inner vesicle assemblies are then 
delivered to the target cell. The term “Trojan exosomes” was coined to describe this 
phenomenon.  Recently, Taylor et al. 46 described the immunosuppressive properties of 
exosomes of tumour origin both in vivo and in vitro e.g. their ability to mediate apoptosis 
of activated cytotoxic T-cells or the impairment of monocyte differentiation into dendritic 
cells. 
3.0.5 Species present in biofluids which impact MV yield 
 
Certain endogenous species present in the sample may interfere with the yield of MVs 
isolated and hence impact adversely on the sensitivity of low abundant species that may 
be present.  In the isolation of exosomes from urine for example, the Tamm-Horsfall 
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protein was found to be an effective MV-trapping agent 47.  Its polymerisation entraps 
urinary exosomes as thus prevents their isolation during the ultracentrifugation stage.  
Therefore, it is necessary to depolymerise this protein before isolating exosomes and this 
was achieved by treatment with dithiothreitol (DTT).  More recently, Musante et al.48 
improved on this method by employing the milder detergent 3-[3-
clolamidopropyl)dimethylammino]-1propanesulfonic (CHAPS), which was found not to 
affect vesicle morphology or exosomal marker distribution. 
For isolating exosomes from human plasma, Looze et al. 49 employed fast protein liquid 
chromatography to remove interfering very low-density lipoproteins (VLDL) and 
intermediate-density lipoproteins before ultracentrifugation. 
With SF it may be the case that viscous hyaluronic acid may entrap MVs.  This will be 
investigated in this project. 
  
3.0.6 Microvesicle studies in synovial fluid 
 
A search through PubMed yields surprisingly little concerning the study of microvesicles 
and the relationship to arthritis in synovial fluid.  Those studies that were made were 
related to inflammation in RA.  Boilard et al. 50 identified platelet microparticles in 
synovial fluid from patients with RA and other forms of inflammatory arthritis.  No 
microparticles were detected in the synovial fluid of patients with OA.  The platelets 
were pro-inflammatory and elicited cytokine responses from synovial fibroblasts via Il-1.  
However, Skriner et al. 18 also isolated exosomes from patients with RA, reactive arthritis 
and OA and this group found that citrullinated proteins (citrullination is a crucial step for 
changing a nonimmunogenic protein into an autoimmunogenic protein) are found in all 
synovial fluid exosomes, including OA.  They acknowledge that further studies will need 
to be undertaken to reveal why the immune system in RA exclusively recognises these 
proteins (fibrin-derived molecules and Spα) as autoantigens.  They did however; find that 
fibronectin and IgG were recovered only in RA exosomes.  
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3.0.7 Project aim 
 
The overarching aim of this project is to characterise the proteome of MV in 
osteoarthritis SF. 
The first objective is to establish a MV isolation protocol for synovial fluid and in 
particular to determine if hyaluronic acid entraps microvesicles in a manner similar to 
Tamm-Horsfall in urine or if ICs co-precipitate with MVs.  This has not been established 
to date. 
With a customised protocol established, isolated MV were prepared for MS analysis and 
the vesicle-associated proteome elucidated.   
.    
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3.1 Materials & Methods 
     
3.1.1 Reagents 
All reagents were obtained from Sigma Aldrich except where noted. 
Absolute Ethanol (HPLC Grade), Acetic Acid (reagent >99.7%), Acetronitrile (HPLC-
grade), Acrylamide (molecular biology), Alcian Blue 8-GX (electrophoresis), 
Ammonium Bicarbonate (anhydrous), Ammonium persulphate (APS) (Ultra ~99%) 
(98%), β-mercaptoethanol (98%),  Calcium Chloride (96%), CHAPS, Coomassie 
Brilliant Blur R, Coomassie Brilliant Blue G-250 (Merck), Dithiothreitol (DTT) 
(molecular biology),  Ethylenediaminetetraacetic Acid (EDTA) Formic Acid (Fluka), 
Glycerol (molecular biology 99%), Glycine (electrophoresis 99%), Hyaluronadase (from 
bovine testes),  Iodoacetamide, Methanol (Thermo Fischer), N-acetylcysteine, Nitric 
Acid (5% v/v), Ponceau Stain (electrophoresis), Sodium Chloride (molecular biology), 
Sodium Deoxycholate, Sodium Dodecyl Sulphate (SDS) (Fluka) (Ultra >99%), Sodium 
Formate, Tris(2-carboxyethyl)phosphinehydrochloride(TCEP),  Tetra-methylethylene-
diamine (TEMED), Tris-HCl, Tris pH 6.8, Tris pH 8.8, Triton x100; Trypsin (Promega), 
Tween-20, Urea 
 
Odyssey blocking buffer and molecular weight standards were obtained from LI-COR 
Biosciences (Lincoln, New England, USA) 
 
3.1.2 Antibodies 
Primary Antibodies: Polyclonal Rabbit Anti-human Orosomucoid (α-1-Acid 
Glycoprotein), Polyclonal Rabbit Anti-human Apolipoprotein A-1, Polyclonal Rabbit 
Anti-human α-2-Macroglobulin, Polyclonal Rabbit Anti-human IgM and Polyclonal 
Rabbit Anti-human IgG were supplied by Dako (Denmark). 
Polyclonal Rabbit Anti-human IgD was supplied by Dako (Denmark). 
Polyclonal Rabbit Anti-human Tsg101 and Polyclonal Rabbit Anti-human CD63 were 
supplied by Sigma. 
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Secondary Antibodies: Goat anti-Rabbit IRDye600CW & 800CW were supplied by 
Licor. 
Protein A immobilised on agarose CL-4B from Staphylococcus aureus was purchased 
from Sigma. 
 
3.1.3 Equipment 
Nitrocellulose, with a membrane pore size of 0.22mm filter paper was purchased from 
Whatman (Springfield, United Kingdom) 
Filter paper purchased from Whatman 
Sep-Pak cartridges were purchased from Waters Corporation. 
Odyssey Infrared Laser Scanner (manufactured byLI-COR Biosciences, Lincoln, NE, 
USA) 
Speed Vac: Model MiVac manufactured by GeneVac (Suffolk, Ipswich, UK) 
Centrifuges: 
Mikro 200R manufactured by Hettich 
Avanti®J-26 XP centrifuge (Beckman Coulter, Fullerton, CA, USA) 
OptimaTM L-90 K preparative ultracentrifuge (Beckman Coulter, Fullerton,                 
CA, USA)                                             
 
 
3.1.4 Synovial fluid sample preparation 
Synovial fluid samples were obtained by informed consent from patients attending the 
Rheumatology Department of the Mater Hospital in Dublin.  Samples were aspirated 
from the patient and placed in plastic sample containers containing 1mM EDTA and 
centrifuged at 2500g for 20 minutes to remove cells and cellular debris.  To reduce the 
high viscosity of synovial fluid due to hyaluronic acid, each sample was treated with 
hyaluronidase from bovine testes (1mg/mL 20mM phosphate buffer pH 7 ) at 37ºC 
overnight.  The requirement to perform this step is detailed in the results section.  
Samples were then stored in aliquots at -80ºC.  Only one freeze/thaw cycle was permitted 
per aliquot. 
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3.1.5 Microvesicle purification from synovial fluid 
A schematic representation of the initial differential centrifugation protocol that was 
employed is shown in Figure 3.8.  Customisation of this protocol for MV analysis is 
developed in the results section.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8:  Flow diagram outlining the standard differential centrifugation process for 
the isolation of microvesicles from biofluids. 
 
Following the initial centrifugation to remove cells and cellular debris, samples were then 
centrifuged in an Avanti®J-26 XP centrifuge (Beckman Coulter, Fullerton, CA, USA) at 
18,000g for 30 minutes at room temperature in a fixed angle rotor (Beckman JA-20, 
Neat Synovial Fluid
Centrifuge @ 2,500 for 20min to remove calls & cellular debris
Centrifuge @ 18,000g for 30min
18,000g Pellet
Centrifuge @ 200,000g for 2hr
200,000g Supernatant 200,000g Pellet MV
18,000g 
Supernatant
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Fullerton, CA) with the brakes applied.  The 18,000g pellet was resuspended in 1mL 
water and stored at -80ºC.  Next the 18,000g SN fraction was then subjected to an 
ultracentrifugation step by an OptimaTM L-90 K preparative ultracentrifuge (Beckman 
Coulter) at 44,000 rpm for 2 hours at 4ºC in a fixed-angle rotor (Beckman 70Ti, 
Beckman) with braking applied.  The 200,000g SN was then stored at -80ºC.  1mL of 
water was added to the crude 200,000g pellet.   
 
3.1.6 Microvesicle lyses  
The resuspended microvesicles were lyased by adding octyl β-D-glucopyrannoside (final 
concentration (1% w/v).  Samples were mixed end-over-end overnight at 4ºC. 
 
3.1.7 Protein assay 
To ensure equal protein loading onto the gel, the protein concentration of each sample 
was carried out using the Bradford assay.  A range of standards are made to generate a 
standard curve, these include the concentrations; 0 to 500µg/ml BSA. The Bradford 
reagent composition was: 100mg Coomassie Brilliant Blue G-250 in 50ml of 95% (v/v) 
ethanol and then mixed with 100ml of 85%(w/v) phosphoric acid 51.  The mixture was 
diluted to 1litre and allowed to dissolve. The dye is then filtered through Whatman filter 
(0.45µm) paper and stored at 4ºC.  Each standard and sample was run in triplicate.   
 
3.1.8 Sample preparation for electrophoresis 
To 100µg protein (based on the Bradford assay), 40µL of x5 sample buffer (10% (w/v) 
SDS, 50% (v/v) glycerol, 5% (v/v) β- mercaptoethonal and 1M Tris-HCl, pH 6.8) was 
added and the final volume made up to 200µL.  This yielded 100µg/200µL protein.  10µg 
(20µL) of protein was loaded into each lane.  To complete protein denaturation, samples 
were boiled for 5 minutes.  For non reducing conditions, omit β-mercaptoethonal from 
the sample buffer and also the boiling step. 
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 3.1.9 Gel electrophoresis  
Proteins were separated using SDS-PAGE employing 6-18% gradient resolving gel 
(80mm x 50mm x 1mm).  Table 3.5 summarises the composition of each solution. 
 
Volume Final Concentration Volume
Final 
Concentration
30% (w/v) Acrylamide 3mL 18% (w/v) 1mL 6% (w/v)
1.5M Tris pH 8.8 1.25mL 0.375M 1.25 mL 0.375M
10% (w/v) SDS 0.05mL 0.1% (w/v) 0.05mL 0.1% (w/v)
100% (v/v) Glycerol 0.7mL 20% (v/v) 0mL 0% (w/v)
Water 0mL 0.7mL
Total 5mL 5mL
Heavy Solution Light Solution
 
Table 3.5: Composition of heavy and light solutions for the resolving gel  
 
2.4mL of each solution was added to each chamber. 
Polymerisation was achieved by adding 22µL 10% (w/v) APS and 3.8µL TEMED.   
The composition of the stacking gel is shown in Table 3.6. 
Volume Final Concentration
30% (w/v) Acrylamide 0.23mL 3.50%
0.5M Tris pH 6.8 0.5mL 0.125M
10% (w/v) SDS 0.02mL 0.1% (w/v)
Water 1.25mL
Total 2.0mL
 
Table 3.6: Composition of stacking gel 
 
Polymerisation was achieved by adding 45µL 10% (w/v) APS and 7.5µL TEMED. 
Separation took place by applying 15mA per plate for 1 hour.  The running buffer was 
25mM Tris; 192mM glycine; 0.1% (w/v) SDS.  
After electrophoresis the gels were either stained with Coomassie or transferred to a 
nitrocellulose membrane for Western Blot (WB) analysis. 
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3.1.10 Colloidal Coomassie Staining   
Gels were removed from the plates and placed in a fixing solution (40% ethanol, 10% 
acetic acid) for 1 hour.  Next, the gel was washed with Milli-Q water (6 x 5minutes).  
This removes SDS.  Incubation in the Coomassie stain [80% Coomassie solution (10% 
(v/v) H3PO4, 10% (w/v) (NH4)2SO4, 0.12% (w/v) brilliant blue coomassie G, water to 
final volume), 20% (v/v) methanol]52 took place overnight. Excess stain was removed 
using 10% (v/v) acetic acid.  The gels were then stored in water.  
Gels were imaged with an Odyssey Infrared Laser Scanner. 
 
3.1.11Transfer to nitrocellulose membrane    
Transfer to the nitrocellulose membrane was carried out using the ‘wet’ transfer method.  
Transfer took place in 25mM Tris, 190mM Glycine, 20% (v/v) ethanol buffer by 
applying 100mA for 1 hour at 4ºC 53.  To confirm if protein transfer took place, the 
membrane was stained with Ponceau and visually inspected before being de-stained with 
PBS.  Membranes were blocked overnight at 4ºC or at room temperature for 1 hour with 
blocking buffer solution [Odyssey Blocking Buffer : PBS ( 1 : 1)]. 
 
3.1.12 Primary and secondary antibody incubation  
Following the membrane blocking stage, the membrane was washed with PBST (PBS + 
0.1% (v/v) Tween 20).  Antibodies were diluted as per the supplier instructions in 
Odyssey blocking buffer/PBST 1:1.  Incubation of the membrane took place for 90 
minutes at room temperature.  Excess antibody was removed employing a series of 4 x 10 
minute washes with PBST.  Next, the membrane was incubated with a secondary 
antibody (to the primary antibody) with a fluorescent tag (either green 680µm or red 
700µm) in Odyssey blocking buffer/PBST 1:1 for 1 hour in the dark.  Finally, washing 4 
x 10mins with PBST took place before imaging with the Odyssey scanner.   
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3.1.13 Determination of proteases activity employing zymography with gelatin 
substrate 
 
6-18% gradient gels (80mm x 50mm x 0.75mm) were prepared as before except gelatin 
was added to the heavy and light solution to a final concentration of 1mg/mL.  Gelatin 
was dissolved into solution by heating to 50ºC for ~ 5 minutes. 
10µg non-reduced total protein was loaded into each lane and protein separation 
performed as above.   
Following electrophoresis, gels were placed into the following solution; 25mM Tris-HCl 
pH 7.8 made up in ice-cold water containing 2.5% (v/v) Triton x100.  Mixture stirred at 
4ºC until required.  This was to remove the denaturing effects of SDS i.e. allow the 
proteins to return to their pseudo-native state. 
Gels were then incubated in the triton x100 solution for 40 minutes at 4ºC 
To activate any proteases present, 50mL 5mM CaCl2 was added to each gel.  Gels were 
then incubated in a water bath at 37ºC for 24 hours. 
Stain with 2% (w/v) Coomassie solution followed by distaining with 40% (v/v) 
MeOH/10% (v/v) acetic acid solution, until clear bands are noted 54.  
 
3.1.14 Determination of hyaluronidase (HAase) activity employing zymography with 
a hyaluronic acid (HA) substrate  
 
The method developed by Miura et al.54 was followed except instead of using a 7%  (v/v) 
acrylamide gel, a 6-18% (v/v) gradient gel was prepared as outlined above. 
HA was added to the heavy and light solution to a final gel concentration of 170µg/mL.  
10µg non-reduced total protein was loaded into each lane and protein separation 
performed as above.   
Following electrophoresis, gels were placed into the following solution; 25mM Tris-HCl 
pH 7.8 made up in ice-cold water containing 2.5% (v/v) Triton x100.  Mixture stirred at 
4ºC until required. 
Gels were then incubated in the triton x100 solution for 40 minutes at 4ºC. 
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The gels were then incubated in 0.1M sodium formate and 0.15M NaCl at pH 3.5 for 16 
hours at 37ºC. 
In order to prevent artifact formation (i.e. unstained bands due to non-enzymatic 
proteins), the gels were incubated with 0.1mg/mL pronase solution (20mM Tris-HCl, pH 
8.0) for 2 hours at 37ºC. 
Following this, washing with 20% (v/v) ethanol/10% (v/v) acetic acid took place for 20 
minutes. 
The gels were then stained with 0.5% (w/v) alcian blue in 20% (v/v) ethanol/10% (v/v) 
acetic acid for 1 hour. 
Finally, destaining took place in 20% (v/v) ethanol/10% (v/v) acetic acid. 
HAase activity was detected a unstained bands which correspond to the positions of 
enzymes which had migrated.      
 
3.1.15 Removal of immunoglobulins employing Protein A affinity chromatography 
Column conditioning: Place 10mL Protein A beads (IgG binding capacity = 35mg/mL) 
into a syringe.  Wash through with 10 column volumes PBS, followed by one column 
volume 0.1M glycine/0.15M NaCl solution.  Finally wash again with 10 column volumes 
PBS. 
Sample Loading: 10mL of SF (40-300mg IgG, Table 1.2) were loaded onto pre-
conditioned Protein A beads and equilibrated for 10 minutes.  Collect flow-through in a 
50mL tube on ice. 
Elution of unbound fraction:  Wash column with PBS until no further protein is detected 
in the wash using a nano-drop.  Dialyse against water overnight and SpeedVac to 10mL. 
Elution of bound fraction: To the column add 0.1Mglycine/0.15M NaCl, pH 2.3.  
Continue to rinse column until no protein is detected using a nano-drop.  Bring to 
physiological pH with tris-HCl.   Dialyse against water overnight and SpeedVac to 
10mL. 
Carry out the MV-isolation protocol as detailed above. 
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3.1.16 Preparation of OA 200,000g CHAPS pellet for mass spectrometry 
200µg of reconstituted 200,00g pellet was dried and then dissolved in 100µL of reducing 
solution (8M Urea, 5mM tris(2-carboxyethyl)phosphine (TCEP) (reducing agent), 
1%(w/v) sodium deoxycholate (detergent that lyases MVs), 200mM Tris pH8.8, 0.2mM 
EDTA; final pH > 8.2) for one hour at room temperature.  Alkylation followed with the 
addition of 10µL 420mM iodoacetamide (final concentration 20mM), mixed end-over-
end in the dark for 90 minutes.  Alkylation was quenched by the addition of 20mM N-
acetylcysteine.  
Proteins were precipitated as follows.  To the above sample 600µL MeOH, 200µL 
chloroform and 600µL water was added. Vortex and centrifuge at 5000g for two minutes.  
Remove aqueous layer and save.  To the organic layer add a further 800µL MeOH.  
Centrifuge at 14,000g for 40 minutes.  Remove the SN and dry the pellet in the SpeedVac 
to remove residual organic solvent 55.  Reconstitute in 50µL HPLC grade water.  Divide 
the sample - 25µL for in-gel and 25µL off-gel (shotgun) MS identification apprpach.  
 
3.1.17 Preparation of polyacrylamide gel bands for mass spectrometry 
Bands were cut into 1mm from the gel on a glass slide previously washed with 5% (v/v) 
HNO3 to remove residual proteins and all traces of keratin.  Gel slices were placed in 
PCR-grade eppendorfs previously washed with acetonitrile.  The bands were destained 
with 0.5mL destaining solution (50% (v/v) H2O, 5% (v/v) acetic acid) for 2 hours.  
Destaining was repeated a second time until the gel slices were completely clear. 
Reduction and alkylation took place as follows.  For reduction to occur, add 30µL 10mM 
Dithiothreitol (DTT) for 30 minutes at room temperature.  Centrifuge and remove DTT 
solution.  Alkylation took place with the addition of 30µL 50mM iodoacetamide in the 
dark at room temperature for 30 minutes.  Centrifuge and remove iodoacetamide solution.  
Wash the gel slices with 100µL 100mM (NH4)HCO3 for 10 minutes and remove.  
The gel slices were then dehydrated in 200µL acetonitrile for 5 minutes. This was 
repeated a second time.  Rehydration with 100µL 100mM (NH4)HCO3 followed.   
Further dehydration of the samples took place with the addition of 200µL acetonitrile, 
followed by a second rehydration with 200µL 100mM (NH4)HCO3.  The samples were 
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then centrifuged to remove (NH4)HCO3.  A further dehydration step with 200µL 
acetronitrile took place before the gel slices were dried in the SpeedVac.   
The trypsin solution was prepared as follows; 20µg Promega trypsin (Promega, Madison, 
WI) was added to 500µL ice-cold 50mM (NH4)HCO3 i.e. trypsin concentration = 
10ng/µL.  This was kept on ice.  The gel slices were then covered with 50µL of the 
trypsin solution and rehydrated on ice for 30 minutes.  Excess trypsin solution was 
removed by centrifugation before covering the slices with 50mM (NH4)HCO3.  
Incubation then took place overnight at 37ºC. 
The resulting peptides were extracted with 30µL 5% (v/v) formic acid for 10 minutes. 
Following centrifugation, the supernatant (SN) was removed and placed into a fresh, 
acetonitrile-washed eppendorfs (Protein LoBind tube).  Extraction of residual peptides 
from the gel slices took place by the addition of 50µL 5% formic acid in 50% acetonitrile.  
Following centrifugation, the SN was removed and placed into the same eppendorf as the 
first SN.  To complete the peptide extraction process from the gel slices, the slices were 
washed with two cycles of 20µL 50mM (NH4)HCO3/20µL 5% (v/v) formic acid/50µL 
5% (v/v) in 100% acetonitrile.  All SNs were pooled before reducing to ~1µL and then 
reconstitute to 20µL total volume with 1% (v/v) acetic acid. 
 
3.1.18 Preparation of microvesicles for separation by HPLC followed by mass 
spectrometry 
 
To the second 25µL sample, add 5µL trypsin (i.e. 2µg trypsin/100µg protein) in 50mM 
Tris-HCl, pH 8.0 and 1% (w/v) sodium deoxycholate which is compatible with trypsin 
activity 56 .  Incubate overnight at 37ºC. 
Sodium deoxycholate was removed as follows.  Add 1% (v/v) formic acid to the sample.  
Centrifuge at 24,000g for 15 minutes and save the SN.  Resuspend pellet in 25mM Tris 
pH8.8 and acidify with 1% (v/v) formic acid.  Repeat centrifugation.  Pool all the SN 
fractions 57. 
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3.1.19 Purification of trypsin-digested peptides 
Condition SepPak cartridge with 1mL 100% (v/v) MeOH followed by 2mL 80% (v/v) 
acetonitrile.  Equilibrate with 4mL 0.1% formic acid.  Acidify sample with 90µL 10% 
(v/v) formic acid to a final pH 2-3.  Load acidified samples onto the cartridge.  Wash 
cartridge with 6mL 0.1% (v/v) formic acid.  Elute peptides into a clean tube with 1mL 
0.1% (v/v) formic acid/80% (v/v) acetonitrile.  Concentrate sample by SpeedVac to about 
20 µL final volume. 
 
3.1.20 Mass spectrometry using LC–MS/MS 
All mass spectrometry analysis was carried out by the National Institute of Cellular 
(NICB) Biotechnology with whom a collaboration was obtained.  The following protocol 
was supplied by NICB. 
Nano LC–MS/MS analysis was carried out using an Ultimate 3000 nanoLC system 
(Dionex) coupled to a hybrid linear ion trap/Orbitrap mass spectrometer (LTQ Orbitrap 
XL; Thermo Fisher Scientific). Five microlitres of digest were loaded onto a C18 trap 
column (C18 PepMap, 300 µm ID × 5 mm, 5 µm particle size, 100 Å pore size; Dionex) 
and desalted for 10 min using a flow rate of 25 µL/min in 0.1% (v/v) TFA. The trap 
column was then switched online with the analytical column (PepMap C18, 75 µm 
ID × 250 mm, 3 µm particle and 100 Å pore size; (Dionex)) and peptides were eluted 
with the following binary gradients of solvent A and B: 0–25% solvent B in 120 min and 
25–50% solvent B in a further 60 min, where solvent A consisted of 2% (v/v) acetonitrile 
(ACN) and 0.1% (v/v) formic acid in water and solvent B consisted of 80% (v/v) ACN 
and 0.08% (v/v) formic acid in water. Column flow rate was set to 350 nL/min. 
Two-dimensional peptide separations in-line using an Ultimate 3000 nanoLC system 
(Dionex) coupled to a hybrid linear ion trap/Orbitrap mass spectrometer (LTQ Orbitrap 
XL; Thermo Fisher Scientific). 20µL of digest were loaded onto a BioX-Strong Cation 
Exchange (SCX) column (5µm. 500µm i.d. x 15mm  µ-PrecolumnTM Cartridge, Dionex) 
for 10 min using a flow rate of 25µL/min in 0.1% (v/v) TFA. Sample complexity was 
reduced by eluting small fractions of peptides from the SCX column with salt plugs at 
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concentrations of 0, 10, 25, 50, 100, 500, 1000mM ammonium formate containing 0.1% 
(v/v) TFA. The SCX fractions containing peptides were then subjected to reverse phase 
separation as described above. 
Data were acquired with Xcalibur software, version 2.0.7 (Thermo Fisher Scientific). The 
mass spectrometer was operated in data-dependent mode and externally calibrated. 
Survey MS scans were acquired in the Orbitrap in the 400–1800 m/z range with the 
resolution set to a value of 60,000 at m/z 400. Lock mass was set at 445.120025 u 
(protonated (Si(CH3)2O)6). Up to seven of the most intense ions (1+, 2+ and 3+) per scan 
were CID fragmented in the linear ion trap. A dynamic exclusion window was applied 
within 40 s. All tandem mass spectra were collected using a normalised collision energy 
of 35%, an isolation window of 3 m/z, and one microscan. 
Proteins were identified using BioWorks 3.2 from Thermo Fisher Scientific using the 
HUPO criteria with XC scores of 1.8, 2.2, 3.75 for single, double and triple charged ions. 
A peptide probability score of 0.05 was also used. The database used was Human 
UniProt-SwissProt downloaded January 2012. Carboxymethylation of Cysteine was set 
as fixed and oxidation of methionine as a variable modification. Two missed cleavages 
were allowed. The mass tolerance for precursor ions was 20ppm and the mass tolerance 
for fragment ions was 0.5Da.  
3.1.21 Comparison of proteome after three modes of analysis 
Lists of proteins generated by MS were analysed using an on-line comparison tool - 
http://sablab.net/venn.php 
 
3.1.22 Gene ontology classification analysis 
The Panther (Protein ANalysis THrough Evolutionary Relationships) Classification 
System (www.pantherdb.org) was used to categorise the MV proteome as described by 
58
.   
3.1.23 Transmission Electron Microscopy (TEM) 
A sample of an OA 200,000g CHAPS pellet was sent to Trinity College Dublin for 
analysis by TEM.  The following preparation procedure was supplied by the technician. 
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Instrument: Jeol 2100 TEM system (Joel Ltd., Tokyo, Japan) 
 
The system was operated at 100kV to maximise contrast. 
Sample preparation: Formavar carbon coated grids (Agar Scientific, Stansted, UK) were 
floated upside down on drops of solution 
1. 50ul drops of sample. (60mins) 
2.  3 washes of 0.1M phosphate buffer (3x10mins) 
3. Transferred to 3% Gluteraldehyde solution. (30mins) 
4. Then 3 washes of 0.1M phosphate buffer (3x10mins) 
5. The 2% Osmium Tetroxide (30 mins) 
6. 1 phospdate buffer wash 
7. 2 dH2O washes. 
8. Uranyl acetate. Drained with filter paper and allowed to dry over night. 
Images were taken the next day. 
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3.2 Results 
3.2.1 Optimisation of microvesicle harvesting protocol 
3.2.1.1 Assessment of the distribution of protein in MV harvested at 18,000g and 
200,000g 
 
MVs from 4 patient samples were isolated as in the materials and methods section 
(Figure 3.8).    The Coomassie gels (top panels) and antibody anti-Tsg101 Western Blots 
(bottom panels) can be seen in Figure 3.9.  Tumour suppressing gene 101 (Tsg101) is a 
specific exosomal marker (Table 3.2). It is one of four components of the ESCRT I 
machinery and like ESCRT 0, its function is to bind to ubiquitinated proteins at the 
endosome surface. 59  It is located on the inner surface of the exosome.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9:  Coomassie and corresponding anti- Tsg101 WBs of four patient samples 
which were differentially centrifuged in order to isolate MVs  
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From the coomassie images in Figure 3.9 above, it can be observed that for any particular 
patient sample, there are different protein patterns between 18,000g pellet, 200,000g 
pellet and 200,000g SN.  A further observation is the remarkable similarity in the band 
profile between the two OA samples (Lanes 5, 6 & 7) and also the differences between 
these and both PSA (Lanes 1, 2, & 3 left) and RA (Lanes 1, 2 & 3 right).  In addition a 
WB of these samples was performed after incubation with an exosomal marker, Tsg101.  
This has a molecular weight ~46kDa.  From these WBs it can be seen that there are 
exosomes in all three fractions i.e. 18,000 g crude pellets, 200,000g crude pellet and the 
200,000g crude SN.  In the case of the OA samples in particular, the exosome yield in the 
targeted 200,000g pellet is poor relative to the other two fractions.  In particular, there is 
a strong signal in the 200,000g SN, implying a less than satisfactory enrichment of 
exosomes in the targeted 200,000g pellet.  Therefore, a method needs to be developed to 
maximise the exosome harvest in the 200,000g pellet and hence increase the sensitivity of 
any proteomic study.     
3.2.1.2 Establishment of the effect of HAase treatment on the yield of MVs 
The 200,000g SN of each sample from the previous study was taken and the following 
protocol was applied (Figure 3.10).  This is an extension of the initial protocol displayed 
in Figure 8. 
 
  
 
 
 
Figure 3.10: Treatment of the 200,000g crude SN with HAase (as outlined in the 
materials and methods section) aimed at recovering additional MV that may be 
entrapped by HA.    
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From Figure 3.10, the original 200,000g SN was treated with HAase followed by a 
second ultracentrifugation step at 200,000g.  This yielded the HAase 200,000g pellet and 
SN.  Proteins from the pallet and SN were separated by SDS-PAGE.  The Coomassie 
stain can be seen in Figure 3.11.  Comparing the 200,000g pellet lanes in Figures 3.9 and 
3.11, it is can be seen that following treatment with HAase, there is considerable 
enrichment of protein in the 200,000g pellet fractions particularly albumin at ~ 60kDa.   
The two OA 200,000g pellet samples (Lanes 4 & 6) have similar band patterns.  
However, the RA and PSA 200,000g pellets (Lanes 2 & 9) have extra bands at ~40kDa, 
80kDa and 90kDa.    
 
    
 
 
 
 
Figure 3.11: Coomassie gel of the same samples run in Figure 3.9 following HAase 
treatment at 37ºC overnight.   
 
Following this, the HAase 200,000g pellet in turn, was treated with 1% (w/v) CHAPS 
and mixed end-over-end overnight at 4ºC as per Musante et al. 48  CHAPS is a non-
denaturing zwitterionic detergent and is ideally suited to disrupt non-specific protein 
interactions, while at the same time preserving protein conformation 60.  A third 
ultracentrifugation at 200,000g was performed and both fractions were analysed by SDS-
PAGE.  The workflow is shown in Figure 3.12 and the resulting Coomassie gel is in 
Figure 3.13. 
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Figure 3.12: An extension to the workflow outlined in Figure 3.10 aimed at further 
enhancing MV recovery by removing those proteins that are loosely associated with the 
vesicle surface, by incubating the original crude pellet with 1% (w/v) CHAPS overnight 
at 4ºC. 
 
 
 
 
 
 
 
Figure 3.13: Treatment of the previous crude 200,000g pellet with 1% (w/v) CHAPS 
solution. 
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enriched in the SN in Figure 3.13 relative to Figure 3.11.  Species that moved from the 
pellet to the SN following CHAPS treatment are indicated with a yellow arrow for one of 
patient samples. Examination of the 200,000g pellet fractions in Figure 3.13 also 
highlights an enrichment of protein following CHAPS treatment due to removal of high 
abundant, soluble/loosely bound protein into the SN.    
To better evaluate the protein profiling pre and post HAase digestion, SDS-PAGE was 
performed, comparing CHAPS-treated 200,000g pellets pre- and post-digestion with 
HAase for each sample.  These were loaded into adjacent lanes to aid comparison.  
Further, each fraction was incubated with antibodies against well known exosomal 
markers i.e. Actin β and CD63.  CD63 is a tetraspanin protein associated with exosomes 
(Figure 3.6 and Table 3.3).  As it is a membrane protein, it is an ideal species to act as a 
positive control to demonstrate that CHAPS, while removing loosely bound proteins from 
the vesicle surface, does not remove strongly associated proteins.  Actin β was listed by 
Mathivanan et al.61 as the third most often found protein in exosomes (behind heat shock 
protein 8 and CD63).   The result of this study may be seen in Figure 3.14. 
 
       
 
 
 
 
 
 
 
Figure 3.14: Treatment of the same samples analysed in Figure 3.11 before and after 
HAase treatment.  A Coomassie staining gel (upper left) and two WBs of known exosomal 
markers – anti-CD63 (upper right) and anti-actin β (lower left) – were prepared. 
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The Coomassie image in Figure 3.13 clearly demonstrates that further treatment of the 
crude 200,000g SN with 1% (w/v) CHAPS, followed by another 200,000g 
ultracentrifugation step, resulted in further recovery of MV.  That these “extra” acquired 
MVs contain exosomes was shown by performing a WB analysis with two well-known 
exosomal markers – actin β and CD63.  Incubation with CD63 exhibited bands with a 
range of molecular weights.  This species is known to be heavily glycosylated 62 and the 
bands in the 75 -100kDa region are due to a high degree of glycosylation by poly N-
acetyl lactosamine 48.  
3.2.1.3 Confirmation of the effectiveness of the HAase/CHAPS steps on MV 
recovery 
Seven new patient samples were taken and the following expanded workflow was applied 
(Figure 3.15).  This additional step (red box) was designed to establish if the 18,000g 
fractions merited further study.  The crude 18,000g pellet was treated with CHAPS and 
centrifuged again at the same speed.  
 
 
 
 
 
 
 
 
 
Figure 3.15:  The workflow employed to establish the repeatability of the previous study 
with new patient samples and ascertain if further analysis of the 18,000g pellet merits 
any further study. 
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SDS-PAGE Coomassie gels for this study are displayed in Figure 3.16. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16: Coomassie gels representing various differential centrifugation fractions as 
shown in the workflow in Figure 3.15, representing seven different patient samples. 
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Examination of Lane 3 in each gel confirms that treatment of the crude SN (Lane 2) with 
CHAPS, followed by a further 18,000g centrifugation step, yields a further enrichment of 
protein in the pellet – bands that are not seen in Lane 2.  This is particularly true in the 
case of the three OA samples, though the other pathologies also display this enhanced 
enrichment.  As before, a redistribution of albumin (~63kDa) from the pellet (Lane 3) to 
the SN (Lane 4) is clearly seen.  An interesting observation is the absence of a band 
(~150kDa) in the PSA 200,000g CHAPS SN (Lane 6) that is present in the other six gels.   
Overall there is a noticeable enrichment of soluble protein in the 18,000g (Lane 4) and 
200,000g (Lane 6) CHAPS SN, relative to the corresponding crude SN fractions (Lanes 2 
and 7) confirming that soluble or loosely-associated protein was removed from the crude 
pellet fraction following CHAPS treatment.     
In order to establish the presence of exosome markers, samples representing different 
pathologies (OA, RA, PSA and Gout) were analysed by WB employing anti-Tsg101 and 
anti-CD63 as known exosomal markers (Table 2).  These images are shown in Figures 
3.17 and 3.18 respectively.      
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Figure 3.17:  Establishing the distribution of exosomes among differentially centrifuged 
fractions of four different arthritic pathologies, by incubation with the exosomal marker 
Tsg101 (18,000g (Blue) and 200,000g (Red)) 
 
 
 
 
 
 
 
Figure 3.18: Establishing the distribution of exosomes among differentially centrifuged 
fractions of one OA and one RA patient sample, by incubation with the exosomal marker 
CD63 (18,000g (Blue) and 200,000g (Red) pellets) 
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In Figures 3.17 and 3.18, it is shown that exosomes are present in each patient sample.  
Further, though they are present in 18,000g pellet (Lanes 2 and 6), exosomes are 
particularly enriched in pellet 200,000g (Lanes 4 and 8).  Finally, as seen in lanes 5 and 9 
for both CD63 and Tsg101, the recovery of exosomes in the pellet is not complete, as 
there are still exosome markers present in the 200,000g CHAPS SN.  Due to the low 
abundance of exosomal markers in the 18,000g pellet, relative to the 200,000g pellet, it 
was decided, in the interest of time available, to pursue a study of the latter and leave the 
study of the former to future research.        
To evaluate the redistribution of soluble proteins following CHAPS treatment, a WB was 
carried out incubating with anti-albumin.  The aim here is to confirm the transfer of 
albumin from the pellet to the SN following CHAPS treatment that was previously 
discussed in relation to a Coomassie-stained gel. 
In addition, in order to establish if there are potential immuncomplexes present, 
incubation with anti-IgM was carried out.  Knowing that IgM can exist either as a 
pentamer of ~900kDa, or as a monomer, a 6-10% gradient gel was prepared (rather than 
the usual 6-18% gradient as outlined in the material and methods section of this chapter) 
in order to enhance resolution.   These are shown in Figure 3.19. 
Inspection of the WB in Figure 3.19 (left) confirms that post CHAPS treatment, there is 
almost a complete relocation of albumin from the 200,000g CHAPS pellet (Lanes 4 and 
8) to the 200,000g SN (Lanes 5 and 9).  There is still albumin present in the pellet 
however, and this could be due to either incomplete removal from the vesicle surface or 
this protein is also a component of the inner vesicle cargo.  
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Figure 3.19: WB analysis with anti-albumin to confirm transfer of soluble or loosely 
associated protein from the pellet to the SN following CHAPS treatment (left).  WB image 
displaying incubation with anti-IgM aimed at confirming the possible existence of ICs 
(right).   
Examination of the WB image on the right in Figure 3.19 (IgM) shows a strong band in 
each fraction at ~ 75kDa which could be the mu chain of IgM.  Incubation with anti-IgM 
shows that IgM is strongly associated with the 200,000g pellet (Lanes 4 & 8) with 
relatively little remaining in the 200,000g CHAPS SN (Lanes 5 & 9).  There is also IgM 
enriched in both the 18,000g pellet and 18,000g SN.  Further, the 18,000g pellet, 18,000g 
SN and 200,000g pellet fractions have high molecular weight bands that are absent in the 
200,000g SN.  The signal for these higher molecular weight species is most intense in the 
200,000g pellet.  At this point it is only possible to speculate that these may be dimers of 
IgM present due to incomplete disulphide bond cleavage.  This speculation is based upon 
the fact that the more intense high molecular weight bands are approximately double the 
weight of mu chain at ~75kDa.  The presence of IgM mu chain was confirmed by MS 
analysis.  In addition, the immunoglobulin J chain was also shown to be present by MS.  
MS data will be discussed later in this section.  This confirmation that IgM is MV-
associated and the possibility that ICs could be present, leads to the hypothesis that 
IgM
1    2      3      4       5       6     7      8   9  10       
250
150
100
75
50
Lane 1: MWM
Lane 2: OA 18,000g CHAPS Pellet
Lane 3: OA 18,000g CHAPS SN
Lane 4: OA 200,000g CHAPS Pellet
Lane 5: OA 200,000g CHAPS SN
Lane 6: Gout 18,000g CHAPS Pellet
Lane 7: Gout 18,000g CHAPS SN
Lane 8: Gout 200,000g CHAPS Pellet
Lane 9: Gout 200,000g CHAPS SN
Lane 10: MWM
Albumin
1    2     3     4    5     6   7    8    9   10   
250
150
100
75
50
37
Lane 1: MWM
Lane 2: PSA 18,000g CHAPS Pellet
Lane 3: PSA 18,000g CHAPS SN
Lane 4: PSA 200,000g CHAPS Pellet
Lane 5: PSA 200,000g CHAPS SN
Lane 6: RA 18,000g CHAPS Pellet
Lane 7: RA 18,000g CHAPS SN
Lane 8: RA 200,000g CHAPS Pellet
Lane 9: RA 200,000g CHAPS SN
Lane 10: MWM
  116 
removal of these species may unearth and enrich other less abundant proteins in the MV 
proteome.   
 
3.2.1.4 Removal of Immunoglobulins employing Protein A chromatography in order 
to maximize MV enrichment by elimination of interference from immunoglobulins 
As ICs are likely to be most abundant in RA, a pooled-patient, HAase-treated RA sample 
was analysed employing Protein A chromatography.  ICs are formed when rheumatoid 
factor reacts with the crystallisable fragment (Fc fragment) of IgG.  Rheumatoid factor is 
one of three subclasses i.e. IgM, IgA and IgG auto-antibodies, with IgM the 
predominating species in arthritis 63.  Protein A binds with high affinity to human IgG 
and moderate affinity to IgM, IgA and IgE.  It does not bind human IgD.  Unbound 
proteins were eluted from the column with PBS while the targeted, bound 
immunoglobulins were eluted from the column with 0.1M glycine (pH2.3).  An SDS-
PAGE gel without CHAPS treatment of the differentially centrifuged fractions was 
prepared for (i) whole SF (blue), (ii) the non-bound (immunoglobulin-free) fraction 
(purple) and (iii) the bound, immunoglobulin fraction (green).  This can be seen in Figure 
3.20. 
     
 
 
   
 
Figure 3.20: Coomassie-stained gel showing the removal of immunoglobulins by Protein 
A chromatography before CHAPS treatment. To aid discussion, the bands of interest are 
represented by asterisks (IgM (yellow), IgG heavy chain (red) and immunoglobulin light 
chains (green).  
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  117 
Lanes 2-4 in Figure 3.20 show the IgM mu chain (~75kDa), IgG gamma chain (~57kDa) 
and IgG light chain (~25kDa) are present in all three fractions of whole synovial fluid.  
There appears to be an enrichment of these species in the 200,000g pellet (Lane 3) 
relative to the other two fractions in Lanes 2 & 4.  Following Protein A affinity 
chromatography, there is a clear redistribution of these immunoglobulins.  For example, 
there is enrichment of the 75kDa species in both the non-bound 18,000g (Lane 5) and in 
the bound 18,000g (Lane 8) pellets.  At the same time, there is low band intensity for this 
molecule in the non-bound 200,000g pellet (yellow asterisks Lane 6) relative to that in 
whole SF (Lane 3).  This same reduction in band intensity also applies to both the 57kDa 
and 25kDa moieties (red and green asterisks respectively).  There are however, still bands 
present at these molecular weights in the 200,000g non-bound pellet (Lane 6), though 
without analysis by WB, it is not possible to say if these moieties are immunoglobulins 
entrapped within or bound to the MV, or else other species that possess the same 
molecular weight as the species which were removed by Protein A chromatography. 
What is clear though is that in the bound fractions (Lanes 8, 9, and 10), these bands 
intensities are much stronger than those in whole SF (Lanes 2, and 4) suggesting a 
significant removal of these proteins following Protein A affinity chromatography. 
Another interesting observation is the large enrichment of what may be IgM in the lower 
speed 18,000g pellet (Lane 8) relative to the 200,000g fractions (Lanes 9 & 10).  On the 
other hand, IgG is redistributed across all three fractions in the bound sample, though 
slightly more so in the SN (Lane 10). 
A study was then carried out to establish the effect of this immunoglobulin 
removal/reduction on further protein enrichment in the 200,000g pellet following CHAPS 
treatment.  Pre- and post-CHAPS treated 200,000g pellets were analysed and a 
Coomassie stained gel is shown in Figure 3.21.  
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Figure 3.21:  Coomassie-stained gel illustrating a comparison between crude and 
CHAPS-treated 200,000g pellets for whole SF (lanes 2-4), non-bound (lanes 5-7) and 
bound (lanes 8-10) fractions following Protein A affinity chromatography.  Different 
immunoglobulin isotypes are indicated with a pink arrow. 
It was observed that in all three samples (whole SF, Protein A non-bound & Protein A 
bound), there is further enrichment of protein following CHAPS treatment i.e. comparing 
lanes 2 & 3, lanes 5 & 6 and lanes 8 & 9.  Removal of loosely associated species with 
CHAPS, and loading the same amount of protein, leads to an enrichment of protein in the 
200,000g CHAPS pellet.  Bands (based on molecular weight) for each immunoglobulin 
isoform in the bound fractions (Lanes 8, 9 and 10) are labeled with a pink arrow.  These 
can serve as a positive control.  
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Lanes 5 and 6 (within the red box) are worth discussing.  These are the 200,000g non-
bound pellets (the targeted proteome), pre- and post-CHAPS treatment respectively.  As 
mentioned, there is considerable enrichment of protein post-CHAPS treatment as seen by 
stronger band intensities in Lane 6 relative to Lane 5.  However, as seen here this 
enrichment also includes both IgM (yellow asterisks) and IgG (red and green asterisks).  
Knowing that Protein A affinity chromatography targeted these species, why are these 
species still associated with the vesicle proteome?  It can only be concluded that IgM and 
IgG are either entrapped within the MV, strongly bound to the surface, or both present on 
the surface and within the vesicle.  An alternative explanation could be the formation of 
immune complexes which may not be dissociated by CHAPS.  At this point it is not 
possible to definitively say what the case is.  Lanes 8 and 9 within the green box are also 
worthy of comment.  It is the case that post-CHAPS treatment (Lane 9) there is a sizable 
increase in band intensity in IgM and IgG.  Without CHAPS treatment, these species 
would have remained associated with the pellet and so prevent enrichment of other 
proteins.  Therefore, Protein A affinity chromatography is an important step in any 
sample preparation protocol.  Further, removal of albumin following CHAPS treatment 
led to an increase in band intensity of the protein in the blue box in Lane 6.  On the basis 
the molecular weight (~ 60kDa), this may be IgA.   
Finally, a WB with anti-Tsg101 of these samples was performed to establish the 
distribution of exosomes across the fractions.  This is shown in Figure 3.22.     
       
 
 
 
 
 
 
  120 
 
 
 
 
 
 
 
 
Figure 3.22:  WB with anti-Tsg101 of all fractions pre- and post-CHAPS treatment. 
As noted before, there is an enrichment of the Tsg101 exosomal marker (~46kDa) in the 
200,000g CHAPS pellet Lane 3, 6 and 9.  Surprisingly, there is also Tsg101 exosomal 
marker present in all three bound fractions (Lane 8, 9 and 10).  A hypothesis for this 
phenomenon will be offered in the discussion section. 
This concludes the customisation of a MV isolation protocol for SF.  The entire workflow 
for this is displayed in Figure 3.23. 
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Figure 3.23: Customised workflow developed for isolating MV from whole synovial fluid.  
Additional steps added to the standard differential centrifugation method (Figure 3.8) 
include treatment with HAase to release potentially entrapped vesicles, removal of 
potential ICs to aid protein enrichment in the targeted 200,000g pellet and finally 
CHAPS treatment to maximize protein enrichment through the removal of loosely 
associated proteins from the vesicle surface.   
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3.2.2 Confirmation of the presence of MV in SF by electro-microscopy (EM)  
Figure 3.24 is a display of MVs isolated from OA SF with increasing magnification. 
A B
C D
E F
20,000x
20,000x 20,000x
25,000x 80,000x
6,000x
 
 Figure 3.24: Electronmicrographs displaying MVs isolated from OA SF.  The figure 
shows different fields with increasing magnification. A 6,000x; B,C and D 20,000x; E 
25,000x and F 80,000x.  In the lower magnifications, MVs are indicated with red arrows.  
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From Figure 3.24 it can be seen that MVs of various sizes are associated with SF 
following the method developed in Figure 3.23.  Using the scale under each micrograph 
in conjunction with Figure 3.2, the vesicles in A and B fall within the size range of 
exosomes (50-100nm), ectosomes (50-200nm) and apoptotic vessels (50-500nm).  The 
vesicles in micrographs C, D and E on the other hand, are certainly outside the exosome 
range.  The vesicle(s) in D is - relative to exosomes - very large.  This is most probably a 
micro-particle(s).  However, F certainly has the dimensions of an exosome.  As 
mentioned before, vesicles cannot be identified on the basis on physical parameters, so 
attempting to classify them on this basis is purely speculative.  They suffice to show that 
MVs have been isolated and that the population is most certainly a heterogeneous 
assortment.  That exosomes are present has already been verified through WB analysis 
with exosomal markers. 
To conclude, it has been demonstrated by electro-microscopy and WB that following the 
application of a newly-developed, SF-customised MV-isolation protocol, a heterogeneous 
population of vesicle-types was obtained.  The next objective is to characterise the 
proteome of these vesicles employing mass spectrometry (MS).   
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3.2.3 Protein characterisation of synovial fluid, CHAPS-treated 200,000g MVs, 
employing “off-gel” and “in-gel” approaches 
Four OA patient samples were pooled and the previously developed MV-isolation 
protocol was employed (Figure 3.23).  It was believed that a pooled sample would be 
more representative of the pathology in addition improving the MV yield for proteomic 
characterization.  The 200,000g CHAPS pellet was prepared as in Figure 3.23 for MS 
analysis by the two methods detailed in the materials and methods section in this chapter 
and outlined here in Figure 3.25.  
  
 
 
 
 
 
 
 
 
 
Figure 3.25:  Workflow of sample processing for MS analysis.  Two different routes are 
employed – In-gel digestion (left) and the “shotgun” approach (right) 
Three modes of analysis were used i.e. 5-hour RP-HPLC, SCX-RP-HPLC and in-gel 
trypsin digestion.  The raw data for each of these modes of analysis (arranged in order of 
decreasing number of peptide hits), is shown in appendices 1, 2 and 3 respectively. An 
on-line comparison tool was employed to aid analysis of the raw data.  The list of 
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accession numbers for each dataset was entered and a comparison diagram generated.  
This Venn diagram is shown in Figure 3.26. 
 
 Figure 3.26: Venn diagram comparing each protein list that was generated follow MS 
analysis using three different methods – 5-hour reverse-phase HPLC(green), SCX-
reverse-phase HPLC(pink) and in-gel digestion of bands generated employing SDS-
PAGE (blue) 
Analysis of the data yielded a total of 264 unique proteins associated with the 200,000g 
CHAPS-treated pellet. 
Table 3.7 list all the proteins identified by MS.  There is an additional column indicating 
which method(s) characterised each protein.  
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Reference P (pro) Score Coverage MW Accession Peptide  Method 
Alpha-2-antiplasmin  7.83E-07 20.16 4.90 54531.2 P08697 2 1 
Complement factor H-related 
protein 3  
3.65E-
13 20.19 7.90 37298.8 Q02985 2 1 
Histidine-rich glycoprotein  1.23E-09 60.23 15.80 59540.9 P04196 6 1 
Ig kappa chain V-II region 
RPMI 6410  
4.11E-
14 20.23 29.30 14697.4 P06310 2 1 
Phospholipid transfer protein  3.49E-08 30.16 8.50 54704.7 P55058 3 1 
Protein S100-A9 4.06E-09 20.19 26.30 13233.5 P06702 2 1 
Aggrecan core protein  4.63E-07 30.18 1.30 250037.6 P16112 3 2 
Angiotensinogen 5.21E-08 20.20 5.20 53120.6 P01019 2 2 
Annexin A2  3.02E-05 20.16 6.20 38579.8 P07355 2 2 
Apolipoprotein A-IV  1.63E-09 20.21 7.30 45371.5 P06727 2 2 
Apolipoprotein D  3.00E-06 20.15 11.60 21261.8 P05090 2 2 
Catalase  5.72E-07 20.18 4.60 59718.9 P04040 2 2 
Chitinase-3-like protein 1  1.67E-08 20.19 6.30 42598.4 P36222 2 2 
Coagulation factor XIII A 
chain  
1.10E-
08 20.17 3.70 83214.7 P00488 2 2 
Complement C1s 
subcomponent  
2.76E-
08 50.16 10.30 76634.9 P09871 5 2 
Coronin-1A  2.10E-06 20.15 6.90 50993.9 P31146 2 2 
EGF-containing fibulin-like 
ECM protein 1  
4.82E-
09 50.16 12.20 54604.3 Q12805 5 2 
Extracellular matrix protein 1  2.93E-07 20.15 5.00 60635.4 Q16610 2 2 
Fibulin-1  3.79E-06 20.14 3.00 77162.4 P23142 2 2 
Fructose-bisphosphate  
aldolase A  
7.89E-
08 40.22 18.70 39395.3 P04075 4 2 
Hyaluronan-binding protein 2  1.65E-05 20.14 3.60 62630.5 Q14520 2 2 
Ig delta chain C region  2.96E-09 20.19 6.80 42227.3 P01880 2 2 
Ig heavy chain V-II region 
ARH-77 
4.88E-
10 20.22 17.10 16218.1 P06331 2 2 
Ig heavy chain V-III region 
GAL  
1.80E-
06 30.21 17.20 12722.2 P01781 3 2 
Ig heavy chain V-III region 
NIE  
7.02E-
08 18.16 19.30 13234.0 P01770 2 2 
Ig kappa chain V-I region 
Wes  
7.88E-
14 28.26 16.70 11600.7 P01611 3 2 
Kallistatin  1.66E- 50.17 13.30 48511.2 P29622 5 2 
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Lactotransferrin  1.09E-09 30.16 6.60 78132.0 P02788 3 2 
L-lactate dehydrogenase A 
chain  
1.61E-
06 20.14 6.60 36665.4 P00338 2 2 
Mannose-binding protein C  6.92E-08 30.21 15.30 26127.0 P11226 3 2 
Plasma serine protease 
inhibitor  
5.28E-
07 40.16 11.10 45645.8 P05154 4 2 
Polymeric immunoglobulin 
receptor  
1.17E-
06 30.19 5.80 83231.7 P01833 3 2 
POTE ankyrin domain family 
member I  
1.80E-
06 20.24 2.00 121204.4 P0CG38 2 2 
POTE ankyrin domain family 
member J 
1.80E-
06 20.24 2.00 117314.7 P0CG39 2 2 
Procollagen C-endopeptidase 
enhancer 1 
5.70E-
11 40.21 13.60 47942.0 Q15113 4 2 
Prolow-density lipoprotein 
receptor-related protein 1  
6.30E-
05 30.15 0.70 504274.2 Q07954 3 2 
Proteasome subunit beta 
type-1  
2.39E-
09 20.16 9.50 26472.4 P20618 2 2 
Putative annexin A2-like 
protein 
3.02E-
05 20.16 6.20 38634.8 A6NMY6 2 2 
Putative heat shock 70 kDa 
protein 7  
7.49E-
04 18.12 6.00 40219.6 P48741 2 2 
Putative macrophage-
stimulating protein MSTP9  
1.09E-
07 20.17 2.90 79642.3 Q2TV78 2 2 
Resistin 4.72E-09 20.17 24.10 11411.5 Q9HD89 2 2 
Serine protease HTRA1 1.06E-05 20.14 4.80 51254.7 Q92743 2 2 
Stromelysin-1  4.59E-07 60.19 12.60 53943.4 P08254 6 2 
Tenascin  7.64E-07 20.20 1.00 240697.7 P24821 2 2 
Transforming growth factor-
beta-induced protein ig-h3  
5.23E-
05 20.14 4.10 74634.1 Q15582 2 2 
Transthyretin  8.33E-09 20.23 23.80 15877.1 P02766 2 2 
Vimentin  4.63E-07 20.17 5.20 53619.2 P08670 2 2 
Vitamin D-binding protein  5.13E-13 30.21 9.10 52929.1 P02774 3 2 
Aconitate hydratase, 
mitochondrial 25 
1.55E-
09 20.25 5.50 85372.0 Q99798 2 3 
ATP synthase subunit beta, 
mitochondrial  
3.30E-
13 70.30 21.70 56524.7 P06576 7 3 
Beta-enolase  5.81E-13 40.25 17.30 46902.3 P13929 4 3 
Citrate synthase, 
mitochondrial  
7.30E-
10 20.18 6.90 51679.6 O75390 2 3 
Collagen alpha-2(I) chain  5.65E-05 40.21 4.00 129235.8 P08123 4 3 
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Creatine kinase M-type  2.21E-10 20.26 8.10 43073.9 P06732 2 3 
Dermcidin  5.80E-06 20.16 20.00 11276.8 P81605 2 3 
Elongation factor 1-alpha 1  8.00E-10 20.25 8.40 50109.2 P68104 2 3 
Ferritin light chain  1.23E-12 30.25 22.90 20007.1 P02792 3 3 
General transcription factor 
IIF subunit 1 
3.13E-
04 20.14 3.30 58205.1 P35269 2 3 
Glial fibrillary acidic protein  3.83E-09 18.20 4.20 49849.7 P14136 2 3 
Histone H2B type 1-B 2.40E-11 38.22 11.90 13941.6 P33778 4 3 
Histone H2B type 1-C/E/F/G/I  2.40E-11 38.22 11.90 13897.6 P62807 4 3 
Histone H2B type 1-D  2.40E-11 38.22 11.90 13927.6 P58876 4 3 
Histone H2B type 1-H  2.40E-11 38.22 11.90 13883.5 Q93079 4 3 
Histone H2B type 1-J  2.40E-11 38.22 11.90 13895.6 P06899 4 3 
Histone H2B type 1-K  2.40E-11 38.22 11.90 13881.6 O60814 4 3 
Histone H2B type 1-L  2.40E-11 38.22 11.90 13943.6 Q99880 4 3 
Histone H2B type 1-M  2.40E-11 38.22 11.90 13980.6 Q99879 4 3 
Histone H2B type 1-N  2.40E-11 38.22 11.90 13913.6 Q99877 4 3 
Histone H2B type 1-O  2.40E-11 38.22 11.90 13897.6 P23527 4 3 
Histone H2B type 2-E  2.40E-11 38.22 11.90 13911.6 Q16778 4 3 
Histone H2B type 2-F  2.40E-11 38.22 11.90 13911.6 Q5QNW6 4 3 
Histone H2B type 3-B   2.40E-11 38.22 11.90 13899.5 Q8N257 4 3 
Histone H2B type F-S  2.40E-11 38.22 11.90 13935.6 P57053 4 3 
Ig heavy chain V-I region 
HG3  
5.63E-
07 20.22 22.20 12937.3 P01743 2 3 
Ig lambda chain V-I region 
HA  
2.64E-
05 20.19 18.80 11888.9 P01700 2 3 
Keratin, type II cytoskeletal 7  3.83E-09 18.20 3.80 51354.4 P08729 2 3 
Keratin, type II cytoskeletal 
72  
3.33E-
05 20.16 1.80 55842.5 Q14CN4 2 3 
Keratin, type II cytoskeletal 8  3.83E-09 28.20 5.60 53671.2 P05787 3 3 
Myosin light chain 3  8.86E-12 30.24 13.80 21917.9 P08590 3 3 
Myosin regulatory light chain 
2, ventricular/cardiac muscle 
isoform  
1.54E-
08 20.22 9.00 18777.4 P10916 2 3 
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Myosin-1  2.16E-05 16.20 1.40 223005.5 P12882 2 3 
Myosin-2  2.16E-05 18.20 1.40 222905.1 Q9UKX2 2 3 
Myosin-4  2.16E-05 16.20 1.40 222931.4 Q9Y623 2 3 
Myosin-6 1.87E-13 58.27 5.00 223594.8 P13533 6 3 
Myosin-7  1.55E-14 60.42 4.90 222957.8 P12883 6 3 
Myosin-8  2.16E-05 18.20 1.40 222623.5 P13535 2 3 
Plasminogen-related protein 
B  
6.05E-
07 20.16 18.80 10963.5 Q02325 2 3 
Proteasome subunit alpha 
type-2  
3.68E-
11 20.21 17.10 25882.3 P25787 2 3 
Proteasome subunit beta 
type-3  
1.02E-
09 20.25 15.60 22933.5 P49720 2 3 
Putative elongation factor 1-
alpha-like 3  
8.00E-
10 20.25 8.40 50153.2 Q5VTE0 2 3 
Tropomyosin alpha-1 chain  8.62E-07 20.23 10.20 32688.7 P09493 2 3 
Troponin C, slow skeletal and 
cardiac muscles  
3.88E-
09 20.22 18.00 18390.5 P63316 2 3 
Apolipoprotein B-100  9.26E-11 450.28 12.20 515283.6 P04114 45 1 & 2 
Apolipoprotein E  1.93E-10 60.22 23.00 36131.8 P02649 6 1 & 2 
Carboxypeptidase N catalytic 
chain  
8.46E-
08 20.25 11.10 52253.4 P15169 2 1 & 2 
Carboxypeptidase N subunit 
2  
3.59E-
09 20.22 6.20 60518.2 P22792 2 1 & 2 
Cartilage oligomeric matrix 
protein  
3.13E-
12 70.24 13.60 82807.7 P49747 7 1 & 2 
Collagen alpha-1(VI) chain  1.80E-10 30.25 4.70 108462.0 P12109 3 1 & 2 
Collagen alpha-3(VI) chain  3.59E-11 150.20 5.40 343454.2 P12111 15 1 & 2 
Complement C2  1.04E-10 80.21 12.90 83214.4 P06681 8 1 & 2 
Hemopexin  1.93E-12 30.22 11.50 51643.3 P02790 3 1 & 2 
Inter-alpha-trypsin inhibitor 
heavy chain H1  
1.05E-
09 90.22 15.10 101325.8 P19827 9 1 & 2 
Inter-alpha-trypsin inhibitor 
heavy chain H2  
3.78E-
09 80.23 12.60 106396.8 P19823 8 1 & 2 
Inter-alpha-trypsin inhibitor 
heavy chain H4  
6.62E-
08 80.21 10.40 103293.2 Q14624 8 1 & 2 
Myeloperoxidase  3.35E-08 70.18 10.50 83815.0 P05164 7 1 & 2 
Myosin-9  3.34E-09 30.22 2.10 226390.6 P35579 3 1 & 2 
N-acetylmuramoyl-L-alanine 
amidase  
1.43E-
09 30.21 8.00 62178.0 Q96PD5 3 1 & 2 
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Plasma kallikrein  7.34E-10 80.20 16.00 71322.8 P03952 8 1 & 2 
Pyruvate kinase isozymes 
M1/M2  
3.29E-
06 50.17 11.90 57900.2 P14618 5 1 & 2 
Thrombospondin-4  6.64E-09 60.23 10.70 105801.8 P35443 6 1 & 2 
 Ig kappa chain V-I region 
DEE 
3.55E-
14 36.31 16.70 11653.8 P01597 4 1,2 & 3 
Alpha-1-antichymotrypsin  6.77E-14 40.26 13.70 47620.6 P01011 4 1,2 & 3 
Alpha-1-antitrypsin  1.77E-10 40.22 13.20 46707.1 P01009 4 1,2 & 3 
Alpha-2-macroglobulin 1.00E-30 630.29 49.60 163187.4 P01023 63 1,2 & 3 
Alpha-enolase  5.81E-13 18.25 10.10 47139.4 P06733 2 1,2 & 3 
Apolipoprotein A-I  4.46E-10 50.20 22.10 30758.9 P02647 5 1,2 & 3 
Beta-2-glycoprotein 1  1.16E-10 50.26 23.80 38272.7 P02749 5 1,2 & 3 
C4b-binding protein alpha 
chain  
1.22E-
14 250.35 50.30 66989.4 P04003 25 1,2 & 3 
C4b-binding protein beta 
chain  
2.60E-
09 30.16 17.10 28338.5 P20851 3 1,2 & 3 
Carboxypeptidase B2  8.61E-09 20.22 13.00 48393.5 Q96IY4 2 1,2 & 3 
Cartilage acidic protein 1  1.91E-11 100.24 19.10 71375.9 Q9NQ79 10 1,2 & 3 
CD5 antigen-like  2.22E-15 110.32 42.90 38063.0 O43866 11 1,2 & 3 
Ceruloplasmin 2.00E-14 160.28 23.00 122127.6 P00450 16 1,2 & 3 
Clusterin  1.20E-12 100.25 18.90 52461.1 P10909 10 1,2 & 3 
Collagen alpha-2(VI) chain  1.09E-06 50.16 5.10 108511.9 P12110 5 1,2 & 3 
Complement C1q 
subcomponent subunit B  
6.12E-
10 50.32 23.70 26704.5 P02746 5 1,2 & 3 
Complement C1q 
subcomponent subunit C  
6.66E-
15 50.31 25.30 25757.1 P02747 5 1,2 & 3 
Complement C1r 
subcomponent  
6.35E-
11 70.25 16.20 80066.8 P00736 7 1,2 & 3 
Complement C3  1.00E-30 940.41 59.20 187029.3 P01024 95 1,2 & 3 
Complement C4-A  5.55E-16 580.38 39.70 192649.5 P0C0L4 58 1,2 & 3 
Complement C4-B  1.00E-30 580.37 39.70 192671.6 P0C0L5 58 1,2 & 3 
Complement C5  7.77E-16 280.25 17.80 188185.3 P01031 28 1,2 & 3 
Complement component C6  1.11E-14 80.26 13.00 104717.9 P13671 8 1,2 & 3 
Complement component C7  1.33E-15 160.23 33.90 93457.3 P10643 16 1,2 & 3 
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Complement component C8 
alpha chain 
3.00E-
14 120.41 27.90 65121.0 P07357 12 1,2 & 3 
Complement component C8 
beta chain  
1.98E-
12 110.28 25.20 67003.5 P07358 11 1,2 & 3 
Complement component C9  1.95E-14 110.27 20.00 63132.8 P02748 11 1,2 & 3 
Complement factor B  8.24E-13 110.21 21.60 85478.6 P00751 11 1,2 & 3 
Complement factor H  9.99E-15 420.34 46.50 139004.4 P08603 42 1,2 & 3 
Complement factor H-related 
protein 1  
2.84E-
10 70.25 27.60 37626.0 Q03591 7 1,2 & 3 
Complement factor H-related 
protein 2  
9.79E-
10 50.20 20.70 30630.6 P36980 5 1,2 & 3 
Complement factor I  1.44E-11 60.15 15.10 65706.7 P05156 6 1,2 & 3 
Fibrinogen alpha chain  1.11E-15 190.31 21.80 94914.3 P02671 19 1,2 & 3 
Fibrinogen beta chain  1.00E-30 338.43 57.40 55892.2 P02675 34 1,2 & 3 
Fibrinogen gamma chain 2.11E-14 240.29 59.60 51478.9 P02679 24 1,2 & 3 
Fibronectin  4.44E-15 640.34 39.20 262457.6 P02751 64 1,2 & 3 
Ficolin-3  2.82E-10 40.28 16.10 32882.0 O75636 4 1,2 & 3 
Galectin-3-binding protein  2.98E-10 50.20 16.20 65289.4 Q08380 5 1,2 & 3 
Gelsolin  1.70E-11 80.23 17.50 85644.3 P06396 8 1,2 & 3 
Haptoglobin  4.12E-10 130.26 26.40 45176.6 P00738 13 1,2 & 3 
Haptoglobin-related protein  1.10E-09 60.20 25.00 39004.7 P00739 6 1,2 & 3 
Ig alpha-1 chain C region  5.55E-15 100.27 36.80 37630.7 P01876 10 1,2 & 3 
Ig alpha-2 chain C region 5.55E-15 70.26 23.20 36503.0 P01877 7 1,2 & 3 
Ig gamma-1 chain C region  8.44E-09 50.23 18.80 36083.2 P01857 5 1,2 & 3 
Ig gamma-2 chain C region  1.44E-08 30.17 8.90 35877.8 P01859 3 1,2 & 3 
Ig gamma-3 chain C region  1.11E-15 100.29 44.00 41260.4 P01860 10 1,2 & 3 
Ig gamma-4 chain C region  1.44E-08 30.17 8.90 35917.9 P01861 3 1,2 & 3 
Ig heavy chain V-III region 
BRO  
2.44E-
14 20.33 25.00 13218.4 P01766 2 1,2 & 3 
Ig heavy chain V-III region 
VH26  
1.90E-
08 30.19 18.80 12574.2 P01764 3 1,2 & 3 
Ig heavy chain V-III region 
WEA  
3.03E-
08 38.21 36.00 12248.5 P01763 4 1,2 & 3 
Ig kappa chain C region  1.00E-30 60.33 82.10 11601.7 P01834 6 1,2 & 3 
Ig kappa chain V-I region AG  1.35E- 36.31 16.70 11984.9 P01593 4 1,2 & 3 
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Ig kappa chain V-I region AU 1.35E-12 36.31 16.70 11931.8 P01594 4 1,2 & 3 
Ig kappa chain V-I region EU  2.71E-12 38.25 26.90 11780.8 P01598 4 1,2 & 3 
Ig kappa chain V-I region Gal 1.35E-12 36.31 16.70 11806.9 P01599 4 1,2 & 3 
Ig kappa chain V-I region Hau 1.35E-12 36.31 16.70 11663.7 P01600 4 1,2 & 3 
Ig kappa chain V-I region Ni  1.43E-07 36.18 30.40 12238.0 P01613 4 1,2 & 3 
Ig kappa chain V-I region Rei  1.35E-12 36.31 16.70 11894.9 P01607 4 1,2 & 3 
Ig kappa chain V-I region Roy  1.35E-12 36.31 16.70 11774.8 P01608 4 1,2 & 3 
Ig kappa chain V-I region Scw  1.35E-12 36.31 16.70 11756.8 P01609 4 1,2 & 3 
Ig kappa chain V-I region 
WAT 
3.40E-
12 26.27 16.70 11729.8 P80362 3 1,2 & 3 
Ig kappa chain V-I region 
WEA  
3.40E-
12 26.27 16.70 11832.8 P01610 3 1,2 & 3 
Ig kappa chain V-III region 
GOL  
1.22E-
11 20.24 22.90 11823.0 P04206 2 1,2 & 3 
Ig kappa chain V-III region 
HAH  
1.22E-
11 30.24 31.80 14064.1 P18135 3 1,2 & 3 
Ig kappa chain V-III region 
HIC  
1.22E-
11 30.24 31.80 14080.1 P18136 3 1,2 & 3 
Ig kappa chain V-III region 
WOL  
2.30E-
12 30.20 39.40 11738.9 P01623 3 1,2 & 3 
Ig lambda-1 chain C regions  1.45E-12 40.31 55.70 11340.6 P0CG04 4 1,2 & 3 
Ig lambda-2 chain C regions  1.45E-12 40.31 55.70 11286.6 P0CG05 4 1,2 & 3 
Ig lambda-3 chain C regions 1.45E-12 40.31 55.70 11230.5 P0CG06 4 1,2 & 3 
Ig lambda-6 chain C region  3.00E-14 30.25 46.20 11269.5 P0CF74 3 1,2 & 3 
Ig mu chain C region  1.67E-14 170.36 38.10 49275.6 P01871 17 1,2 & 3 
Ig mu heavy chain disease 
protein 
1.67E-
14 110.36 29.40 43030.3 P04220 11 1,2 & 3 
Immunoglobulin J chain  8.13E-10 40.22 32.10 18087.0 P01591 4 1,2 & 3 
Immunoglobulin lambda-like 
polypeptide 5  
1.29E-
11 40.25 32.20 23048.6 B9A064 4 1,2 & 3 
Keratin, type I cytoskeletal 10  4.59E-11 170.25 31.30 58791.6 P13645 17 1,2 & 3 
Keratin, type I cytoskeletal 14  2.91E-09 110.22 24.60 51529.4 P02533 11 1,2 & 3 
Keratin, type I cytoskeletal 16  6.33E-12 130.29 34.00 51236.3 P08779 13 1,2 & 3 
Keratin, type I cytoskeletal 9  1.00E-30 188.39 46.20 62026.7 P35527 19 1,2 & 3 
Keratin, type II cytoskeletal 2 
epidermal  
6.66E-
14 190.26 37.60 65393.2 P35908 19 1,2 & 3 
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Keratin, type II cytoskeletal 5  1.97E-09 110.24 16.80 62340.0 P13647 11 1,2 & 3 
Keratin, type II cytoskeletal 
6A   
2.67E-
06 20.15 4.10 60008.3 P02538 2 1,2 & 3 
Keratin, type II cytoskeletal 
6B  
1.97E-
09 210.24 36.90 60030.3 P04259 21 1,2 & 3 
Keratin, type II cytoskeletal 
6C  
5.37E-
11 220.24 39.90 59988.4 P48668 22 1,2 & 3 
Keratin, type II cytoskeletal 
75  
6.33E-
08 70.24 10.70 59524.1 O95678 7 1,2 & 3 
Keratin, type II cytoskeletal 
79  
6.33E-
08 40.24 7.10 57800.2 Q5XKE5 4 1,2 & 3 
Neutrophil defensin 1  4.25E-06 20.15 19.10 10194.2 P59665 2 1,2 & 3 
Neutrophil defensin 3  4.25E-06 20.15 19.10 10238.2 P59666 2 1,2 & 3 
Pigment epithelium-derived 
factor  
7.01E-
12 90.22 21.80 46283.4 P36955 9 1,2 & 3 
Plasma protease C1 inhibitor  7.70E-09 50.20 11.60 55119.5 P05155 5 1,2 & 3 
Plasminogen  9.99E-16 280.30 44.30 90510.2 P00747 28 1,2 & 3 
Pregnancy zone protein 9.92E-10 100.23 8.00 163759.1 P20742 10 1,2 & 3 
Protein S100-A8  8.54E-08 40.19 39.80 10827.7 P05109 4 1,2 & 3 
Proteoglycan 4  2.50E-13 90.26 7.70 150983.2 Q92954 9 1,2 & 3 
Prothrombin  1.11E-16 220.27 53.50 69992.2 P00734 22 1,2 & 3 
Serotransferrin  1.04E-11 240.27 37.00 77013.7 P02787 24 1,2 & 3 
Serum albumin  1.00E-30 430.33 68.10 69321.6 P02768 43 1,2 & 3 
Serum amyloid P-component  4.36E-10 50.22 23.80 25371.1 P02743 5 1,2 & 3 
Serum 
paraoxonase/arylesterase 1  
1.04E-
10 40.17 18.90 39706.3 P27169 4 1,2 & 3 
Vitamin K-dependent protein 
S  
5.57E-
11 80.25 12.60 75074.1 P07225 8 1,2 & 3 
Vitronectin  7.22E-15 70.28 15.10 54271.2 P04004 7 1,2 & 3 
Complement C1q 
subcomponent subunit A  
1.14E-
07 20.12 13.10 26000.2 P02745 2 1 & 3 
Ig heavy chain V-III region 
TIL  
4.12E-
13 20.22 26.10 12348.1 P01765 2 1 & 3 
Ig kappa chain V-II region 
TEW 
4.79E-
10 20.27 32.70 12308.2 P01617 2 1 & 3 
Ig lambda-7 chain C region 1.45E-12 30.31 41.50 11295.6 A0M8Q6 3 1 & 3 
Lysozyme C 1.29E-12 40.24 39.90 16526.3 P61626 4 1 & 3 
Properdin  6.80E-06 30.24 8.50 51242.0 P27918 3 1 & 3 
 Keratin, type I cytoskeletal 1.86E- 20.16 3.90 50536.0 Q7Z3Y7 2 2 & 3 
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Actin, alpha cardiac muscle 1  1.80E-06 40.24 11.10 41991.9 P68032 4 2 & 3 
Actin, alpha skeletal muscle 1.80E-06 40.24 11.10 42023.9 P68133 4 2 & 3 
Actin, aortic smooth muscle  1.11E-15 80.30 23.60 41981.8 P62736 8 2 & 3 
Actin, cytoplasmic 1  1.80E-06 40.24 11.20 41709.7 P60709 4 2 & 3 
Actin, cytoplasmic 2  1.00E-30 30.36 14.90 41765.8 P63261 3 2 & 3 
Actin, gamma-enteric smooth 
muscle  
1.11E-
15 80.30 23.70 41849.8 P63267 8 2 & 3 
Coagulation factor XI  1.36E-09 40.16 6.90 70063.6 P03951 4 2 & 3 
Hemoglobin subunit alpha  8.51E-09 30.26 39.40 15247.9 P69905 3 2 & 3 
Hemoglobin subunit beta  1.39E-05 30.19 21.80 15988.3 P68871 3 2 & 3 
Hepatocyte growth factor 
activator  
8.50E-
08 30.16 6.00 70636.2 Q04756 3 2 & 3 
Histone H4  8.05E-07 40.19 38.80 11360.4 P62805 4 2 & 3 
Ig kappa chain V-I region 
CAR 
2.71E-
12 28.25 16.80 11696.3 P01596 3 2 & 3 
Ig kappa chain V-I region Lay  2.34E-06 18.17 8.30 11826.8 P01605 2 2 & 3 
Ig kappa chain V-III region 
CLL  
1.59E-
09 28.18 19.40 14266.2 P04207 3 2 & 3 
Ig kappa chain V-III region 
NG9 (Fragment)  
3.05E-
07 46.17 41.00 10722.3 P01621 5 2 & 3 
Ig kappa chain V-IV region 
(Fragment)  
8.45E-
08 30.20 24.80 13371.6 P06312 3 2 & 3 
Ig kappa chain V-IV region 
B17  
3.00E-
06 20.17 13.40 14956.5 P06314 2 2 & 3 
Ig kappa chain V-IV region JI  4.86E-08 30.19 22.60 14623.3 P06313 3 2 & 3 
Ig kappa chain V-IV region 
Len  
1.29E-
09 50.22 42.10 12632.2 P01625 5 2 & 3 
Ig kappa chain V-IV region 
STH (Fragment)  
4.86E-
08 20.19 19.30 12052.9 P83593 2 2 & 3 
Ig lambda chain V-III region 
LOI  
1.55E-
08 20.20 21.60 11927.8 P80748 2 2 & 3 
Keratin, type I cytoskeletal 13  4.33E-08 40.20 7.40 49557.4 P13646 4 2 & 3 
Keratin, type I cytoskeletal 15 4.33E-08 40.20 7.00 49181.1 P19012 4 2 & 3 
Keratin, type I cytoskeletal 17  3.56E-09 50.16 10.20 48076.1 Q04695 5 2 & 3 
Keratin, type I cytoskeletal 19 1.09E-05 20.20 4.50 44079.2 P08727 2 2 & 3 
Keratin, type I cytoskeletal 20  2.34E-05 26.16 4.00 48457.0 P35900 3 2 & 3 
Keratin, type I cytoskeletal 25  1.86E-06 20.16 4.00 49287.4 Q7Z3Z0 2 2 & 3 
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Keratin, type I cytoskeletal 27 5.77E-06 20.17 3.90 49791.6 Q7Z3Y8 2 2 & 3 
Keratin, type II cytoskeletal 2 
oral  
5.98E-
06 30.19 4.50 65800.1 Q01546 3 2 & 3 
Keratin, type II cytoskeletal 3  1.66E-06 30.16 4.60 64377.6 P12035 3 2 & 3 
Keratin, type II cytoskeletal 4  6.49E-08 18.19 3.70 57249.9 P19013 2 2 & 3 
Macrophage receptor 
MARCO  
2.28E-
04 20.14 5.20 52625.4 Q9UEW3 2 2 & 3 
Malate dehydrogenase, 
mitochondrial  
6.11E-
06 30.18 10.90 35480.7 P40926 3 2 & 3 
Plasma serine protease 
inhibitor  
5.28E-
07 40.16 11.10 45645.8 P05154 4 2 & 3 
POTE ankyrin domain family 
member E  
1.37E-
11 20.23 2.40 121285.6 Q6S8J3 2 2 & 3 
POTE ankyrin domain family 
member F  
1.80E-
06 20.24 2.00 121366.6 A5A3E0 2 2 & 3 
Table 3.7: Proteome of a pooled OA patient sample (n=4).  This table is a condensed 
summary of appendices 1, 2 and 3.  Also included (in the right hand column) is an 
indication of the method(s) that identified each particular protein – 1=5Hr RP-HPLC, 
2=SCX/RP-HPLC, 3=In-gel digestion.  
 
A total of 104 proteins are common to all three methods of analysis. Of these, 17% are 
complement-related, while 34% belong to the immunoglobulin family.  Surprisingly, the 
highly abundant proteins albumin and α-2-macroglobulin are included in this sub-group.  
It was expected that CHAPS treatment would remove these soluble species.  It may be 
that they are members of the vesicle cargo.  However, a very interesting protein, S100-
A8, which will be discussed later, is also common to all three modes of analysis.  This 
protein was cited as being unique to RA in the literature.  
From Figure 3.26 it is revealed that SCX-RP-HPLC characterized the highest number of 
proteins (206) with in-gel digestion (192) next and finally the 5-hour RP-HPLC with 136 
proteins.  
Examination of Figure 3.26 reveals SCX-RP-HPLC and in-gel digestion yielded almost 
equal numbers of unique proteins (47 and 46 respectively), while the 5-hour RP-HPLC 
uncovered around 10 times less.  This also supports the trend in the literature towards a 
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combination or coupling of orthogonal methodologies as a proteomic strategy 64.    Table 
3.4 reveals that all histone (with the exception of histone H4) and myosin subtypes are 
exclusively unique to the in-gel trypsin digestion method.  This maybe be due to protein 
enrichment in a particular band, while in the methods employing HPLC shotgun 
approach, these proteins may be masked by other more abundant proteins e.g. 
complement C3, fibronectin, alpha-2-macroglobulin, which are detected simultaneously.   
Comparing any two methodologies in Figure 3.26 highlights that all actin associated with 
MV proteome, is a result of SCX-RP-HPLC and/or “in gel” digestion.  No actin was 
found by employing RP-HPLC only.  In addition, the commonality between SCX-RP-
HPLC and in-gel digestion (35 proteins – mainly immunoglobulin fragments and skeletal 
proteins) is greater than the other two pairs (20 and 7).  However, it is interesting to note 
that the important cartilage ECM protein, cartilage oligomeric matrix protein (COMP), 
which is widely cited as a putative OA marker (to be discussed later) was not detected by 
MS analysis of the gel bands, where as both shotgun approaches identified this protein.  
These findings highlight an important point.  To attempt a proteomic profiling of any 
biofluid, it may be prudent to employ a variety of techniques and assess the list of 
proteins generated from each method.  Reliance on any one single method may result in 
the loss of some potentially useful information.      
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Proteins were then classified with an on-line bioinformatics tool, known as Panther 65.  
The goal of Panther is to sub-divide proteins into families and sub-families and therefore, 
classify proteins by function.  Position-specific amino acids are used to determine if 
certain segments of a protein are conserved (e.g. hydrophobicity), and this leads to 
information on protein function. Thomas et al.65 state that families can overlap so 
proteins may be members of multiple families.  For example, an immunoglobulin 
variable region (Ig-V) appears in nine families while myosins appear in the largest 
number of families.  Of the 264 proteins found, 50 were not recognized by the database.  
These are listed in Appendix A.  Of these, 82% are immunoglobulin fragments.  Two 
interesting proteins not classified by Panther are heat shock protein 70 (HSP70) which is 
a known exosome-associated protein (Figure 3.6) and dermcidin. 
The Panther database classified 214 (264-50) proteins under four headings; 
(i) Cellular Components 
(ii) Protein Molecular Function 
(iii) Biological Process 
(iv) Protein Class  
These complete protein classification lists are displayed in Appendices B, C, D, & E 
respectively. 
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3.2.3.1 Cellular Components 
Three sub-groups make up this classification and these are shown in Figure 3.27. 
 
Cellular Components
20
49
16
0 10 20 30 40 50 60
Extracellular Region
Intracellular
Protein Complex
Number of Proteins
 
Figure 3.27: Panther “Cellular Components” sub-classification.    
In addition to an expected intracellular and extracellular division, a protein complex sub-
group is present.  This is interesting in light of the recent work by György et al. 14 who 
issued a note of caution relating to the presence of immune complexes co-existing with 
isolated MVs.  Proteins in this group include IgA, IgD, IgG and IgM.  At this point it is 
not possible to state whether these are (i) in the form of immune complexes or (ii) 
vesicle-associated i.e. engulfed or trans-membrane species.  Intracellular species are 
almost exclusively skeletal and motor proteins. Included in the extracellular region are 
some collagen species and COMP.  As mentioned above, of the 264 proteins found, 50 
were not classified by Panther.  This means 214 were recognized.  However, it is 
surprising that only 85 proteins are included in this sub-classification, leaving 129 not 
classified by location.      
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3.2.3.2 Protein Molecular Function  
A complete list of each sub-group is shown in Appendix C.  Figure 3.28 is a summary of 
this list in bar chart form. 
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 Figure 3.28: Panther “Molecular Function” sub-classification of 214 uniquely 
identified proteins  
Three major molecular function sub-groups emerge from Figure 3.28, i.e. binding, 
catalytic activity and structural molecule activity.  The binding sub-group includes 
antigen binding species such as immunoglobulins, fibrinogen, α-2-macroglobulin, 
COMP, complement components, cartilage acidic protein and the actin-scavaging 
protein, gelsolin.  Serine-type peptidases represent a large proportion of molecules 
classified under catalytic activity e.g. MMP3 and serine protease Htra1.  Type I and type 
II keratins were particularly represented in the sub-group, structural molecule activity.  
However, keratin is a well-known MS contaminant that comes from skin and dust.  Care 
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was taken when preparing samples for MS.  One interesting keratin species that was 
found was type I keratin 17 which was referred to as “exosomal cytokeratin 17” by 
Welton et al. 66  
3.2.3.3 Biological Process 
A complete list of each sub-group is shown in Appendix D and a summary bar-chart is 
shown in Figure 3.29.  
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Figure 3.29: Panther “Biological Process” sub-classification of 214 uniquely identified 
proteins  
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Five proteins were classified as associated with apoptosis.  Based on the information in 
Table 3.2 and a study by 67, histones are protein markers of apoptotic bodies, so it was 
surprising that even though histones (H2B and H4) are present in the 200,000g pellet 
proteome, Panther did not classify these species as apoptotic-related. 
Some proteins involved in the cell adhesion subgroup include vitronectin, collagen α-
3(VI) chain, collagen α-2(VI) chain, aggrecan core protein 2 (binds avidly to hyaluronic 
acid and resists cartilage compression), low-density lipoprotein receptor-related protein 1 
intracellular domain (α-2 Macroglobulin and apolipoprotein E receptors).  Another 
interesting MV-associated protein in this sub-group is transforming growth factor-beta-
induced protein ig-h3, which, according to the UniProtKB database binds to type I, II, 
and IV collagens. This adhesion protein is also thought to play an important role in cell-
collagen interactions. In cartilage, it may be involved in endochondral bone formation.  
As mentioned above, four classes of immunoglobulin are vesicle-associated and it was 
hypothesised that they are entrapped within the vesicle or else associated with the outer 
membrane (particularly IgM and IgD 68).  This hypothesis may have some merit due to 
the presence of IgGFc-binding protein.  As protein A only binds to the Fc region of the 
molecule, IgGFc-binding protein may be already bound to IgG and may help explain why 
this immunoglobulin remains vesicle-associated.  Shed vesicles/ectosomes may be the 
likely vesicle-type that has membrane-bound IgG.   
In the cell communication sub-group interesting inflammation-inducing proteins include 
the calgranulins, protein S100-A8 and S100-A9.  These will be discussed later.  Also 
present are galectin-3-binding protein and CD5 antigen-like (IgM-associated peptide) -
both involved in macrophage activation - and macrophage receptor MARCO.  
Procollagen C-endopeptidase enhancer 1 is cell surface receptor that, according to 
UniProtKB, may have a metalloproteinase inhibitory activity.  
  
The cell cycle, cellular component organisation and cellular process sub-groups are 
largely composed of actin, keratin and myosin. 
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Species that are involved in activation of the immune system form a large proportion of 
this sub-classification e.g. immunoglobulins and components of the complement cascade.  
Components belonging to each of the three complement cascade pathways, are included 
i.e. classical pathway (C1q, C1r andC1s), lectin pathway (mannose binding lectin) and 
alternative pathway (complement factor B and properdin).  
3.2.3.4 Protein Class 
Classification of the MV proteome based on protein class or protein function is displayed 
in Figure 3.30. 
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Figure 3.30: Panther classification of MV proteome according to “Protein Class” or 
protein function 
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As with the preceding classifications, cytoskelatal and immune system proteins form the 
largest subgroups.  Proteases and protease inhibitors are also represented. Transporter 
proteins include apolipoproteins, ceruloplasmin and the transmembrane ion transporter, 
ATP synthase subunit β.     
 
3.2.4 Selected protein analysis by Western Blot (WB) – a confirmatory study  
It is important to ascertain the validity of some proteins identified by MS by confirming 
their presence by other techniques. In order to confirm the data obtained by MS, some 
proteins were selected for analysis by an orthogonal mode of analysis i.e. incubation with 
polyclonal antibodies and detection employing WB.  It is also important to establish the 
presence of proteins that were not detected by MS, but which may be present and masked 
by more abundant species.  Finally, the absence of a protein by MS analysis should be 
confirmed by WB. 
Exosomal markers e.g. Tsg101 and CD63, were not detected by MS in our study.  
However, both proteins were detected by WB analysis (Figures 3.9, 3.17 and 3.22 for 
Tsg101) and (Figures 3.14 and 3.18 for CD63).  This echoes the observation made by 
Welton et al. 66  There, due to a minimum of two peptides required for positive 
identification “cut-off”, these species were not included as part of the proteome of 
exosomes derived from bladder cancer cells, but their presence was confirmed by WB.   
Both IgM and albumin were identified by MS and their presence in MVs was confirmed 
by WM in Figure 3.19.  The exosomal protein β-actin, which was shown to be present in 
Figure 3.14, was not identified by MS analysis (thought six other actin species were 
identified).   
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Apolipoprotein A-I was found as part of the proteome of OA MVs when analysed by MS.  
It presence was confirmed by WB (Figure 3.31, at ~25kDa)  
 
 
 
 
 
 
 
 
 
 
Figure 3.31: WB analysis of the 200,000g CHAPS pellet for five different patient 
pathologies following incubation with anti-apolipoprotein A-I 
 
Orosomucoid (α1-acid glycoprotein) is one of the most abundant plasma proteins, 
accounting for about 1% of all plasma proteins and is expressed in hepatocytes and 
secreted into the plasma under stressful conditions such as tissue injury, infection, and 
inflammation 69.  It is known to be involved in three biological functions: 
immunomodulatory function, barrier function, and carrier function.  Therefore, it came as 
a surprise that this versatile species was not included in the list of proteins returned 
following MS analysis.  It was decided to confirm its absence by WB analysis.  The WB 
of the 200,000g CHAPS pellet is displayed in Figure 3.32. 
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Figure 3.32: Incubation of 200,000g CHAPS pellet fractions with anti-orosomucoid and 
detection by WB 
 
In Figure 3.32 it shown that with the exception of gout (Lane 5) and IA (Lane 3), there is 
practically no orosomucoid present at 44kDa, the molecular weight of this protein 70.  It is 
completely absent in the RA sample and a low amount is present in the OA sample.  This 
explains why this species was not detected by MS.  The peptides for this protein are most 
likely masked by the most abundant species which are present e.g. complement factors, 
α-2-macroglobulin, fibronectin etc.   
 
So far, (with the exception of IgM), confirmatory studies were carried out on monomeric 
proteins.  Two further analyses were carried out to include polymeric moieties.   These 
were the high abundant protein α-2-macroglobulin (63 peptide hits and 50% coverage) 
and the low abundant IgD (2 peptide hits and 6.8% coverage).  
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α-2-macroglobulin (α-2-M) is a 720kDa homotetrameric glycoprotein (each monomer ~ 
180kDa) that can cleave into a dimer of dimers under very mild denaturating conditions 
71
.  WB analysis under both reducing and non-reducing conditions was performed.  This 
is displayed in Figure 3.33. 
 
 
 
 
 
 
 
 
 
   
Figure 3.33: Incubation of 200,000g CHAPS pellet fractions with α-2-macroglobulin 
under non-reducing conditions (left) and reducing conditions (right) 
Under reducing conditions (Figure 3.33, left), fragmentation took place due to the 
reduction of its 13 disulphide bridges.  There was no such fragmentation under non-
reducing conditions (Figure 3.33, right).  Here there was a single band at a molecular 
weight > 250kDa and may be the dimer structure (~ 360kDa).  The fragmentation may be 
explained by proteases activity whereby the α-2-M monomer molecules were cleaved 
along their amino acid backbones.  The entire structure remained intact due to the linkage 
of the disulphide bridges which held the cleaved fragments together.  However, under 
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reducing conditions these disulphide bridges were broken and the entire molecular edifice 
collapsed and fragmented at the points along the chain where cleavage occurred.    
From appendix 1 (i.e. raw MS data), it can be seen that IgD was identified with SCX-RP-
HPLC only, with two peptide matches and a protein coverage of 6.8%.  Therefore, to 
establish the presence of this antibody, analysis by SDS-PAGE under both non-reducing 
and reducing conditions was performed followed by WB.  The WB images are shown in 
Figure 3.34. 
 
 
 
 
 
 
 
 
 
 
Figure 3.34:  Incubation of 200,000g CHAPS pellet with anti-IgD under non-reducing 
condition (left) and under reducing conditions (right)  
 
Under reducing conditions (Figure 3.34, left), it is the case that IgD is present in the 
200,000g CHAPS pellet.  Repeating the experiment under non-reducing conditions 
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(Figure 3.34, right) confirmed that the whole IgD protein is present in all five 
pathologies.  As immunoglobulins were removed using Protein A chromatography prior 
to differential centrifugation, the likely source of IgD is either direct binding to the 
vesicle membrane or/and engulfed within the vesicle.  There is an interesting point to 
note here.  IgD has a molecular weight of 185kDa.  However, in this analysis it was noted 
that the molecular weight of the entire molecule is ~250kDa.  What could explain this 
discrepancy?  Vladutiu et al. 68 studied the properties, measurement and the clinical 
relevance of IgD and advanced that there are two forms of IgD – membrane-bound and 
secreted.  They explain that both forms are antigenetically similar; they differ in their 
proteolysis by plasmin.  Moreover, the δ chains of each type possess different molecular 
weights, with the membrane-bound species having a higher weight than the secreted 
form.  Therefore, it is possible that the species if IgD present in MV, is membrane bound.   
All these protein-confirmation studies are important for definitively establishing the 
presence/absence of proteins listed/not listed on algorithm-generated MS data.  Of course 
it is neither possible nor practical to complete an exhaustive confirmation study.  
However, for proteins identified as potentially interesting, it would be wise to establish 
their status employing an orthogonal method e.g. by analysis with antibodies.     
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3.2.5 Determination if proteases are associated with SF MVs employing zymography 
Appendix E displays the Panther classification “Protein Class”.  Included in this list is the 
sub-heading “Proteases”.  A zymography experiment was carried out in order to confirm 
if there are proteases associated with MVs.  Other groups have already characterized the 
protease activity in whole SF 72-75 76, 77, but to my knowledge no study has been 
performed to establish if MVs may harbour proteases.  Figure 3.35 shows the proteinase 
activity of various fractions across four patient pathologies.  
 
 
 
 
 
 
 
 
 
 
Figure 3.35: Proteases activity of various differentially centrifuged fractions across four 
patient pathologies.  The substrate was gelatin. Light bands indicate protease activity. 
The lanes highlighted in a yellow box are the targeted 200,000g CHAPS pellet for each 
pathology. 
Protease activity is spread across all fractions.  In the OA sample (Red) there are 
differences between the 18,000g and 200,000g CHAPS pellets with the 18,000g pellet 
(Lane 1) having a wider molecular weight range of proteases.  In the RA sample (blue) 
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there is a striking similarity between the 200,000g Crude and 200,000g CHAPS pellets 
(Lanes 5 and 6) – the difference being one of intensity - with the CHAPS pellet having a 
lower overall intensity.  This may indicate that these particular proteases are mainly 
membrane associated, which on treatment with CHAPS, move to the SN.  There is also 
further enrichment of proteases in the CHAPS SN relative to the crude SN (lanes 7 and 
8).  In the IA sample (green), there is a clear enrichment of protease activity in the 
200,000g CHAPS pellet (lane 3) and the 200,000g CHAPS SN (Lane 5) relative to the 
crude fractions (Lanes 2 and 4 respectively).  Finally in the PSA patient (purple), there is 
clear enrichment of proteases in the 200,000g CHAPS pellet (Lane 8) relative to all the 
other fractions.  This could be interpreted as an indication that for this sample the 
proteases are engulfed with the vesicle or else so strongly bound to the vesicle membrane 
that CHAPS treatment does not remove them. 
Of interest though is a comparison between the 200,000g CHAPS pellets.  These are 
highlighted in yellow boxes.  The RA sample exhibits the least protease activity, possibly 
due to amount of protein loaded.  High molecular weight proteases are most strongly 
expressed in the PSA sample.  Close inspection shows that the RA and IA samples have 
similar band patterns, though they differ in intensity.  The OA sample has a band 
(highlighted in a red box) that is either absent from or more intensely expressed relative 
to, the other three pathologies.      
 
3.2.6 Determination of hyaluronidase (HAase) activity employing zymography with 
a hyaluronic acid (HA) substrate  
 
As mentioned in the literature review for this project (Chapter 1), HA is the component of 
synovial fluid that imparts viscosity and gives the joint fluid an “egg-like” appearance 
and consistency.  It is known that the size of the HA molecule decreases while its actual 
abundance increases with age and with the onset of arthritic diseases. This decrease in 
size is attributed to degradation and is thought to involve the action of hyaluronidases or 
free radicals.  Girish et al. 78 explain that HAase-mediated degradation of HA increases 
the permeability of connective tissues and decreases the viscosity of body fluids and is 
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also involved in bacterial pathogenesis, the spread of toxins and venoms, acrosomal 
reaction/ovum fertilization, and cancer progression.  Tranchepain et al. 79 demonstrated 
that (HA) has different biological functions according to its molar mass with short HA 
fragments being involved in the inflammation processes whereas native, full-length HA is 
not. 
In order to establish if there is endogenous HAase activity in SF, a zymography 
experiment was carried out employing HA as a substrate.  As bovine HAase was used in 
the sample preparation in order to maximize the yield of MVs, it is important to establish 
that this does not produce “false-positive” bands and that any bands that may be present 
are due to HAase endogenous to SF.  Therefore, 1mg/mL bovine HAase was used as a 
control in this study.  Figure 3.36 is a display of the images acquired following the 
experiment. 
The lane enclosed within the blue box is bovine HAase control.  It can be seen that there 
is no HAase activity in this lane.  Therefore, the original sample treatment with HAase 
does not interfere with the analysis here.  The reason for this is a matter of pH.  
Originally, newly acquired SF samples were treated with bovine HAase at physiological 
pH i.e. ~ pH 7.  However, in this experiment the gels were incubated at pH 3.5 as per the 
protocol by Miura et al.54.       
The lanes enclosed by a yellow box are the targeted 200,000g CHAPS pellet that contains 
exosomes and other MVs.  Examination of these reveals that there is no HAase activity 
(or very little in the case of the PSA patient sample).  This suggests that there are no HA 
proteases associated with MVs following CHAPS treatment.  
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Figure 3.36: HAase activity of various differentially centrifuged fractions across four 
patient pathologies.  The substrate was hyaluronic acid. Light bands indicate protease 
activity. The lanes highlighted in a yellow box are the targeted 200,000g CHAPS pellet.  
The lane highlighted in blue is the bovine HAase control. Boxes are included to aid 
discussion.  
In the OA and IA samples there is HAase activity in the crude 200,000g pellet, which is 
completely removed post CHAPS-treatment.  The bands showing this activity reappear in 
the CHAPS 200,000g SN (Lane 6 for the OA sample and Lane 4 for the IA sample).  
Therefore any HA proteases that are present are likely to be associated with the MV 
membrane.   
When the SN fractions are examined, it may be seen that there is definite HAase activity.  
The evidence for this activity is for the most part in the form of clear bands at two 
separate molecular weights in the middle of the gels.  Also, close examination of the 
imaged also show hints of activity at high molecular weights at the top of the gels. 
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3.4 Discussion 
 
Throughout this report the generic term microvesicle (MV) was intentionally used in 
order to emphasise that a heterogeneous assortment of microparticles is more likely to be 
present, rather than a homogeneous population of exosomes or any other vesicle class.  
Table 3.2 suggested that no physical characteristic e.g. centrifugation speed, size and 
shape, can be employed in order to secure a homogeneous population of any one vesicle 
type.  A vesicle “signature species” was deemed a better aid to classification.  Exosomes 
were never-the-less present in SF as shown by incubation with established exosomal 
markers e.g. CD63 and Tsg101.  MS analysis found another exosome-associated protein - 
heat shock protein 70 (HSP70) (see Tables 3.3, 3.4 and Figure 3.6).  Table 3.2 also lists 
the main protein markers for each of the other vesicle types while Table 3.8 shows the 
top ten proteins found in exosomes. 
 
  
Protein 
Found in 
MV in 
this 
study 
Method 
of 
detection 
1 Heat shock protein 8 No   
2 CD63 antigen Yes WB 
3 Actin, β Yes WB 
4 Glyceraldehyde-3-phosphate dehydrogenase No   
5 Enolase 1, α Yes MS 
6 Heat shock protein 90, α (cytosolic), class A member 1 No   
7 CD9 antigen No   
8 CD81 antigen No   
9 Tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta polypeptide No 
  
10 Pyruvate kinase, muscle Yes MS 
 
Table 3.8:  List of the top ten proteins found in most exosomes.  Data adapted from 
Mathivanan et al. 61.  Included is an indication if any of these species were found in the 
200,000g CHAPS pellet in this project.  Also included is the method of detection that was 
used to characterise any proteins that were found to be associated with MVs. 
 
However, some element of uncertainty still remained.  For example, in Table 3.2 the 
biological signature of apoptotic bodies is the presence of histones, which Thery et al.80  
suggested are not present in exosomes. They believe that during the exosome purification 
step, a slight contamination with apoptotic blebs at the top of the sucrose cushion 
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occurred.  Histone molecules H2B and H4 were found to be present in MVs in the current 
study. 
A number of members from the apolipoprotein family were identified following MS 
analysis e.g. Apolipoprotein A-I, Apolipoprotein A-IV, Apolipoprotein B-100, 
Apolipoprotein D, Apolipoprotein E and clusterin [Apolipoprotein J or SP40SP40 
(protects cells against cytolysis by complement)].  Apolipoprotein A-I (apo A-I) is the 
main protein associated with high density lipoproteins (HDL), in addition to apo C, apo 
E, apo D and apo J 81.  HDLs have a density 1.063-1.210g/mL16 while that of exosomes 
lies in the range 1.13-1.19g/mL.  Therefore, the possibility HDLs were present in both the 
200,000g pellet and the corresponding SN was realised.  This was confirmed by western 
blot (Figure 3.31), where similar band intensities in the 200,000g CHAPS pellet of each 
pathology were observed.  HDLs therefore, represent another possible “contaminant” in 
any exosome isolation protocol and subsequent characterisation.  The role of 
apolipoproteins and HDLs in the immune system will be discussed later. 
   
In a recent study aimed at isolating exosomes and assessing the yield purity, Bobrie et 
al.82, employing electron microscopy and SDS-PAGE/WB, concluded “sucrose gradients 
are not resolutive enough to separate vesicles with small differences in densities, which 
use different intracellular machineries for their secretion”. Therefore, definitive MV 
classification remains uncertain, and a suggestion to exercise caution when laying claim 
to the isolation of a homogeneous population of any particular MV type, is proposed.  
Any isolation protocol based on physical characteristics may result in varying s of MV 
heterogeneity.  
 
One of the aims of this project was to customise a protocol for isolating MVs from whole 
SF.  During method development, it was discovered that sample treatment with 
hyaluronidase (HAase) was necessary in order to increase the MV yield.  For example, it 
was appreciated that in purifying MVs from urine, the Tamm-Horsfall protein adversely 
affected the yield of MV recovery, due to polymerisation and subsequent vesicle 
entrapment 47.  Therefore, sample treatment with dithiothreitol (DTT) was employed as a 
critical step in urine vesicle preparation.  In the case of SF, it was hypothesised that 
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hyaluronic acid (HA) would influence the MV yield.  This hypothesis was realised on 
finding a paper in the literature stating that HA possesses a CD44 receptor 83.  This is 
particularly relevant in light of the fact that all exosomes contain CD44 66 on the surface 
membrane as confirmed by the exosome-specific ExoCarta database     
(http://exocarta.org/gene_summary?gene_id=960).  This project demonstrated HA does 
trap MV (Figures 3.11 & 3.14) and so adversely impacts on the yield on MV obtained, 
which in turn, may affect the proteomic characterisation of such vesicles due to reduced 
sensitivity.  It was therefore concluded, that treatment of SF samples with HAase prior to 
differential centrifugation, was desirable in order to maximise vesicle yield. 
 
Another important step towards optimal MV protein enrichment, was removal of loosely 
associated/soluble proteins or weak protein-protein interactions with 1% (w/v) CHAPS 
followed by a further 200,000g ultracentrifugation step.  It was not established if these 
species were “contaminants” or if they had a specific interaction with the vesicle.  
Sodium deoxycholate and SDS are well known detergents.  However, SDS is 
incompatible with down-stream MS analysis.  Sodium deoxycholate, on the other hand 
can be removed by acid precipitation prior to MS analysis.  However, this detergent has 
been used previously to successfully solubilise membrane-bound proteins prior to trypsin 
digestion 56, 57, 84.  Therefore, this would most likely solubilise the membrane surrounding 
MVs.  CHAPS, by contrast, was known to be able to break protein-protein interactions 60, 
85
 without being able to disrupt strong protein-protein interactions, such as those found in 
tetraspanin-membrane interactions 86.  Musante et al. 48 employed 1% (w/v) CHAPS to 
remove loosely bound proteins from MVs isolated from urine.  That soluble/loosely 
bound proteins are removed from MVs, was demonstrated in Figure 3.13, where there is 
a redistribution of protein from the original 200,000g pellet to the SN following CHAPS 
treatment.  Here for example, the bulk of albumin moved from the pellet to the SN, 
though both MS and WB analysis indicated that albumin was still vesicle-associated 
despite CHAPS treatment.  This was believed to indicate that albumin was a constituent 
of the inner vesicle cargo, or else strongly associated with the vesicle membrane.  The 
integrity of the MV was preserved following CHAPS treatment as shown by the presence 
of exosomal markers Tsg101 (Figures 3.17 and 3.22) and CD63 (Figure 3.18) in the 
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200,000g CHAPS pellet fraction.  If the vesicle was compromised by CHAPS, then all 
the Tsg101 and CD63 would have been moved to the corresponding SN.    However, the 
overarching merit of CHAPS treatment was an enrichment of the lower abundant vesicle-
associated proteome that was previously masked by high-abundant soluble proteins.    
 
To offset any interference of immuncomplexes which can potentially co-precipitate with 
the targeted 200,000g pellet, immunoglobulin removal took place employing Protein A 
affinity chromatography (Figure 3.20).  Further protein enhancement was achieved 
through the use of Protein A chromatography, followed by CHAPS treatment (Figure 
3.21).  This step not only enhanced the band intensities of some proteins, but led to the 
discovery of bands previously masked by high abundant proteins.   
 
The customisation of a MV-harvesting protocol for SF resulted in the workflow displayed 
in Figure 3.23.                    
 
Mass spectrometry was then employed in order to identify proteins associated with the 
isolated 200,000g CHAPS pellet. 
 
In this project, MVs isolated from a four-patient-pooled sample was sent for analysis by 
MS.  A multi-dimensional approach employing three methods was applied i.e. (i) 5 hour 
gradient elution RP-HPLC, (ii) SCX/RP-HPLC and (iii) SDS-PAGE followed by in-gel 
digestion of individual bands.  The aim here was to identify as many proteins as possible.  
The first two methods involved trypsinisation in solution followed by two different 
modes of chromatography, while the third approach consisted of a gel separation 
followed by digestion with trypsin.   A comparison of the three methods in terms of the 
number of individual proteins returned was made and displayed in Figure 3.26.  There, it 
was shown that there are proteins unique to each particular mode of analysis, proteins 
common to any two methods and finally a subset common to all three modes.  For the 5-
hour gradient elution RP-HPLC, 4% of the proteins are unique to that method, while for 
SCX/RP-HPLC and the in-gel techniques the percentage of unique proteins are 23% and 
24% respectively.    That there are proteins unique to each method is testament to the fact 
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that the method employed will influence the output in terms of proteins identified.  
Therefore, for a thorough, comprehensive shotgun proteomic study, it may be prudent to 
adopt an experimental design that utilises a suite of orthogonal techniques.  A study of 
the literature makes it clear that there is no “one method catches all” approach in 
proteomics.  An example of this is in the simultaneous analysis of soluble and membrane-
bound/transmembrane proteins, with the former possessing a high degree of hydrophilic 
moieties while the latter are known to be characterised with hydrophobic domains.  Of 
the proteins unique to the relatively simple 5-hour RP-HPLC, none of them (according to 
UniProt) are membrane-associated.      
Gilmore et al. 87 reviewed the proteomic toolbox available to the researcher wishing to 
characterise membrane proteins.  All methods discussed were based on the principle of 
coupling orthogonal techniques, two of which were SCX/RP-HPLC and in-gel digestion.  
 
The bioinformatic tool Panther, was then used to classify the resulting list of proteins.  It 
was noted with some surprise that 19% of proteins characterised by MS were not 
identified by Panther, while 40% of those that were identified, could not be classified by 
location.  From Appendix A it can be seen that Panther also included the sub-family 
“Protein Complex” which was exclusively composed of members of the immunoglobulin 
family.  This came a surprise result in light of the fact that the MV isolation protocol 
included an immunoglobulin-removal step i.e. Protein A chromatography.  Further, the 
experiment was carried out under non-saturating conditions, where the binding capacity 
of the beads was not exceeded (see Materials and Methods 3.1.15).  A sizable proportion 
of the total OA MV proteome in this project (Table 3.7) was composed of members of 
the immunoglobulin family i.e. IgA, IgD, IgG and IgM.  The presence of IgM (Figure 
3.19) and IgD (Figure 3.34) was also confirmed by WB.  Therefore a discussion of these 
species and their possible role within the targeted 200,000g CHAPS pellet deserves 
attention. 
In the introduction to this chapter a precaution urged by György et al. 14 was noted.  This 
concerned the possible co-precipitation of immune complexes (ICs) with MV since both 
species share many of the same biophysical properties (size, light scattering and 
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sedimentation centrifuge speed).  They expressed concern that any MV purification 
method will be compromised by the presence of ICs. 
A recent post-György study carried out by Neilson et al.88 into plasma microparticles in 
systemic lupus erythematosus (SLE) set out with the aim of “evaluating the putative role 
of MPs in SLE as circulating antigenic targets and carriers of ICs”.  It is important to 
note that they used the term “microparticles” throughout, which they said are shed from 
cells constitutively or during activation or during apoptosis.  Therefore, analogous with 
the current project, there is likely to be a heterogeneous host of vesicle types present.  
They found that cell-derived MVs carried increased cargos of IgG, IgM and also C1q and 
that IgG containing MVs were associated with auto-antibodies and compliment 
activation.  They listed three possible consequences for this, namely; (i) autoantigen-
presenting MVs may be highly autoimmunogenic, (ii) bound immunoglobulins invite the 
classical complement cascade to occur and (iii) MVs traffic ICs to other cells and deposit 
them there (they gave an example of trafficking ICs to endothelial cells in kidney 
glomeruli).  The group also found that patients with active disease had the highest levels 
of IgG, IgM and C1q and concluded that the compliment system is activated by cell 
derived MVs carrying ICs in SLE.  A possible role for MVs in off-setting compliment-
associated damage to chondrocytes will be discussed later.  Draeger et al. 89 found that on 
activation, an influx of extracellular Ca2+ by the cell is sensed and interpreted as a danger 
signal.  They believed that the cell responds to this with the formation shedding vesicles 
or underwent blebbing.  These processes serve to eject dangerous moieties that have 
become attached to the membrane.  
However, it also needs to be acknowledged that MV (in light of Nielson’s work) could be 
involved in trafficking ICs to the chondrocytes and off-loading their cargo there. 
 
Pisetsky 90 offers an insightful commentary on the study carried out by Nielsen.  This 
editorial point out that while Nielsen did not specify how auto-antibodies appear on 
vesicles, a correlation with the presence of nuclear proteins and the presence of 
antibodies was observed, suggesting a display of nuclear autoantigens by MVs arising 
during apoptosis.  As noted above and in Table 3.2, the presence of histones is indicative 
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of apoptotic blebbing and Pisetsky notes “These considerations put the bleb at centre 
stage during the generation of self antigens that drive autoimmunity”.  In addition to 
histone H2B and histone H4, two other nucleus-associated proteins were found in the 
200,000g CHAPS pellet i.e. general transcription factor IIF and elongation factor 1α 
(Appendix C).  By definition, for these nuclear species to be antigenic and form ICs, they 
must be accessible to the antibody.  Therefore, these proteins may also be present on the 
surface of MVs and hence acquire a role as auto-antigens.  However, Pisetsky pointed out 
that particles/vesicles originating from apoptotic cells have undergone membrane 
permeability changes and so their membranes are likely to be sufficiently porous to allow 
an in-flow of antibodies along with other proteins.  Therefore immunoglobulins may be a 
constituent of the vesicle inner cargo.  
 
In the discussion on immunoglobulins thus far, two models for the presence of these 
species on/in MVs were outlined i.e. (i) IC formation on the vesicle surface and (ii) an in-
flux of antibodies into the vesicle through the membrane.  A third possibility exists.  The 
presence of IgGFc-binding protein in the 200,000g CHAPS pellet was confirmed by MS 
(Table 3.7).  In this model, IgG binds directly to the receptor leaving the Fab region 
exposed to the ECM and bind to a target antigen. 
 
In the results section it was shown that protein A chromatography is a necessary step for 
the removal of soluble and loosely associated immunoglobulins leading to a subsequent 
enrichment in the MV yield and an increase in the band intensities of less abundant 
proteins.  Changes in band intensities were discussed at that point.  However, this study 
culminated in a surprise finding.  Following incubation with anti-Tsg101 (Figure 3.22), it 
was seen that exosomes were present in each of the bound fractions (Lanes 8, 9 &10).  
How can exosomes bind to protein A (an immunoglobulin, Fc-region binding protein)? A 
possible answer to this question is found in the above discussion.  IgG or IgM possibly 
binds to an auto-antigen exposed on the exosome surface.  In turn, the Fc region of the 
antibody becomes bound to the stationary protein A.  This finding expands on the work 
of others which was already discussed here.  Throughout this discussion it was 
highlighted that other research groups discovered auto-antigens to be associated with 
  160 
MVs such as apoptotic blebs and ectosomes/shedding vesicles.  The result here suggests 
that exosomes (products of the endocytic pathway) possibly present auto-antigens on 
their membrane surface and this is why total recovery of exosomes in the targeted 
unbound fraction was not achieved. 
 
Finally, recent research by Ramirez-Alvarado et al. 91 into differences in immunoglobulin 
light chain species in urinary exosomes yielded a very interesting result.  The group 
found that particular high molecular weight, SDS-resistant light-chain species were 
present on the surface of exosomes of light chain amyloidosis patients.  They suggested 
that as only patients suffering from amyloidosis possessed this feature, this would 
warrant further investigation as a marker for this pathology.  In light of this study, it is 
also conceivable that these immunoglobulin fragments are also present on the surface of 
SF exosomes.  As with the above-mentioned research, the significance of this in terms of 
arthritic pathologies may be the subject of interesting future research.                              
    
A search of PubMed for papers relating to synovial fluid MVs reveals that there is no 
proteomic characterisation study performed on MVs isolated from whole SF.  A number 
of SF proteomic studies appear in the literature.  Four recent, representative proteomic 
studies relating to SF and OA were found.  They are; 
1. Analysis of SF exosomes for citrullinated proteins 18 
2. Differential profiling of whole SF from RA and OA patients 92 
3. Differential profiling of whole SF from healthy and OA patients 93 
4. Analysis of articular cartilage vesicles (ACVs) from normal and OA cartilage 94   
 
One interesting study into a specific sub-proteome of SF MVs was carried out by Skriner 
et .al. 18 in 2006.  The subject of this research was to establish an association of 
citrullinated proteins with exosomes among RA, OA and reactive arthritis patients.  No 
control SF was analysed.  Citrullination is an enzyme-catalysed conversion of arginine 
residues to citrulline by peptidyl arginine deiminase.  Previously, Van Venrooij at al. 95 
argued that citrullination may be a modification that could create a novel epitope or 
uncover a previously “hidden” epitope in a protein.  This modification could thus create 
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an auto-antigen and so induce a primary and specific immune response.  Skriner et al. 18  
extended this work to exosomal analysis of citrullinated proteins in RA, OA and reactive 
arthritis patients.  They list a number of proteins and indicate those that are citrullinated.  
This list is shown in Table 3.9. 
 
Protein Citrullination
Fibronectin/IgG immune complex No
? 2-macroglobulin No
Fibrinogen fragment D Yes
Fibrinogen β-chain precurser Yes
Fibrinogen β-chain Yes
IgG1 γ-chain C region No
Unidentified protein Yes
Fibrin ?-chain N-terminal fragment Yes
Spa (CD5 antigen-like protein) Yes
 
Table 3.9:  A list of proteins generated by Skriner et al.18 found in exosomes of OA, RA 
and reactive arthritis patients.  The authors indicate those that were found to be 
citrullinated.  Though each pathology possessed these species, only RA patients produced 
auto-antibodies. 
 
The authors found the same proteins present in all three pathologies (one protein was 
unidentified).  However, auto-antibodies to these citrullinated proteins were present in the 
RA cohort only.  With the exception of Spa, the other species were soluble proteins.   
To the best of my knowledge, this current project is the only research carried out with the 
aim to characterise the proteome of SF MVs.  Therefore, the characterisation of this sub-
proteome in this project is novel.  Other research groups identified the proteome of whole 
SF and some of these will now be discussed and compared with proteins found to be 
associated with MV.  The purpose of this comparison is to compare a whole biofluid 
proteome with that of a sub-proteome of the same biofluid to ascertain if there are species 
present in the latter that were absent in the former, possibly due to masking by high 
abundant soluble proteins.       
 
Recently, Mateos et al. 92 carried out a differential proteomic study of whole SF from OA 
and RA patients.  Prior to analysis, the top 20 must abundant proteins were removed by 
immuno-depletion in order to enrich the lower-abundant, potentially more interesting 
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proteins and a total of 136 proteins were identified.  This was followed by a relative 
quantification between OA and RA by spectral counting analysis, in order to compile a 
list of pathology-specific proteins.  The authors stress that “extreme ratios do not 
necessarily indicate that a given protein is absent in one of the conditions, only that the 
concentration in SF of such proteins is below the detection limit of the followed 
technique”.  A summary of these findings is shown in Table 3.10.  Also included is a 
yes/no indication of whether a specific protein was found to be vesicle-associated in the 
current project. 
 
The authors listed 18 proteins that were relatively more abundant in RA.  Of these, 12 
were not found in the OA pooled sample, while the remaining six were found in both 
pathologies, with a higher expression in RA.  However, five of the 12 proteins not present 
in OA SF were found in the proteome of OA MVs.  They included: complement C4 
gamma chain, pregnancy zone protein, transforming growth factor-beta-induced protein 
ig-h3, histone 4 and Protein S100-A8.  Four of the seven proteins not found in the OA 
MV proteome - azurocidin, neutrophil gelatinase-associated lipocalin, neutrophil defensin 
2 and leucocyte elastase inhibitor – are according to the authors, of neutrophil origin.  
They stated that neutrophil enzymatic activities were closely related to the persistence of 
inflammation, cartilage damage and progression of joint disease.  Though neutrophil 
defensin 2 was not found to be associated with MVs, neutrophil defensin 1 and neutrophil 
defensin 3 were.  The UniProtKB database cited defensin 2 as a cleaved species from 
defensin 1.  Therefore a sub-population of MV found in the current study is likely to be 
of neuclophilic origin, confirming an association of OA with inflammation.       
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Protein Name Unique to RA a
Present in OA 
microvesicles b
Azurocidin Yes No
Complement C4 gamma chain Yes Yes
Apolipoprotein B-48 Yes No
27 kDa interstitial collagenase Yes No
Leucocyte elastase inhibitor Yes No
Pregnancy zone protein Yes Yes
Transforming growth factor-beta-induced protein ig-h3 Yes Yes
Histone H4 Yes Yes
Neutrophil gelatinase-associated lipocalin Yes No
Neutrophil defensin 2 Yes No
Protein S100-A8 Yes Yes
Plastin 2 Yes No
Complement component C8 gamma chain No Yes
Proteoglycan 4 C-terminal part No Yes
Apolipoprotein E No Yes
Stromelysin-1 No Yes
Ficolin-3 No Yes
Complement component C8 gamma chain No Yes
Protein Name Unique to OA c
Present in OA 
microvesicles b
Aggrecan core protein 2 Yes Yes
Cartilage oligomeric matrix protein (COMP) Yes Yes
Complement factor D Yes No
Tetranectin Yes Yes
Inter-alpha-trypsin inhibitor heavy chain H1 No Yes
Gelsolin No Yes
Plasma protease C1 inhibitor No Yes
35kDa inter-alpha-trypsin inhibitor heavy chain H4 No Yes
Alpha-2-antiplasmin No Yes
Cartilage acidic protein1 No Yes
Fibronectin No Yes
Pigment epithelium-derived factor No Yes
Low molecular weight growth-promoting factor No No
Histidine-rich glycoprotein No Yes
Thrombin heavy chain No Yes
Cjitinase-3-like protein 1 No Yes
Alpha-1B-glycoprotein No No
 
 
Table 3.10: A list of differentially expressed proteins between pooled OA and RA 
samples compiled by Mateos et al.92 The top table lists differentially expressed proteins in 
RA synovial fluid, while the bottom table displays proteins relatively enriched in the OA 
pooled sample. Also shown is an indication of whether these species were found in SF 
micro-vesicles 
a adapted from Table 1 92  b proteome of MV in this study  c taken from Table 2 92 
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Examination of the four proteins cited by Mateos et al. 92 as being unique to OA (lower 
half of Table 3.10), shows that three of them are also found in the MV sub-proteome i.e. 
aggrecan core protein 2, COMP (to be discussed below), and tetranectin.  Complement 
factor D was not found to be vesicle-associated.  Further, low molecular weight growth-
promoting factor and alpha-1B-glycoprotein were absent in OA MV.  Finally, as was the 
case in the current project, the authors sought verification of their proteomic data by an 
orthogonal study employing incubation with antibodies and analysis by WB.  They 
confirmed that some proteins that were previously thought to be RA-exclusive, were 
actually present in OA samples e.g. 27kDa interstitial collagenase (MMP-1) and 
transforming growth factor-beta-induced protein ig-h3.  This highlights a limitation to 
any shotgun strategy, which is the possibility of masking low abundant peptides by those 
from high abundant proteins or proteins that undergo extensive fragmentation.  As this 
current research study represents a specific sub-proteome, it follows that proteins 
previously deemed absent in whole SF, may actually be present and associated with 
MVs.  Therefore, experimental design and specific proteome targeting will have a 
bearing on the final outcome in any proteomic study.   
      
The above study by Mateos was a differential proteomic study whose aim was to identify 
proteins that differ between OA and RA in whole synovial fluid.  Gobezie at al.93 also 
performed a differential study in whole SF, only this study examined the proteome 
differences between SF from 20 healthy subjects and 39 patients with OA.  They reported 
135 unique proteins, from which 15 were found to be unregulated in the OA patient 
cohort, while three down-regulated relative to the control group.  Table 3.11 summarises 
this group’s findings.  Also included is confirmation whether these proteins were found to 
be associated with MV in this project. 
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Protein Name 
Upregulated/Down-
regulated relative 
to control group  
Present in OA 
MV 
Cystatin A (stefin A) Down No 
Aggrecan 1 (Chondroitin sulfate proteoglycan core protein 1) Down Yes 
Dermcidin Down Yes 
Albumin Up Yes 
α1-Microglobulin/bikunin precurser Up No 
Fibrinogen, α chain Up Yes 
Fibrinogen, γ chain Up Yes 
α2-Macroglobulin Up Yes 
Apolipoprotein E Up Yes 
Apolipoprotein H (β2-glycoprotein I) Up Yes 
Complement component 3 Up Yes 
Ceruloplasmin Up Yes 
Haptoglobin Up Yes 
Orosomucoid 1 (Alpha-1-acid glycoprotein 1) Up Yes 
Vitamin D binding protein Up Yes 
Complement component 4B Up Yes 
Apolipoprotein A-1 Up Yes 
Retinol-binding protein 4 Up No 
   
Table 3.11:  Eighteen proteins which Gobeize et al.93 found to be significantly 
differentially expressed across control and OA groups.  Also shown is an indication of 
whether these same species were found to be present in OA synovial fluid MVs. 
 
All of these proteins, with the exception of cystatin A, α1-microglobulin and retinol-
binding protein 4 were found within the MV proteome in this project.  Cystatin A (a 
cysteine protease inhibitor) was found to be down-regulated in OA SF relative to the 
control group, suggesting that cysteine proteases may play a significant role in OA 
pathogenesis.  The authors expressed surprise in finding that although serine protease 
inhibitors were present in both OA and healthy SF, there was not a significant difference 
in these species between control and OA samples.  Serine protease inhibitors were also 
found to be associated with OA synovial fluid MVs in this project.  Table 3.12 compares 
the serine protease inhibitors found by Gobezie’s group with those found to be associated 
with OA MVs (as classified by Panther) in this project.  They classified eight serine 
protease inhibitors in their study of whole synovial fluid.  The authors speculate that the 
abundance and large number of these inhibitors is consistent with their importance in 
joint function.  They cite examples of processes within the joint regulated by these 
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species, and include, regulation of MMPs, aggrecanase, plasmin, tissue mitogens (initiate 
cell division), angiogenesis (growth of new blood vessels) activity, inhibition of 
inflammatory leukocyte proteases e.g. neutrophil elastase and finally, regulation of 
fibroblast mitogen binding to extracellular matrix. Of the eight protease inhibitors found, 
five were found to be associated with MVs in this study.  
  
Microvesicle-associated Whole Synovial Fluid
Alpha-1-antichymotrypsin Alpha-1-antichymotrypsin 
Alpha-1-antitrypsin Alpha-1-antitrypsin
Pigment epithelium-derived factor Pigment epithelium-derived factor
Plasma protease C1 inhibitor Plasma protease C1 inhibitor
Pregnancy zone protein Pregnancy zone protein
Alpha-2-antiplasmin Kinninogen
Alpha-2-macroglobulin C1q (with C1s & C1r)
Angiotensin-3 AT III
Inter-alpha-trypsin inhibitor heavy chain H1
Inter-alpha-trypsin inhibitor heavy chain H2
Kallistatin
35 kDa inter-alpha-trypsin inhibitor heavy chain H4
Plasma serine protease inhibitor
Plasmin light chain B
Serine Protease Inhibitors
 
 
Table 3.12: Comparison of serine protease inhibitors found to be associated with MV 
(left column) and those found in whole SF (right column) by Gobeize et al. 93.  Common 
species are displayed in red, while differences are in black.  Classification of proteins in 
microvesicles was achieved by the Panther Classification System. 
 
It was urged by the authors that continued focus on the contribution of both classes of 
protease inhibitors to OA pathogenesis should continue. The study by Mateos (discussed 
above) made no mention of cystatin A.  Bearing in mind that they analysed RA and OA 
samples i.e. pathologic samples, a tentative conclusion may be drawn, that decreasing 
levels of cystatin A could be an interesting OA biomarker.  This would merit further 
study. 
 
As stated above, there is a relative paucity of studies on MVs in synovial fluid in the 
literature by comparison with plasma or urine.  One interesting study however, was that 
carried out by Rosenthal et al. 94.  This research consisted of a proteomic analysis of 
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articular cartilage vesicles (ACV) isolated from normal and OA cartilage.  These vesicles 
fall into the same size category as exosomes but are said by the authors to possess a 
different cargo composition and function.  The proteome was characterised and listed.  A 
comparison was made between both proteomes i.e. ACVs (151 unique proteins) and 
synovial fluid MVs (263 unique proteins).  This comparative analysis is shown in Figure 
3.37 
       
Figure 3.37: A comparative analysis between the proteomic profiles of articular 
cartilage vesicles (red) generated by Rosenthal et al. 94 and synovial fluid MV generated 
in the present study (green).  The number of proteins common to both sets of data is in 
yellow. 
 
Proteins common to both data sets are displayed in Table 3.13.  In terms of proteins 
unique to each particular proteome, 80% (211 proteins) of MV proteins and 66% (99 
proteins) of ACV proteins are unique.  The total number of proteins associated with SF 
MV was 1.7 times that associated with ACVs.  This was likely due to the fact that MVs 
originate from multiple sources i.e. cartilage, lymphocytes, synovium etc., while those 
associated with ACVs came from a specific tissue i.e. cartilage.  It must be borne in mind 
throughout the discussion that follows, that the ACVs may be a subset of SF MVs.  
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P68032 Actin, alpha cardiac muscle 1 
P68133 Actin, alpha skeletal muscle
P62736 Actin, aortic smooth muscle 
P60709 Actin, cytoplasmic 1 
P63261 Actin, cytoplasmic 2 
P63267 Actin, gamma-enteric smooth muscle
P16112 Aggrecan core protein 
P01009 Alpha-1-antitrypsin 
P01023 Alpha-2-macroglobulin
P06733 Alpha-enolase 
P07355 Annexin A2 
P02647 Apolipoprotein A-I 
P06727 Apolipoprotein A-IV 
P05090 Apolipoprotein D 
P02649 Apolipoprotein E 
P13929 Beta-enolase 
P49747 Cartilage oligomeric matrix protein 
P10909 Clusterin 
P00488 Coagulation factor XIII A chain 
P12109 Collagen alpha-1(VI) chain 
P12110 Collagen alpha-2(VI) chain 
P12111 Collagen alpha-3(VI) chain 
P01031 Complement C5 
P13671 Complement component C6 
P07357 Complement component C8 alpha chain 
P68104 Elongation factor 1-alpha 1 
P02671 Fibrinogen alpha chain 
P02751 Fibronectin 
P06396 Gelsolin 
O60814 Histone H2B type 1-K 
P62805 Histone H4
P01876 Ig alpha-1 chain C region 
P01877 Ig alpha-2 chain C region 
P01857 Ig gamma-1 chain C region 
P01859 Ig gamma-2 chain C region 
P01860 Ig gamma-3 chain C region 
P01861 Ig gamma-4 chain C region 
P01834 Ig kappa chain C region 
P01871 Ig mu chain C region 
P04220 Ig mu heavy chain disease protein 
P04264 Keratin, type II cytoskeletal 1 
P00338 L-lactate dehydrogenase A chain 
P61626 Lysozyme C 
P06702 Protein S100-A9
Q92954 Proteoglycan 4 (Lubricin)
P14618 Pyruvate kinase isozymes M1/M2 
Q92743 Serine protease HTRA1
P02743 Serum amyloid P-component 
P24821 Tenascin 
P35443 Thrombospondin-4 
Q15582 Transforming growth factor-beta-induced protein ig-h3 
P04004 Vitronectin 
Proteins common to the proteome of ACVs and OA synovial 
fluid MVs
 
Table 3.13: List of proteins common the proteome of ACVs and OA synovial fluid MVs 
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It was expected that some commonality was shared by the two proteomes, which include, 
cytoskelatal (e.g. actin, keratin, elongation factor 1-alpha 1), extracellular matrix 
(collagen, lubricin, COMP, aggrecan) and cell adhesion (clusterin) proteins.  The author 
noted that while inflammatory components probably originate from SF, chondrocytes are 
capable of synthesising components of the classical complement pathway e.g. C1, C2 and 
C4 and concluded that “the presence of complements and immunoglobulins in OA AVCs 
warrants further consideration”.  It may be hypothesised that the other complement 
components i.e. C5, C6 and C8 and all the other inflammatory-related species (Table 
3.13) come from SF to the cartilage either as soluble proteins or possibly packaged in 
MVs.  Nauta et al. 96 described the role of MVs in inflammation through activation of the 
complement cascade.  The recognition unit of the classical complement pathway, C1q, 
binds to MVs released from apoptotic cells.  Gasser et al. 97 also found C1q on the 
surface of ectosomes/shedding vesicles.  In turn, C1q activates the complement pathway 
by binding to C3 and C4 on the MV surface.  Distler et al.40 interpreted this as a trigger to 
inflammation while Gasser et al.97 hypothesised that the binding of C1q to the cell 
surface triggers the release of ectosomes, which they suggested is important for the 
prevention of the compliment cascade on the cell surface, thus inhibiting the development 
of autoimmunity.  Further, the likely source of these species was the local synovial tissue 
cells and the complement cascade was implicated in the innate immunologic defence of 
the avascular cartilage and also had a role in the patho-physiology of both OA and RA 93. 
A host of complement components were found to be associated with MVs in OA synovial 
fluid in the current project.  Further discussion on complement components will take 
place in relation to COMP (below).  
  
Rosenthal et al. 94 then listed all those proteins that were found (i) in OA ACVs only, (ii) 
in normal ACVs only, (iii) up-regulated in OA and finally, (iv) down-regulated in OA.  
This list is produced in Table 3.14, and as before, a column was added indicating if each 
protein was found in synovial fluid OA MVs.  
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Present in OA MV
P02671 Fibrinogen alpha chain Yes
P02649 Apolipoprotein E Yes
P01857 Ig gamma-1 chain C  region Yes
P01031 Complement C5 Yes
P60174 Triosephosphate isomerase No
P01834 Ig kappa chain C region Yes
P21589 5'-nucleotidase No
P00738 Haptoglobin Yes
P06727 Apolipoprotein A-IV Yes
Q9UKU9 Angiopoietin-related protein 2 No
P68104 Elongation factor 1-alpha 1 Yes
Q14055 Collagen a2(IX) chain No
Q16674 Melanoma-derived growth regulatory protein No
P13611 Versican core protein No 
P57053 Histone H2B type F-S Yes
P02768 Serum albumin Yes
Q15582 Transforming growth factor-beta-induced protein ig-h3 Yes
O43854 Intgrin-binding protein No
P02743 Serum amyloid P-component Yes 
P04004 Vitronectin Yes
Q92743 Serine protease HTRA1 Yes
P12111 Collagen alpha-3(VI) chain Yes
P12109 Collagen alpha-1(VI) chain Yes
P12110 Collagen alpha-2(VI) chain Yes
P10915 Proteoglycan link protein No
Q08431 Lactadherin No
P02458 Collagen a1(II) chain No
P10909 Clusterin Yes
P26038 Moesin No
P21810 Biglycan No
P51888 Prolargin No
O75339 Carti lage intermediate-layer protein 1 No
P16112 Aggrecan core protein Yes
O15335 Chondroadherin No
Q92954 Proteoglycan 4 (Lubricin) Yes
Q8IUL8 Carti lage intermediate-layer protein 2 No
O60687 Sushi repeat-containing protein SRPX2 No
P49747 Carti lage oligomeric matrix protein Yes
P02751 Fibronectin Yes
P35443 Thrombospondin-4 Yes
P35241 Radixin No
O15232 Matril in 3 No
P29992 Guanine nucleotide-binding protein a11 subunit No
P15311 Ezrin No
P07996 Thrombospondin-1 No
P98160 Perlecan No
Down-regulated in OA
Differentially Expressed ACV Proteome
Normal Only
OA Only
Up-regulated in OA
 
Table 3.14: Comparison of the proteome of ACVs derived from normal and OA cartilage 
as performed by Rosenthal et al. 94Also included is whether each protein was found to be 
associated with OA MV. 
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In the OA only category, nine proteins were listed as significantly increased in OA 
ACVs.  Many of these were markers of inflammation i.e. fibrinogen, complement, 
immunoglobulins and lipoproteins.  Of these nine moieties, two were not found in the 
MV proteome i.e. Triosephosphate isomerise and 5'-nucleotidase.  
 
In the Normal only category, six proteins were down-regulated in OA cartilage relative to 
normal cartilage.  With the exception of histone 2B and elongation factor 1, none of the 
remaining four species were found in MVs from OA patients.  One of these was 
angiopoietin-related protein which is a member of the tumour necrosis factor α family 
and was said to be related to the development of connective tissue and cartilage 98.  
Another interesting protein absent in OA MVs was versican.  Research by Matsumoto et 
al. 99  revealed that versican is a large chondroitin sulfate proteoglycan of the 
extracellular matrix mainly present on the surface of developing cartilage.  Interestingly, 
an inverse relationship exists between levels of versican and aggrecan – as the expression 
of one is increased, the other decreases.  Neither of these proteins was present in the 
afore-mentioned studies on whole SF.  That these proteins are not found in ACVs or SF 
MVs lead one to speculate that their expression was either arrested or greatly reduced in 
OA.   
 
The third category - Up-regulated in OA- was comprised of nine proteins.  Eight of these 
were found to be associated with OA vesicles.  Integrin-binding protein DEL-1 was the 
single protein not found in MVs and the authors claim its role in ACVs and in cartilage is 
not known.  Transforming growth factor-beta-induced protein ig-h3 (TGFBIp) was found 
to be both ACV- and MV-associated.  According to UniProtKB this protein binds to type 
I, II, and IV collagens and may play an important role in cell-collagen interactions.  In 
cartilage, it may be involved in endochondral bone formation.  This protein was also 
listed in Table 3.10 above as being found in RA SF only, though the authors later 
confirmed its presence in OA by WB 92.  As its name implies, TGFBIp is a result of 
transforming growth factor-beta protein (TGF-β) which Rosenthal 94 believed supports 
the idea of the putative role for the latter in OA.  However, Nam et al. 100 found this 
protein to be also induced by IL-1β and TNF-α in fibroblast-like synoviocytes in RA 
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patients. It may be that those MVs which contained TGFBIp isolated in this project 
originated from synoviocytes, or may actually be ACVs that are present in the SF as 
mentioned above or indeed be present in exosomes released by activated chondrocytes.  
TGFBIp was found to be associated with chondrocyte-collagen interactions 101.  These 
interactions were recently elucidated by Zhang et al. 102 in their study of the pericellular 
matrix (PCM) - a thin layer of extracellular matrix that immediately surrounds the 
chondrocyte where chondrocytes and extracellular matrix exchange signals.  They 
concluded that TGFBIp is “located pericellularly but its distribution is beyond the 
PCM…….The distribution pattern of TGFBIp indicates that it is not a restrict PCM 
component”.  This conclusion may be explained by the proposition that TGFBIp was 
now MV and/or ACV cargo and departed the PCM micro-environment.  Of interest 
though, TGF-β itself (a precursor to TGFBIp) was not found to be associated with ACVs 
or SF MVs, though this protein has an important role in cartilage homeostasis103.  
Interesting questions presented themselves here in relation to TGFBIp.  Which species 
are precursors to this PCM protein that was found in OA MVs?  Was it TGF-β in the 
cartilage or cytokines (IL-1β & TNF-α) from synoviocytes?  In MVs isolated from OA 
whole SF, it probable that both scenarios were the case.  As this protein is involved in 
cell-collagen interactions via integrins as the sole cell surface receptors 104, it maybe that 
activation of chondrocytes may induce TGFBIp endocytosis followed by trafficking 
through the cell via the endosomal pathway, and finally released into the ECM in 
exosomes.  It could be speculated that this may be a precursor stage to subsequent 
collagen type VI degradation.  Another possibility is that as TGFBIp can undergo both 
covalent and non-covalent interactions with collagen type VI 105 and hence, these two 
species were present in MVs bound to each other.  Finally, as mentioned in the 
introduction to this chapter, exosomes are also known to be antigen-presenting entities.  It 
is possible that if TGFBIp is associated with exosomes it may fulfil this role, especially in 
light of the work published by Cao et al. 106 which detailed an immune regulatory role for 
this protein through stimulation of macrophage endocytosis.         
 
Zhang’s group 102 also noted fragmentation of collagen type VI in the PCM when the 
cartilage was treated with Il-1β and TNF-α and interestingly, mechanical compression.  
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Three collagen type VI fragments (collagen α1(VI) chain, collagen α2(VI) chain and 
collagen α3(VI) chain) were also present in ACVs under the heading “Up-regulated in 
OA” in Table 3.14 and the same three fragments were found associated with SF MVs in 
the current project (Table 3.7).  Disruption of collagen type VI in the PCM is believed to 
destabilise chondrocyte phenotype 107.  This may be very relevant in the early 
pathogenesis of OA.  Polur et al. 108 suggested that biomechanical stress may initiate a 
disruption of the pericellular matrix through serine protease HtrA1.          
 
Serine protease HtrA1 (High-Temperature Requirement A serine peptidase 1), is a 
51.3kDa species that was also found in microvesicles in OA synovial fluid in this project 
and also up-regulated in OA ACVs by Rosenthal 94.  It is known to be associated with a 
variety of targets, including extracellular matrix proteins such as fibronectin and within 
the context of arthritis it was concluded that it contributes to cartilage catabolism and 
degradation 109.  Elevated synovial HtrA1 levels were detected in fluids obtained from 
RA and OA patients, with synovial fibroblasts identified as a major source of this protein, 
and the study confirmed that fibronectin was the major target of this protease.  
Interestingly, fibronectin was also detected in microvesicles in this project despite the 
assertion that this protein is solely associated with RA exosomal fractions 18.  Treatment 
of synovial fibroblasts with HtrA1 or HtrA1-generated fibronectin fragments, in turn 
resulted in the specific induction of MMP1 and MMP3 expression, suggesting that HtrA1 
contributes to the destruction of extracellular matrix through both direct and indirect 
mechanisms 109.  It is worth noting that MMP3 (stromelysin-1) was found associated with 
synovial fluid MV in this project, though MMP1 was not.  In order to establish the extent 
of protease activity in MVs, a zymography experiment was carried out (Figure 3.35) 
which demonstrated that gelatinases are associated with SF MVs.  This is the first study 
to identify protease activity in SF MVs.  However, without WB analysis it is not possible 
to definitively identify these species, though other studies 72, 74-77, 110 have identified 
proteases in whole SF.  No MMPs were found in ACVs.   Tsuchiya et al. 111 examined 
HtrA1 expression pattern during bone and cartilage development and in articular cartilage 
affected by experimental arthritis.  They found that HtrA1 digests other major 
components of cartilage, such as aggrecan, decorin, fibromodulin, and soluble type II 
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collagen, and concluded that HtrA1 may promote degeneration of cartilage by digesting 
cartilage matrix.  Examples of matrix proteins found to be associated with SF MVs 
include, fibrinogen, COMP, fibronectin and collagen type VI.  Polur et al. 108 found that 
pericellular type VI collagen was absent in chondrocytes expressing HtrA1 and that the 
expression of HtrA1 was associated with the expression of discoidin domain receptor 2 
(DDR2) in the chondrocytes.  The activation of DDR 2 in turn led to binding with its 
ligand, namely type II collagen. They argued that these results indicated that HtrA1 may 
disrupt the pericellular matrix network, resulting in alteration of chondrocyte 
metabolisms which eventually led to OA.  Xu et al. 112 recently supported this theory and 
reminded us that type II collagen is not present in the pericellular matrix, so there is 
unlikely to be direct contact between chondrocytes and type II collagen in healthy 
cartilage.  The group concluded that damage to the pericellular matrix induced by HtrA1 
occurs in the early development of OA and this led to aberrant interactions between 
chondrocytes and type II collagen.  MVs from the OA-pooled patient sample in the 
current study, contains three isoforms of collagen type VI (collagen α1(VI) chain, 
collagen α2(VI) chain and collagen α3(VI) chain) along with HtrRA1 and TGFBIp.    
Further study of MV isolated from a larger cohort of OA patient samples and control SF 
would be required to verify if these species are unique to OA MVs.  Markers of PCM 
destruction in MV could have useful early-stage OA diagnostic value.  This can be 
appreciated as important given that once the collagen type II structure is severely 
degraded, the chondrocyte is unable to undertake repair steps 113 .  
 
As mentioned above, MMP3 (~54kDa) was also found to be associated with synovial 
fluid microvesicles.  Figure 3.35 was the result of a zymography study, which is an 
extremely sensitive technique (10pg of a gelatinase may be detected 114), and it 
demonstrated that a host of gelatinases were present in/on MVs and the corresponding 
supernatants.  The list of proteins generated by MS included MMP3.  The stromelysins 
MMP3 and MMP10, digest ECM components such as collagen IV and fibronectin 115, 
with MMP3 having a higher proteolytic efficiency higher than that of MMP10 116.  
Indeed MMP3 is the most strongly expressed MMP in OA cartilage, but its expression 
decreases in late OA 73.  Though MMP3 is incapable of cleaving collagen type II (the 
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major structural protein in cartilage) 72, it does play an important role in cartilage 
degradation either by direct cleavage of proteoglycans from the cartilage matrix, or 
indirectly by activation of other members of the MMP family (namely MMP1, MMP9 & 
MMP13).  This indirect activation of other members of the MMP family (notably 
MMP9), by MMP3 in OA and RA, was studied by Dreier et al. 117.  They noted that 
MMP-9 was secreted as a stable, inactive zymogen (pro-MMP9) and was subsequently 
proteolytically converted to the active form.  Importantly, macrophages extensively 
expressed and secreted pro-MMP-9 whereas chondrocytes failed to produce this enzyme.  
Of interest though, is the fact that MMP3 production was triggered by chondrocytes from 
OA, but not normal joints.  This study led the authors to conclude that, “articular 
chondrocytes are not innocent bystanders in joint diseases”.  Recognising that MMP3 is 
associated with MV cargo, it is interesting to speculate that this species may transit from 
the chondrocyte to the pro-MMP9 producing cells via microvesicles.  Somehow 
disrupting this vesicle trafficking may go towards inhibiting the activation of destructive 
proteases, particularly MMP9 and MMP13.  A question worth asking is; why not explore 
MMP3 inhibition?  In that way MMP1, MMP9 and MMP13 may remain in the inactive, 
zymogen form.  The literature appears to have mixed views on this.  Some studies with 
MMP3 and MMP9 knock-out mice demonstrated protection against cartilage loss and 
aggrecan cleavage 118 119, while others 120, 121 found the converse to be true.  It is worth 
bearing in mind that these are animal models and that the onset of arthritis was artificially 
produced and instant.  In humans, OA has a heterogeneous assortment of causes and 
develops over time. Therefore, the development and progression of the disease may be 
quite different in humans relative to that in artificially-induced OA murine models.   
     
Sinz et al. 122 conducted a 2-DE comparative proteomic study of synovial fluid and 
plasma from patients suffering from RA, reactive arthritis, and OA, which identified two 
spots unique to the SF of RA patients.  These were not observed in the other two 
pathologies or in any of the plasma samples studied.  MS identified these spots as 
calgranulin B (MRP14 or S100-A9) - a 13.2kDa species.  The S100 proteins are also 
known as alarmins.  The authors concluded that calgranulin B is a “sensitive marker for 
the molecular characterisation of RA, as it can be detected quite easily in SF”.  However, 
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this project would appears to counter that hypothesis, as this protein (identified as Protein 
S100-A9) was found associated with MVs in an OA SF sample.  Calgranulin B is a 
calcium-binding protein, which is primarily expressed together with another calcium-
binding protein, calgranulin A (MRP8 or S100-A8) 123 by circulating neutrophils and 
monocytes.  Sinz et al. 122 acknowledged that they did not identify calgranulin A (S100-
A8) in any of the pathologies (including RA) in their study, though S100-A8 was found 
associated with MVs in an OA patient sample in this project.  One of the functions of the 
S100-A8/S100-A9 complex is to mediate leukocyte migration and adhesion to vascular 
endothelium 124.  A possible explanation for the presence of S100-A9 and S100-A8 in 
OA MVs is the fact that this fraction represents a highly concentrated sub-proteome.  The 
difficulty experienced by Sinz to detect these moieties in other samples may simply be a 
matter of low abundance in OA, exasperated by the fact that their study characterised the 
proteome of whole synovial fluid.  However, their research did identify calgranulin C 
(S100-A12) in RA patients, whereas this species was not identified to be associated with 
OA MVs.  Therefore, experimental design and specifically targeted proteomes are a 
factor and an influence on the generated list of proteins.  Other studies 125-127 showed that   
S100-A8 and S100-A9 may have a sustained role in cartilage degradation in 
inflammatory arthritis.  However, while these proteins may have a role in initiating early 
cartilage degradation in OA by up-regulating MMPs and aggrecanases, their reduced 
expression in late stages of OA suggested they do not have an ongoing role in cartilage 
degradation.  Therefore, these proteins could be important early OA markers and 
suppression of their expression may instigate a possible halt to the subsequent signalling 
cascade that leads to cartilage decay, thus closing down one of the many pathways 
implicated in this complex disease.  
 
In their very recent review paper, Loeser et al. 128 made a very interesting point.  They 
advise that as articular cartilage matrix proteins are degraded, fragments of these 
degraded proteins can feedback and stimulate further matrix destruction thus self-
perpetuate the disease. They cited examples of protein fragments that can stimulate this 
feedback loop.  These include fragments of fibronectin, collagen and small leucine-rich 
proteoglycans.  Fibronectin and collagen fragments were said to stimulate the production 
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of inflammatory cytokines, chemokines and MMPs.  A hypothesis that was proposed 
earlier, in which collagen VI fragments from the pericellular matrix may enter the 
endosomal pathway and re-enter the EMC in exosomes or become vesicle-associated in 
the ECM, may also have some credence here.  MVs ferrying fragmented collagen VI 
cargo may be destined for uptake by neutrophils or macrophages, which results in the 
stimulation of an inflammatory response.  As fibronectin is also associated with OA 
MVs, the same hypothesis may apply. 
 
Another protein fragment that can induce an immunological response is Cartilage 
Oligomeric Matrix Protein (COMP/thrombospondin 5).  From Table 3.14, Rosenthal 
listed this species under the heading Down-regulated in OA.  COMP is a 524kDa 
pentameric glycoprotein expressed primarily in cartilage, tendon, ligament and synovium 
129
.  From Figure 1.2 in the introduction chapter, it was shown that COMP is an ECM 
protein and is known to bind collagens type I, II and IX (fibrillogenesis), as well as 
fibronectin and aggrecan 130.  DiCesare et al. 131 performed a study of COMP metabolism 
in cartilage obtained from a cohort of healthy, OA and RA patients and their conclusions 
indicated that the degree of COMP fragmentation mirrored degenerative processes 
occurring in the matrix.  
From the analysis of OA SF in this project, it was found that COMP is associated with 
MVs.  However, further study will be required to elucidate the exact structure of this.  
Many questions immediately present themselves.  Is the structure/fragmentation of 
COMP found in MVs uniform, or is there heterogeneous fragmentation?  Is there any 
difference in the structure/fragmentation of COMP found to be associated with MVs and 
that found in whole SF?  Indeed, why are some fragments associated with MVs while 
other fragments (possibly the major part) are in the exo-vesicular milieu?  These are 
important questions, especially in light of the research performed by Gagarina et al.132  
This group showed for the first time that the “carboxyl-terminal half” of COMP played a 
critical role in chondrocyte survival.  It accomplished this by the induction of members of 
the inhibitor of apoptosis (IAP) family of survival proteins, which were very effective at 
blocking the activation of caspase 3, and so effected inhibition of apoptosis.  Their work 
suggested that during the process of cartilage breakdown, some fragments of COMP still 
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retain their anti-apoptotic function.  They further hypothesised that these fragments may 
be bioactive; leading to a reduction in the level of apoptosis in OA cartilage, and finally, 
that COMP fragments may also affect tissues at sites removed from cartilage.  All these 
theories lead to a suggestion that MVs could play a COMP- trafficking role here.  This 
reverts back to establishing the nature of COMP associated with MVs and whole SF.  
 
Wang et al. 133 recently identified the complement cascade as a key factor in OA.  They 
stated that cartilage ECM components released by or exposed in OA cartilage may trigger 
the complement cascade; “dysregulation of gene expression in joint tissues may 
contribute to a local preponderance of complement effectors over inhibitors in 
osteoarthritis, permitting complement activation to proceed unchecked”.  A consequence 
of triggering this effect was the formation of membrane attack complex (MAC) on 
chondrocytes, which the authors stated either kills the cells or causes them to produce 
matrix-degrading enzymes, inflammatory mediators and other complement effectors.  
These species further propagate joint disease.  This whole concept of protein 
fragmentation promoting the complement cascade was studied by Happonen et al. 134 in 
relation to COMP.  Theirs was the first study to demonstrate that an extracellular protein 
has an active role in inflammation in vivo.  They found that COMP fragments can 
activate the alternative complement pathway due to a direct interaction with properdin, 
while simultaneously inhibiting the classical and lectin pathways due to interaction with 
C1q (classical pathway) and mannose-binding lectin (lectin pathway) precursors.  A 
simplified schematic diagram of the three known complement cascade pathways is 
displayed in Figure 3.38. 
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Figure 3.38: A simplified schematic diagram of the three complement cascade pathways. 
Diagram taken from Cook et al. 135 
 
With the exception of complement factor D, all complement components required for 
each of the three possible pathways in Figure 3.38 (including properdin) were found to be 
present in/on OA MVs.  It may be worth considering the function of COMP and MVs in 
relation to the complement cascade.  Is it possible that COMP fragments are exposed on 
the surface of MVs with the purpose of initiating the complement cascade there, rather 
than on the surface of chondrocytes and so preventing a sustained inflammatory response 
at the cartilage?    
 
Hunter et al. 136 performed a longitudinal study on a number of markers of cartilage 
turnover in serum, to ascertain if they could serve as predictors of cartilage loss on 
magnetic resonance imaging (MRI).  The authors concluded that, with the exception of 
COMP, none of the other markers was a statistically significant predictor of cartilage 
Figure 1 A simplified overview of the complement system
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loss.  They claimed that a single measurement of increased COMP predicted subsequent 
cartilage loss, but added that the “association was modest”.  Williams et al. 137 predicted 
that COMP will be useful as a biomarker of early-stage OA and urge serious research 
into the behavior of COMP, which may shed light on early pathogenic pathways and thus 
determining its clinical usefulness as a biomarker. 
 
Having discussed the role of COMP fragmentation in relation to the complement cascade 
and the hypothesis that MVs may have a function in off-setting continued damage to the 
chondrocytes, another family of proteins with the same function (i.e. complement cascade 
regulation) was also found to be associated with SF MVs.  These are the apolipoprotein 
family.  The complement cascade is essentially a bacterial killing mechanism by means 
of rupturing the cell wall of the invading pathogen.  From Figure 3.38 it can be seen that 
in the final stage of the complement assembly, C9 binds to the C5b-C8 unit.  C9 then 
undergoes polymerisation ultimately forming a circular polymer, which then penetrates 
the lipid bilayer of the bacteria resulting in cell lysis.  Hamilton et al. 138  studied the 
interaction of apoA-I and apoA-II with the membrane attack complex of complement.  
They found that apoproteins interacted with a site on the C9 polymerised complex which 
interferes with the assembly of the MAC and its subsequent ability to penetrate the cell 
wall.  The authors interpreted this as a means to protect cells which were exposed to 
complement i.e. apoproteins act as complement inhibitors.  Finally, they advanced that 
identification of the binding site for apoA-I or apoA-II on C9 is a potential target for 
complement inhibitory agents.  In a recent review paper Norata et al. 81 discussed the 
current thinking around high density lipoproteins (HDL) in the immune system.  This 
paper was extremely interesting in terms of relevance to the current project.  At the 
beginning of this discussion it was advised exosomes and HDLs possess similar density 
values.  Therefore, co-precipitation of HDLs with MVs is a possibility.  The author 
claimed that HDL particles are enriched in complement pathway and complement 
regulatory proteins such as C3, C4a, C4b, C9 and vitronectin.  All of these species were 
found in OA MVs.  Therefore, it is possible that there are HDL particles in the 200,000g 
CHAPS pellet as apoA-I was found to be vesicle-associated (Figure 3.31).  It was 
hypothesised that HDL could bind these proteins promoting their clearance and so 
  181 
preventing over-activation of the complement system.  In their conclusion the authors 
noted that HDLs are a reservoir for a number of biologically active substances that may 
impact the immune system.  They expressed a need for understanding the role of HDLs 
as delivery agents of these biologically active substances to relevant targets in the 
immune system.               
 
As mentioned above, HA is the component of synovial fluid that imparts viscosity and 
gives the joint fluid an “egg-like” appearance and consistency.  It is known that the size 
of the HA molecule decreases while its actual abundance increases with age and with the 
onset of arthritic diseases.  But what are the agents of HA fragmentation?   This decrease 
in size is attributed to degradation and is thought to involve the action of hyaluronidases 
or free radicals.  This project established for the first time, by employing zymography 
with a HA substrate, that there are hyaluronidases (HAase) associated with SF MV.  
Figure 3.36 demonstrates HAase activity by two different species.  One band is very well 
expressed in the middle of the gel, while the other is present at a higher molecular weight, 
though the latter is less intense than the former.  Interestingly, there does not appear to be 
HAase activity in the 200,000g pellet post-CHAPS treatment.  This may be compared 
with the same sample pre-CHAPS treatment, suggesting that any HAase species present 
are associated with the vesicle surface.  Is it possible to speculate on the identity of these 
proteases?  Csoka et al. 139 identified six genes that code for HAases.  They are HYAL-1, 
HYAL-2, HYAL-3, HYAL-4, PH-20/ SPAM 1 and HYALP-1.  Hyal-1 is an acid-active 
HAase - a single polypeptide chain of 57-kDa (49 kDa with approximately 8 kDa of post-
translational glycosylation).  Hyal-2 is also an acid-active HAase which is present on the 
outer cell membrane.  The authors stated that it has unusual substrate specificity, cleaving 
high-molecular-weight HA polymers to intermediate size fragments of approximately 20 
kDa.  Hyal-3 is believed to be important in stem cell regulation, while Hyal-4 is restricted 
to placenta and skeletal muscle.  PH-20/ SPAM 1 is a testicular HAase which is 
important for egg fertilisation by sperm.  HYALP-1 was termed a pseudogene and the 
authors don’t list a protein that is expressed by this.  It was then suggested that Hyal-2 
and Hyal-1 are the major mammalian hyaluronidases in somatic tissues, and that they act 
in concert to degrade high molecular weight HA to a tetrasaccharide.  As mentioned, 20 
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kDa HA fragments are generated by Hyal-2 digestion in an acidic environment at the cell 
surface.  Bourguignon et al. 140 explain that it is the interaction of CD44, 
Sodium/hydrogen exchanger 1 and Hyal-2 that creates the acidic microenvironment 
necessary for the catabolism of HA.  These fragments are first endocytosed, then 
transported intracellularly, and finally further digested by Hyal-1.  Two β-
exoglycosidases remove sugars from reducing termini of HA oligomers, and supplement 
hyaluronidases in their catabolism of HA.  The process can be seen in Figure 3.39.   
 
 
 
 
Figure 3.39: Schematic diagram outlining the process of HA digestion by the concerted 
action of two HAases, Hyal-1 and Hyal-2.  HA is first digested into 20kDa fragments at 
the cell surface by Hyal-2, followed by endocytosis to the lysosome for final digestion to 
the tetrasaccharide by Hyal-1.  Exoglycosidases remove any sugars present in the 
fragments.  Image taken from Csoka et al. 139 
 
From the location descriptions of HYAL-3, HYAL-4, PH-20/SPAM 1 and HYALP 
above, it is reasonable to speculate that the clear bands in Figure 3.36 are manifestations 
of Hyal-1 and Hyal-2 activity.  An alternative hypothesis may be that, as Hyal-1 appears 
to be located in the lysosome (Figure 3.39), both bands could be due to different Hyal-2 
isoforms or indeed be Hyal-2 and a different protease.  A positive identification would 
only be possible by incubation with the respective antibodies and analysis by WB.   
  183 
At this point it may be instructive to put forth a potentially interesting hypothesis.  In 
Figure 3.3 (reproduced here to aid the reader) it can be seen that during the endosomal 
pathway there comes a point whereby the cell encounters two alternate pathways – either 
target the MVB to the lysosome for cargo destruction, or fuse with the plasma membrane 
and shed its load in the form of exosomes.  The point of alternate routes is highlighted 
with a red box.  Theoretically, it may be possible for the endosome carrying the 20kDa 
HA fragments to avoid the lysosome pathway, hence avoiding further digestion by Hyal-
1 to the tetrasaccharide.  The MVB may then fuse with the plasma membrane and release 
these fragments within exosomes into the ECM milieu.   
   
 
 
 
 
 
 
 
 
 
 
 
 
           
Figure 3.3: A schematic diagram of the endosomal pathway.  Proteins (in red) are 
endocytosed and enter the endosomal pathway with the formation of MVBs. At the point 
highlighted by a red box, there two destination routes possible, – destruction by fusion 
with the lysosome or exocytosis via fusion with the plasma membrane in the form of 
exosomes. Diagram is taken from Fevrier et al. 26 
 
This hypothesis may have some merit in light of a paper published by Scanzello et al. 141.  
Here it was suggested “that initial responses to tissue injury may be triggered by 
endogenous danger signals - damage-associated molecular patters (DAMPS also called 
alarmins)”.  Some examples of DAMPS were cited e.g. HA and fibronectin fragments, 
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heat-shock proteins and members of the S100/calgranulin (discussed above) family.  
These species were said to bind to either toll-like receptors (TLRs) or the receptor for 
advanced glycation endproducts (RAGE).  The authors advised that this process has been 
implicated in cartilage catabolism in OA and concluded that DAMP interaction with 
TLRs may stimulate the inflammatory response in synovium, bone and cartilage in an 
attempt to initiate repair.   
 
An appropriate and informative diagram by Loeser et al. 128 indicating a host of possible 
factors involved in the OA process was published very recently.  A number of species 
that were found to be associated with OA MVs and argued as being associated with OA 
in this project are shown in the diagram.  Figure 3.40 is an amended copy of this diagram, 
highlighting any species that were discussed here (red arrows).   
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.40: Factors involved in the OA process.  Those factors that were discussed 
above are indicated with red arrows.  A number of proteins (S100-A8, S100-A9, DAMPS 
and complement components released from the synovium) can activate articular 
chondrocytes though the activation of cell surface receptors e.g. TLRs, membrane attack 
complex.  Pericellular matrix destruction by HtrA-1 leads to the exposure of the DDR2 
receptor to its ligand, type II collagen. Matrix fragments e.g. fibronectin and COMP can 
induce an inflammatory response.  Transforming growth factor β stimulate osteophyte 
formation.  Diagram taken from Loeser et al. 128      
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3.5 Conclusions 
A novel workflow for isolating microvesicles (MVs) from synovial fluid was established.  
For optimal recovery of MVs, this necessitated prior treatment with hyaluronidase (to 
avoid vesicle entrapment by hyaluronic acid via a CD44 receptor), and protein A 
chromatography (to remove interfering immunoglobulins).  This was followed by a 
differential centrifugation process which included treatment with 1% CHAPS (to remove 
loosely associated proteins from the vesicle surface. 
 
A four-patient-pooled sample was prepared employing the newly developed method and 
the 200,000g CHAPS pellet was characterised by mass spectrometry employing three 
methods (RP-HPLC, SCX-RP-HPLC and in-gel digestion).  The generated protein lists 
were classified by a bioinformatic tool (Panther).  A number of confirmation studies were 
carried out on selected proteins using the western blot technique, aimed at supporting the 
MS data.  Proteases activity associated with MVs was established employing 
zymography (including hyaluronidases). 
 
In the discussion section, the intention was to postulate plausible explanations for the 
presence of a number of interesting proteins based on a thorough search and 
understanding of the literature, rather than a comparison of the number of proteins 
identified with other researchers.  This approach tendered a number of possibilities for a 
role MVs might mirror the pathophysiological events in the genesis and development of 
OA.  It is hoped that these hypotheses may spark interest in this topic and stimulate 
further research. 
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Chapter 4 
 
Characterisation of differentially expressed 
glycoproteins in synovial fluid between the various 
arthritic pathologies employing lectin affinity 
chromatography and mass spectrometry 
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4.0 Introduction 
4.0.1 Glycobiology 
 
The term glycobiology or glycoscience is generally reserved for the study of sugar 
functionality in living organisms.  The function of carbohydrates in the context of energy 
metabolism in cells, fall outside the scope of what is generally termed glycobiology.  
Specifically, it is usually defined as the study of the role of covalently bound sugars to 
biomolecules (e.g. proteins and lipids) in the form of mono-, oligo- or polysaccharides 1.  
These glycosylated moieties are termed glycoconjugates in general, and glycoproteins 
and glycolipids in particular.  Thus glycobiology is the science of glycoconjugates 2.  
Sugar decorated proteins or lipids are referred to as glycans.  These glycans are hetero-
oligomers and are structurally more diverse than the homo-polymeric storage 
carbohydrates e.g. glycogen and amylase. 
 
4.0.2 Glycan Composition – monosaccharides are the building blocks of 
glycosylation 
 
Glycans are mainly composed of hexoses – monosaccharides with the general formula 
C6H12O6.  Four of the six carbon atoms in a hexose are chiral centres since C2, C3, C4 and 
C5 are bonded to four chemically distinct groups.  As there are four chiral centres, each of 
which has two isoforms, there are therefore 16 hexose stereoisomers.  The prefixes D- 
and L- are used to distinguish between a pair of stereoisomers.  For example, D-glucose 
and L-glucose are stereoisomers.  The D- and L- forms differ in the orientation of the      
–OH group at C5.   The most common monosaccharides found in human glycan structures 
are shown in Figure 1.  Also included are the three letter abbreviations for each sugar.
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Figure 4.1:  Structure of common monosaccharides found in mammalian 
glycoconjugates.  
 
Epimerisation is the term given to a change in the stereochemical configuration of a 
single carbon atom in a sugar.  From Figure 4.11, it can be seen that D-glucose and D-
galactose are epimers as are D-glucose and D-mannose.  Substitution of the C2-OH group 
of glucose or galactose with an acetylated amino group yields N-acetyl-D-glucosamine 
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and N-acetyl-galactosamine respectively.  Fucose is structurally related to galactose 
whereby the C6 -OH group of Gal is replaced with a –CH3 group.  C1 is referred to as the 
anomeric carbon and two configurations or anomers are known by the labels α and β.  
The α anomer is distinguished by possessing an axial –OH group on the anomeric 
carbon, while in the β anomer, the –OH group is in the equatorial position.  
Monosaccharides can react with each other to form di-, oligo- and polysaccharides.  The 
bond between any two monosaccharides is referred to as a glycosidic linkage.  Formation 
of the glycosidic linkage occurs following a condensation reaction between two 
monosaccharides with the concomitant elimination of a water molecule.  For example, 
the formation of lactose - a disaccharide composed of galactose and glucose – is shown in 
Figure 4.2.    
 
 
 
 
  
 
 
 
 
 
 
 
          
 
 
 
 
Figure 4.2: Formation of a glycosidic linkage between galactose and glucose 
monosaccharides to form a lactose disaccharide molecule. 
The synthesis of a di-, oligo- and polysaccharides through glycosidic linkages requires an 
input of energy 1.  In general, glycosyl-transferase catalyses a transfer of one 
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monosaccharide -in the form of a nucleotide sugar donor- to another monosaccharide 
acceptor molecule.  Each transferase is specific for a particular glycosidic linkage 
between any two specific monosaccharides.  The hydrolysis of glycosidic bonds also 
requires specific enzymes known as glycosidases.  Each glycosidase catalyses cleavage 
of a specific link between specific sugars. 
 
4.0.3 Major classes of glycoconjugates 
 
In broad terms, there are two main groups of glycoconjugates: those attached to lipids 
(glycolipids) and those attached to proteins (glycoproteins).  The analysis of glycolipids 
is beyond the scope of this project and so will receive no further attention.  Glycoproteins 
are generally sub-divided into two classes; N-linked and O-linked glycans.  The N and O 
refer to the species of atom on the amino acid residue of the protein, to which the glycan 
is attached.  Thus an N-linked glycan is covalently bonded to a nitrogen atom in the 
amino acid side chain, while for an O-linked glycan the bonding site is to an amino acid 
oxygen atom.  The synthesis of both N- and O-linked species is initiated in the lumen of 
the endoplasmic reticulum (ER) and further processed in the Golgi apparatus of the cell.  
Ultimately, many types of glycoprotein are found at the extracellular surface of the 
plasma membrane or secreted into biological fluids and the extracellular matrix that 
surround cells. 
4.0.3.1 N-linked glycosylation 
 
In this class of glycoprotein, the carbohydrate structures are attached to the amide 
nitrogen atom of an asparagine (Asn) side chain.  More specifically, a specific amino acid 
sequence is generally required for N-glycosylation.  These sequences are usually either –
Asn-Xaa-Ser- or –Asn-Xaa-Thr- where Xaa is any amino acid residue except proline.  In 
animal cells the monosaccharide attached to the Asn residue is almost always N-acetyl-
D-glucosamine (GlcNAc).  N-linked glycan synthesis is believed to be divided into three 
stages: (1) formation of a dolichol (Dol) lipid-linked precursor oligosaccharide in the 
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cytosol of the ER; (2) complete transfer of this 14-saccharide core oligosaccharide unit to 
a nascent, unfolded polypeptide in the lumen of the ER; and (3) processing the 
transferred oligosaccharide i.e. trimming some of the original sugars and completion of 
terminal glycosylation in the Golgi body.  An overall schematic diagram depicting the 
entire N-glycosylation biosynthesis process is shown in Figure 4.3. 
   
Figure 4.3 Sequence of stages leading to the biosynthesis of N-linked glycans.  Synthesis 
begins in the cytosol surface of the ER.  Following a flip across the ER membrane, 
individual monosaccharides are attached one at a time.  Transfer of the sugar structure 
to the nascent protein takes place by means of a catalytic reaction with 
oligosaccharyltransferase.  The entire edifice then transfers to the Golgi body, where 
further trimming and processing takes place.  Diagram taken from Helenius et al.3  
 
Biosynthesis of the precursor dolichol-linked oligosaccharide is achieved by the 
sequential addition of monosaccharides catalysed by specific glycosidases.  The final 
precursor has a total of two GlcNAc residues, nine mannose residues (Man) and three 
glucose residues (Glc) i.e. Dol-(GlcNAc)2 (Man)9(Glc)3.  The structure of complete 
precursor can be seen in Figure 4.4.     
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Figure 4.4: The dolichol- oligosaccharide core structure.  The letters in red indicate the 
order of addition of the monosaccharide units 4 . 
 
The entire core glycan sequence is then transferred to the newly-formed polypeptide as it 
emerges from the ribosome in the cytosol of the ER.  This is achieved through use of the 
enzyme, oligosaccharyltransferase and it is this enzyme that recognises the –Asn-Xaa-
Ser/Thr- sequence.  The next stage is the removal of the glucose residues.  This is 
important for the protein folding stage.  The precise detail as to how this comes about is 
not yet clear 5; i.e. whether all three glucose residues are removed at once and then one 
put back later or, just two are removed initially remains uncertain.  However, one glucose 
residue is required for the next step – the attachment of the molecular chaperone, 
calnexin.  Calnexin is a lectin that is crucial for aiding the folding of the linear 
polypeptide in the cytosol of the E. 
Glycans are usually classed as having high mannose, complex, hybrid or truncated 
structures. The degree of heterogeneity is not only determined by the individual sugar 
residues, but by the number of antenna and/or polylactoseamine extensions.  Glycans can 
be bi-, tri-, tetra- or more rarely, penta-antennary.  Figure 4.5 displays the various 
structures that N-glycans may adapt. 
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Figure 4.5:  The various structure types possible in N-linked glycosylation. 
 
Polylactoseamine extensions are composed of number of (Galβ1-4GlcNAcβ1-)n 
disaccharide units within one of the antenna.  Fucosylation of the GlcNAc residue 
directly attached to the Asn residue or on the antennae is another modification possibility 
3
.  Despite the structural composition of each antenna, all N-linked glycans may be 
capped with an N-acetylneuraminic acid- galactose (NeuAc-Gal) disaccharide. The sialic 
acid, NeuAc residue is either α2-3 or α2-6 to the galactose.  A summary of the various 
potential modifications that can occur are shown in Figure 4.6. 
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Figure 4.6:  A summary of the various potential modifications that N-glycans may adopt 
which leads to heterogeneities in structure and composition 
 
 
4.0.3.2 O-linked glycosylation 
 
O-linked glycans are synthesised following an initial attachment of a GalNAc 
monosaccharide to either a Ser or Thr amino acid residue.  The point of attachment to the 
Ser/Thr amino acid is the oxygen atom in the side chain.  Following attachment of the 
GalNAc residue to Ser/Thr, a Galβ1-3 attachment to the GalNac forms what is termed a 
core-1 O-linked glycan.  This is either disialyated to complete the core-1 structure or 
further extended to produce a core-2 O-linked glycan.  Core-1 and -2 structures may be 
seen in Figure 4.7.  
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Figure 4.7: Core 1 and 2 structures attached to Ser and Thr side chains through a 
GalNAc sugar residue.  
 
Unlike N-glycosylation, there is no preformed core structure that is formed before the 
final glycan structure is established.   Further, O-glycosylation is prominent in regions 
containing high levels of proline and alanine.  A further difference between O- and N-
linked glycosylation is that O-linked glycans are considered post-translational 
modifications that take place in the Golgi apparatus 3.   
There are two groups of glycoproteins in particular that are dominated by a large number 
of O-linked sugars.  These are mucins and proteoglycans.  In mucins, sialylation of the 
core 1 structures imparts regions of negative charge on the glycans.  This charge in turn 
has the capacity to bind large amounts of water, which in turn, aids retention of water for 
cells lying close to the outside environment.  In addition to water retention, mucins serve 
as lubrication and help protect the organism from invasion by microorganisms.  Finally, 
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cross linking between the glycans through di-sulphide bonds allows for the formation of 
gels.   
Proteoglycans also have the ability to bind water, but their primary function is to provide 
structure rather than lubrication.  Another notable difference between mucins and 
proteoglycans is that the O-linked glycans on mucins are small, whereas those attached to 
proteoglycans may contain approximately 100 residues each.  These long structures 
possess an underlying repeating disaccharide unit and are known as glycosaminoglycans 
(GAGs).  Examples of these GAGs are hyaluronic acid, chondroitin sulphate, dermatan 
sulphate, heparin sulphate and keratin sulphate.  Aggrecan is one the major proteoglycans 
of cartilage.  Here, chondroitin sulphate is O-linked to a polypeptide filament, while 
keratin sulphate is N-linked 6.  These in turn are linked in their hundreds to a central 
filament of hyaluronic acid. 
It is generally acknowledged that understanding the structure-function relationship for 
glycans is much more difficult than for any other class of biopolymer 1.  This is a 
consequence of the high degree of heterogeneity that glycosylation can entail by virtue 
of, for example, potential multiple branching, a diversity of linkages, fucosylation of the 
outer arm and various types and differing extents of terminal sialylation 7 8 9.  There are 
more than 30 sialic acid structural types that may have significance in recognition 
processes 2.  Though proteins possess a range of biological roles e.g. signalling, 
transportation, enzymatic, channelling etc., their structure-function relationship is better 
understood.  Each protein is generally synthesised by translation of an mRNA template 
and the subsequent function results from the precise nature of the three-dimensional 
structure after folding.  By contrast, for glycan assembly, monosaccharides are attached 
one-at-a-time through a series of individual enzymatic reactions, without a template 
mechanism.  This permits the possibility of a heterogeneous glycan composition.  For 
example, analysis of DSPAα1 (a thrombolytic agent present in vampire bats) revealed 
around thirty glycoforms present at a single N-linked site 10.  Another example of a high 
degree of heterogeneity can be found in IgG 11.  This molecule is one of the least 
glycosylated in our system (2.8% sugar coverage), and yet a single glycosylation site was 
found to possess 36 different glycoforms.  Though glycan structures are not encoded 
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directly in the DNA sequences, they are encoded indirectly by the transcription and 
translation of genes that generate glycolsyltransferases 5.  These enzymes control the 
synthesis of the glycans that attach to the protein.  Experiments with knockout mice in 
which certain glycolsyltransferases are eliminated, show that although the individual cell 
remains viable, complete elimination of any of these enzymes is fatal to the organism as a 
whole.  
 
4.0.4 Lectins 
 
Lectins are defined as ‘proteins or glycoproteins of nonimmune origin derived from 
plants, animals, or microorganisms that have specificity for terminal or subterminal 
carbohydrate residues’ 12.  Another feature of lectins is that they have no enzyme 
activity.  They are multivalent as two or more sugar binding sites are required for cross-
linking or agglutination of cells to occur 13.  The nominal or preferred sugar specificity of 
lectins is ascertained by the simple monosaccharides that inhibits their effect.  However, 
that said, lectin-binding inhibition by a simple monosaccharide is an over-simplification 
and binding involves three monosaccharides with a particular three dimensional spatial 
arrangement.  Hydrophobic and electrostatic interactions also aid binding.   
Lectins isolated from plants and animals are used in the study of glycans 14 15.  
Sometimes more than one lectin with different binding specificities may be obtained from 
a single source and these are termed isolectins.  Examples of isolectins used in this 
project include MAL I and MAL II which are isolated from Maackia amurensis seeds. 
Mislovičová et al. 13 and Gremenier et al. 16 published a two-part joint review on 
“Lectinomics” and in particular the relevance of plant lectins in biomedicine.  In these 
extensive and comprehensive reviews, there are tables detailing a large number of studies 
relating to protein glycosylation changes, the particular lectins used in the screening 
process, the diseases concerned and finally the methods of analysis employed.  Figure 4.8 
summarises the applications that lectins have found in biomedical diagnostics. 
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Figure 4.8: A schematic diagram displaying the many applications of lectins in clinical 
diagnostics. Diagram taken from Mislovicova et al. 13 
 
 
4.0.5 The role of glycans 
 
Glycans have a variety of roles and functions, comparable to the multiple and diverse role 
of proteins.  Glycoproteins are found on the surface of our entire cellular network, in the 
extracellular matrix (ECM) and in various biofluids 17.  Also, the cell surfaces of bacterial 
and viral pathogens are decorated with glycoconjugates 11.  A summary of the functions 
of glycans can be seen in Figure 4.9. 
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Figure 4.9:  A schematic summary of the biological functions of glycans 
 
The composition of the bacterial cell wall is an example of a structural role attributed to 
carbohydrates.  The cell wall is composed of a macromolecular network called 
peptidoglycan which imparts a rigidity not found in eukaryotes.  This consists of a 
repeating N-acetylglucosamine/N-acetlymuramic disaccharide unit linked in rows of 10 
to 65 sugars to form a polysaccharide.  Adjacent polysaccharides are attached to each 
other by polypeptide bridges.  In mammals, bone sialoprotein (BSP) is an example of a 
glycoprotein which functions as a structural entity 18.  BSP has a mass of 65 – 75,000Da, 
half of which is attributed to carbohydrate attachments.  It accumulates in areas of bone, 
dentin and cartilage and is also considered very important as a cell adhesion molecule and 
is also known to be involved in mineralising tissue. 
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As monosaccharides are polar entities, attachment of sugars to a protein can modify its 
properties e.g. solubility and stability.  Modifications in solubility, for example, may 
occur due to differences in the number monosaccharide units which possess polar –OH, 
sulphate and sialic acid groups, each to a varying degree.  Other protein modifications 
that occur due to glycosylation include altered folding, secretion, targeting and greater 
resistance to protease lysis 19.  Helenius et al. 3 state that when glycosylation is inhibited, 
the most commonly observed effects is the generation of misfolded aggregated proteins 
that fail to attain a functional state.  It was noted that the dependence of correct folding on 
glycosylation ranges from proteins that are completely dependent on glycosylation, 
through partial dependence to no dependence at all.  Though a protein conformation may 
exhibit no dependence on any particular individual carbohydrate structure, multiple site 
modifications can compromise folding.  An example of enhanced stability was 
demonstrated by studies of the β-sheet core in the PMP-C protease inhibitor 20.  Here, a 
single fucose residue attached to threonine at position nine (Thr-9), imparted greater 
stability to the entire structure relative to the stability of the glycan after the fucose was 
removed.   Protection from protein degradation was demonstrated in another study by 
Raju et al. 21.  This study proved that glycosylation of the crystallisable fragment (Fc) 
domain in IgG offered resistance to proteolysis by the enzyme, papain. 
 
In order for glycans to mediate as trafficking, adhesion or signalling entities, the sugar 
epitope must selectively bind with sugar receptors e.g. lectins, collectins, adhesion 
molecules and anti-carbohydrate antibodies 11.  Cells of the immune system that 
participate in inflammatory responses (i.e. T-cells, neutrophils, macrophages and 
endothelial cells) are also known to synthesise glycoproteins that play a key role in the 
attachment of endothelial cells to L-selectin during the attachment of lymphocytes 22.  
Here, glycosylation-dependent cell adhesion molecule 1 (GlyCAM 1), a mucin-like, 
sialylated and sulphated endothelial glycoprotein, acts as an adhesive ligand for L- 
selectin by presenting one or more O-linked carbohydrates to the lectin domain of this 
cell surface selectin which is present on the surface of leukocytes.  This process aids the 
“rolling” effect of leucocytes (e.g. neutrophils) along the epithelial cells prior to entry 
into the tissue.  Mammalian lectins are known to mediate control of the immune system 
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through recognition of cell surface glycoproteins 23.   For example, in the innate immune 
system, lectins such as the macrophage mannose receptor (a mannose binding lectin), 
bind to microbial carbohydrates.  The ability of the human body to convert high mannose 
N-glycans to complex N-glycans is thought to offer protection against self-recognition by 
the innate immune system and so prevent inflammation and autoimmune disease 24, 25. 
Some glycoproteins on the cell surface act as receptors for cytokines, growth factors or 
apoptosis factors.  Indeed, glycosylation is often a requirement for the expression of these 
receptors 26.  In this study it was found that the presence of two large, N-linked glycans 
bound to Fas (a cell surface receptor involved in the induction of apoptosis) is required 
before the attachment of Fas-ligand can take place. 
 
4.0.6 Glycosylation in various diseases including arthritic pathologies 
 
It is now believed that glycans are directly involved in almost every biological process 
and play a significant part in most human diseases 27.  The multifunctional importance of 
glycoconjugates range from developmental biology, immune response (both innate and 
adaptive), homing of pathogens to their host tissues, cell division processes, cancer cells’ 
ability to ‘camouflage’ in order to avoid detection by the immune system, injury and 
inflammation and prion diseases 2.   
Bones et al. 28 discovered alterations in the glycosylation of four highly abundant serum 
glycoproteins (IgG, haptoglobin, transferrin, and alpha 1-acid glycoprotein) which they 
claim may offer potential as biomarkers for stomach cancer.  Alterations in the 
glycosylation of these four proteins isolated from the pathologically staged cancer serum 
using either UPLC-fluoresence or two-dimensional electrophoresis were investigated as 
possible markers for stomach cancer progression. They observed an increase in 
sialylation on haptoglobin, transferrin, and alpha 1-acid glycoprotein in the cancerous 
state.  Increased levels of core fucosylated biantennary glycans and decreased levels of 
monogalactosylated core fucosylated biantennary glycans were present on IgG with 
increasing disease progression.  
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Studies have been carried out on the lectin derived from Helix pomatica (HPA) in 
relation to cancer metastasizes.  HPA recognises terminal GalNAc and to a lesser extent 
GlcNAc and Gal residues.  Brooks et al. 29 proposed that HPA recognises a glycoprotein 
that is associated with metastasis (to auxiliary lymph nodes and elsewhere) and poor 
prognosis in breast cancer.  80% of breast cancers stained strongly for the binding of 
HPA and 20% were completely negative.  The positively stained cancers tend to be 
aggressive and undergo metastasis to other sites whereas the negative cases tend not to 
spread and have a much more favourable prognosis.  They conclude that HPA binding to 
paraffin sections of primary tumour could aid difficult treatment decisions by providing 
an additional assessment of staging and likely long-term patient prognosis.  This study 
was further developed more recently by Welinder et al. 30.  Here the authors state that the 
aberrant glycosylation modification on protein function remains unknown.  The major 
HPA binding proteins in serum were found to be IgA1, complement factor C3, von 
Willebrand factor (vWF), alpha-2-macroglobulin and IgM.  However, the study also 
found that blood group phenotypes can have a major impact on any conclusions when 
analysing HPA lectin binding. 
Smith et al. 31 studied the glycosylation of α-1-acid glycoprotein (a 41kDa plasma 
glycoprotein of hepatic origin) in the sera and synovial fluid of a rheumatoid arthritis 
patient employing the lectin concanavilin A (ConA) affinity chromatography.  The study 
indicated that there maybe localised production of α-1-acid glycoprotein in the joint 
based on glycosylation differences between serum and synovial fluid.  It was found that 
serum α-1-acid glycoprotein was largely composed of fucosylated tri- and tetra-
antennary oligosaccharide chains while synovial fluid contained mainly bi-antennary 
chains that were fucosylated to a less extent.  They also noted that this glycosylation 
heterogeneity also resulted in a difference in α-1-acid glycoprotein function - serum but 
not synovial fluid α-1-acid glycoprotein was able to inhibit binding to the cell adhesion 
molecule through expression of antigen sialyl Lewis X.   
Sialylation and fucosylation of synovial and plasma fibronectins in relation to the 
progression and activity of rheumatoid arthritis has been studied by Przybysz et al. 32 
employing lectin-ELISA.  They established three distinct phases in the disease namely, 
early, established and late.  The study showed that synovial fibronectin sialylation and 
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fucosylation was significantly increased in patients with established and late-phase RA, 
relative to those with early-phase RA. However, sialylation showed a slight decrease in 
the late-phase group relative to the established group.  Fucosylation remained at almost 
the same level in the late group relative to the established group.  It was noted that the 
expression of α1-6-linked fucose was found to correlate to disease activity.  It is worth 
pointing out that there was no control group in the study of synovial fluid.  The 
glycosylation of fibronectin in plasma on the other hand displayed different dynamic 
alterations.  In the early RA group the reactivity of the lectins with fibronectin was 
similar to that of a control group.  Fucosylation and sialylation increased significantly in 
the established group.  Surprisingly, the reactivity in the late RA group decreased to a 
level similar to that of the normal group.  The authors concluded that lower expressions 
of terminal sugars in synovial fibronectin were mainly associated with the early 
degenerative processes of RA and that the higher expression of terminal sugars in 
fibronectin could be associated with repair and adaptation processes.  Kratz et al. 
33screened the terminal monosaccharides of synovial immunoglobulins IgA, IgG and IgM 
for the early detection of RA employing lectin-immunoblotting.  In these studies the 
relative amounts of terminal monosaccharides in the synovial fluid of two RA groups 
(early and late) were compared to a control plasma sample by means of lectin-
immunoblotting employing seven lectins.  Their results showed differences between early 
and advanced RA stages in the terminal sugar profile of synovial IgG and IgA, but not 
IgM.  A galactose-deficient glycotype with exposed GlaNAc appeared exclusively in the 
IgG 33.1kDa fragment of the early RA sample. However, in the intact form of both 
immunoglobulins, this glycotype was present in both groups, although to a greater extent 
in the late RA group.  Sialyl and fucosyl moieties of intact IgG and IgA were notably 
lower in the early RA group relative to the late group.  
It is acknowledged that, although the study of glycans and glycomics is not as advanced 
as proteomics and genomics in terms of understanding biologic processes, advances are 
being made over recent years to close this gap.  A complete understanding of the 
causation of any disease will depend on the elucidation of all post-translational 
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modifications, but most especially glycosylation, which is the most abundant and most 
heterogeneous modification. 
 
4.0.8 Aim of Project 
 
From the introduction above, it may be appreciated that glycoconjugates are extremely 
important in all aspects of our system.  Over a half of all known proteins are glycosylated 
34
.  
With the development of experimental techniques, up- or down-regulation of a particular 
glycoconjugate and/or changes to the glycan structure and/or changes in the activity 
levels of enzymes which are responsible for particular glycan synthesis, have been 
studied and correlated to disease. 
  
The objective of this study is to characterise differentially expressed glycoproteins in OA 
relative to other joint pathologies.  This will be achieved in three stages: 
1. Screen SF samples from patients diagnosed with different arthritic pathologies 
employing a panel of lectins.  Determine which lectins exhibit differential 
glycosylation patterns and select these for further study. 
2. Perform lectin affinity chromatography (LAC) employing the most promising 
lectins.  The bound fractions will then be analysed by gel electrophoresis and 
differentially expressed bands noted. 
3. Bands of interest will be excised and characterised by MS. 
4. With the identity of the glycoprotein(s) now known, it may be possible to obtain 
antibodies and then assess the up- or down-regulation of this species in various 
pathologies.   
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4.1 Materials & Methods 
4.1.0 Reagents 
Absolute Ethanol (reagent, >99.5%), Acetic Acid (reagent, >99.7%), Acrylamide (for 
molecular biology, >99%), Ammonium Sulphate (for molecular biology, >99.0%), 
Ammonium persulphate (APS) ((for molecular biology, >98%), β-mercaptoethanol ((for 
molecular biology, >98%), Bovine Serum Albumin (BSA) (lyophilised powder, >96%), 
Calcium Chloride (anhydrous, >96%), Coomassie Brilliant Blue G-250, 
Ethylenediaminetetraacetic Acid (EDTA) (BioUltra, anhydrous,>99%), Glycerol (for 
molecular biology, >99%), Glycine (for electrophoresis, >99%), HEPES (99.5%), 
Manganese Chloride (reagent, >98%), Methanol (LC/MS Ultra) , α-methyl mannoside, 
Phosphoric Acid (Bioreagent, 85%), Ponceau Stain, Sodium Chloride (for molecular 
biology, >98%), Sodium Dodecyl Sulphate (SDS) (for molecular biology, >98.5%), 
Tetramethylethylenediamine (TEMED) (BioReagent, 99%), Tris-HCl, Tris pH 6.8, Tris 
pH 8.8, Tween-20 were obtained from Sigma-Aldrich (Ireland) 
All biotinylated lectins and Agarose Lens culinaris Agglutinin (LCA) were obtained from 
Vector Laboratories (Peterborough, UK) and are listed in Table 4.1. 
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Table 4.1: A list of plant lectins employed in the screening of synovial fluid of patients 
with a variety of arthritic diseases.  Also included is the binding specificity for each lectin 
which were obtained from 1. Kratz et al. 332. Mislovicova et al. 13 3. Kumada et al.35  
 
Odyssey blocking buffer and molecular weight standards were obtained from LI-COR 
Biosciences (Lincoln, New England, USA) 
 
 
 
 
 
Lectin Common Abbreviation Preferred Sugar Specificity
Sambucus nigra SNA NeuNAcα2-6Gal; GalNAc   1, 3
Maackia amurensis I MAL I NeuNAcα2-3Gal; Galβ1-4GlcNAc  1, 3
Maackia amurensis II MAL II NeuNAcα2-3Gal  1, 3
Lens culinaris LCA Fucα1-6GlcNAc; a-Man; a-Glc 2, 3
Pisum sativum PSA Fucα1-6GlcNAc; a-Man  2, 3
Ulex europaeus I UEA-I Fucα1-2LacNAc; a-Fuc 1, 3
Ricinus communis RCA120 β-Gal  2
Phaseolus vulgaris PHA(L) 3 or 4-antennary complex type  3
Phaseolus vulgaris PHA(E) 2 or 3-antennary complex type  3
Canavalia ensiforms ConA a-Man; a-Glc 2,3 
Triticum vulgaris WGA Terminal N-acetylglucosamine or chitobiose; NeuNAc 2
Triticum vulgaris succinylated WGA Terminal N-acetylglucosamine or chitobiose 2
Arachis hypogea PNA Galβ1-3GalNAc  3
Artocarpus integrifolia Jacalin Galβ1-3GalNAc-Thr/Ser also mono- or disialyted forms of this structure  2
Griffonia simplicifolia GSI α-GalNAc  2
Dolichos biflorus DBA α-GalNAc 2, 3
Glycine max SBA Terminal a- or β-linked GalNA; Gal  3
Sophora japonica SJA β-GalNAc; β-Gal 2
Fuc L-Fucose
Gal D-Galactose
GalNAc N-Acetylgalactosamine
Glc D-Glucose
GlcNAc N-Acetylglucosamine
Man Mannose
NeuAc N-Acetylneuraminic acid (sialic acid)
Thr Threonine
Ser Serine
Sugar Abbreviations
Other Abbreviations
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4.1.1 Equipment 
Solid-phase extraction columns obtained from Waters 
Nitrocellulose, with a membrane pore size of 0.22mm filter paper and filter paper were 
purchased from Whatman (Springfield, United Kingdom) 
Odyssey Infrared Laser Scanner (manufactured by LI-COR Biosciences, Lincoln, NE, 
USA) 
Electrophoretic chamber, Western blot transfer chamber and power supply by BioRad 
(UK).  
Stuart mini see-saw rocker (Staffordshire,UK) 
Invitrogen iBlot dry gel transfer apparatus and Invitrogen iBlot gel transfer stacks, 
nitrocellulose (regular) were purchased from Invitrogen (Dublin, Ireland)   
 
 
4.1.2 Synovial fluid sample preparation 
As in section 3.1.4 
 
4.1.3 Protein assay 
As in section 3.1.7 
 
4.1.4 Sample preparation for electrophoresis 
As in section 3.1.8 
 
4.1.5 Gel electrophoresis  
As in section 3.1.9 
The lectin screening study was carried out using 4 – 20% commercial pre-cast gels 
(1mm) with a HEPES buffer (12.1g Tris, 23.8g HEPES, 1.0g SDS to 1L final volume, pH 
8.0).   
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4.1.6 Coomassie Staining  
As in section 3.1.10 
  
4.1.7 Transfer to nitrocellulose membrane    
As in section 3.1.11 
The lectin screening study was carried out employing the dry gel transfer method.  
4.1.8 Lectin Incubation  
Following the membrane blocking stage, the membrane was washed with PBST (PBS + 
0.1% (v/v) Tween 20).  Lectins were diluted 1:2,000 in Odyssey blocking buffer/PBST 
1:1.  Incubation of the membrane with the lectin took place for 1 hour at room 
temperature.  Excess lectin was removed employing a series of 6 x 5mins washes with 
PBST.  Next, the membrane was incubated in streptavidin (1:10,000) in PBST for 1 hour 
in the dark.  Finally, washing 6 x 5mins with PBST took place before imaging with the 
Odyssey scanner.   
4.1.9 Lectin affinity chromatography 
500µL of Lens culinaris Agglutinin (LCA) agarose beads were added to the disposable 
column.  The column was conditioned by washing with 25mL buffer (10mM HEPES, 
pH7.5, 0.15M NaCl, 0.1mM Ca2+, 0.01mM Mn2+ ) as per the manufacturer’s instructions.  
Dilute 500µL SF to 1mL with buffer and add to beads.  Mix end-over-end overnight.  The 
non-bound fraction was eluted and the column washed with a further 10mL buffer.  The 
bound (targeted) proteins were removed with 0.5M α-methyl mannoside + 1mM EDTA) 
as per the manufacturer’s datasheet.  Removal of elution buffer was performed by 
dialysis against water.  The bound fraction was dried under vacuum and 20µLx1 reducing 
sample buffer was added.  Electrophoresis was carried out followed by Coomassie 
staining.      
4.1.10 Mass spectrometry using LC–MS/MS 
All mass spectrometry analysis was carried out by the National Institute of Cellular 
(NICB) Biotechnology with whom collaboration was obtained.  The following protocol 
was supplied by NICB. 
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Nano LC–MS/MS analysis was carried out using an Ultimate 3000 nanoLC system 
(Dionex) coupled to a hybrid linear ion trap/Orbitrap mass spectrometer (LTQ Orbitrap 
XL; Thermo Fisher Scientific). Five microlitres of digest were loaded onto a C18 trap 
column (C18 PepMap, 300µm ID × 5mm, 5µm particle size, 100 Å pore size; Dionex) 
and desalted for 10 min using a flow rate of 25µL/min in 0.1% (v/v) TFA. The trap 
column was then switched online with the analytical column (PepMap C18, 75µm 
ID × 250 mm, 3µm particle and 100 Å pore size; (Dionex)) and peptides were eluted with 
the following binary gradients of solvent A and B: 0–25% solvent B in 120 min and 25–
50% solvent B in a further 60 min, where solvent A consisted of 2% (v/v) acetonitrile 
(ACN) and 0.1% (v/v) formic acid in water and solvent B consisted of 80% (v/v) ACN 
and 0.08% (v/v) formic acid in water. Column flow rate was set to 350nL/min. 
Data were acquired with Xcalibur software, version 2.0.7 (Thermo Fisher Scientific). The 
mass spectrometer was operated in data-dependent mode and externally calibrated. 
Survey MS scans were acquired in the Orbitrap in the 400–1800 m/z range with the 
resolution set to a value of 60,000 at m/z 400. Lock mass was set at 445.120025 u 
(protonated (Si(CH3)2O)6). Up to seven of the most intense ions (1+, 2+ and 3+) per scan 
were CID fragmented in the linear ion trap. A dynamic exclusion window was applied 
within 40 s. All tandem mass spectra were collected using normalised collision energy of 
35%, an isolation window of 3 m/z, and one microscan. 
Proteins were identified using BioWorks 3.2 from Thermo Fisher Scientific using the 
HUPO criteria with XC scores of 1.8, 2.2, 3.75 for single, double and triple charged ions. 
A peptide probability score of 0.05 was also used. The database used was Human 
UniProt-SwissProt downloaded January 2012. Carboxymethylation of Cysteine was set 
as fixed and oxidation of methionine as a variable modification. Two missed cleavages 
were allowed. The mass tolerance for precursor ions was 20ppm and the mass tolerance 
for fragment ions was 0.5Da.  
 
 
  223 
4.2 Results 
4.2.1 Patient sample screening with a panel of plant lectins 
Samples taken from a number of patients suffering representing a variety of arthritic 
diseases were screened with a number of biotinylated plant lectins.  As this is a pilot 
study and OA is the most prevalent form of arthritis and the pathology of interest in this 
project, four separate patient samples were analysed while one pooled (four different 
patients) samples from each of the other arthritic diseases were compared.   All lectins 
employed were shown seen in Table 4.1.  Also included in the table is the binding 
specificity for each lectin.  The choice of these lectins was made based on availability, 
specificity for a broad range of sugars and glycosylation types i.e. N-linked and O-linked 
species, complex versus non-complex (Figure 4.4) and finally to establish differences 
between the same sugars in different binding arrangements e.g. three different fucose-
binding lectins were included (LCA, PSA and UEA-1) because fucose possesses different 
binding options (Table 4.1).         
4.2.2 Profiling of SF proteome  
Employing the Bradford protein assay, 10µg of protein were loaded into each lane.  The 
gel was then stained in colloidal Coomassie solution overnight (Figure 4.10). 
 
 
 
 
 
                  
 Figure 4.10:  Coomassie stained gel of various patient samples 
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In terms of band patterns there is practically no difference between the five pathology 
types and within the same type i.e. OA.  No important naked-eye differences in terms of 
band intensities were apparent so a qualitative differential study by lectin blot was 
undertaken with these well balanced (in terms of protein amount) samples.  It was 
hypothesised that there may be glycosylation changes that are disease-specific 
 
4.2.3 SF sample screening with a panel of lectins  
The panel of lectins displayed in Table 1.1 were then used to probe for differentially 
expressed glycoproteins in the same SF samples as in Figure 4.10.  Western blot images 
of each lectin are displayed in Figures 4.11- 4.18 along with details of the nominal 
binding specificity for each lectin.  The grouping of lectins in each figure was made 
based on similar sugar-binding specificities. 
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Figure 4.11: WB images of whole SF samples incubated with sialic acid-binding lectins 
SNA, MAL 1 and MAL 2. 
These three lectins are mainly sialic acid-binding proteins though SNA and MAL differ 
in terms of the sialic acid-galactose stereochemistry.  Each OA sample (Lanes 2-5 in each 
blot) possesses the same band pattern, though the sample in Lane 3 in the SNA blot has 
higher intensity bands in the 100-200kDa range.  For each lectin, there is an increase in 
the intensity of the ~90kDa band in the PSA, IA and gout samples (Lanes 6, 7 & 9) 
relative to the OA samples.  SNA exhibits more clearly defined bands and coverage over 
a broader molecular weight range than the MAL family, suggesting NeuNAc2-6Gal 
bonding is more prevalent than NeuNAc2-3Gal bonding.  MAL 1 and MAL 2 are similar 
in terms of bands present, though the band intensities of the former are increased relative 
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Lectin Common Abbreviation Preferred Sugar Specificity
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Maackia amurensis I MAL I NeuNAca2-3Gal; Galβ1-4GlcNAc  
Maackia amurensis II MAL II NeuNAca2-3Gal  
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to the latter suggesting that a NeuNAc2-3Galβ1-4GlcNAc binding site may afford 
stronger affinity for the lectin than that without the GlcNAc monosaccharide.  This 
supports the statement about three monosaccharide binding sites made in section 4.0.4.  
Inter-patient differences with any one specific lectin are of intensity rather than bands 
unique to any particular disease type, possibly suggesting differences in protein amount 
or degree of glycosylation.     
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12: WB images of whole SF samples incubated with lectins LCA, PSA and UEA. 
LCA, PSA and UEA-1 share commonality in that they bind fucose, with LCA and PSA 
specific for N-linked glycans, while UEA-1 binds to O-linked glycans 35.  From Table 4.1 
above, it can be seen that LCA and PSA are remarkably similar in terms of binding 
specificity (fucose and mannose) with LCA having additional affinity for α-Glc.  
However, though the fucose-binding capabilities of both are identical in terms of 
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Lectin Common Abbreviation Preferred Sugar Specificity
Lens culinaris LCA Fucα1-6GlcNAc-Asn; α-Man; α-Glc  
Pisum sativum PSA Fucα1-6GlcNAc; α-Man  
Ulex europaeus I UEA-I Fucα1-2LacNAc; α-Fuc  
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monosaccharide-binding orientation, LCA possesses preferential binding to core fucose 
(i.e. fucose attached to GlcNAc, which in turn is attached to the asparagine amino acid 
residue) while PSA binds fucose without this locational restriction.   UEA-I on the other 
hand binds to Fucα1-2LacNAc rather than Fucα1-6GlcNAc and this lectin is fucose-
specific. 
PSA and UEA did not display any glycosylation changes – either in terms of band 
differences or intensity differences- between disease types.  Both also exhibited bands 
within the same molecular weight range, with the strongest bands down to 50kDa.  When 
the two blots are compared there is identical banding in the 50-75kDa region.  However, 
in the 75-100kDa region, rather more interesting differences were manifest.  The OA and 
OA/CPPD samples (Lanes 2-5 inclusive and Lane 8) are identical in terms of band 
patterns.  However, extra banding is found in the PSA, inflammatory arthritis (IA) and 
gout samples when incubated with LCA.  PSA and IA each feature an extra band at ~ 
90kDa, while gout also had this band in addition to a unique band at ~80kDa.  With 
reference to Table 4.1, additional affinity by LCA for α-glucose may account for this 
observation.  Alternatively, the case may be that the location-specific fucose-binding 
character of LCA may account for this.  It may be that LCA interacts with the asparagine 
amino acid residue or indeed another amino acid on the protein chain.  Brooks et al. 36 
deemed this possible by stating that when the binding site of the lectin combines with the 
sugar, it does so in a particular spatial arrangement and “sometimes even part of the 
protein or lipid to which the oligosaccharide is attached”.  UEA-1 did not exhibit any 
inter-patient differences, suggesting that there are no fucosylation differences between 
patient pathologies in any O-linked glycoproteins that may be present in whole SF.  In 
light of this analysis LCA was considered a good candidate lectin for further study.  The 
additional bands in PSA, IA and gout relative to OA for this lectin may be due to 
additional glycoprotein species or else changes in the glycosylation decoration of a 
commonly expressed glycoprotein present in each pathology.  It is not possible at this 
stage to speculate on the nature of these bands.  Are they glycoproteins specific to PSA, 
IA and gout, or are they ubiquitous glycoproteins which are absent in OA?  An enlarged 
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image of the LCA WB can be seen in Figure 4.13 with differentially expressed bands 
highlighted.   
 
                  
 
 
 
 
 
 
Figure 4.13: Enlarged image of WB showing whole SF from patients with different 
arthritic pathologies incubated with the lectin LCA.  This is the same image that was 
shown in Figure 4.11.  Differentially expressed bands are highlighted with an arrow.  
 
PHA-E and PHA-L bind to complex or branched glycans that terminate with a galactose 
residue.  RCA-120 also binds to terminal galactose glycans.  The WB analysis for these 
lectins is shown in Figure 4.14    
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Figure 4.14: WB images of whole SF samples incubated with terminal galactose-binding 
lectins RCA-120, PHA(L) and PHA(E). 
Close examination of Figure 4.14 reveals a very intense band in the IA sample (Lane 7) 
at ~50kDa in both blots.  This band is present in all the other pathologies, though the 
intensity is somewhat less intense.  Therefore, a glycan species with this molecular 
weight possesses a higher degree of complex glycosylation in IA relative to the other 
arthritic pathologies. 
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Ricinus communis RCA120 β-Gal  
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With the galactose-binding lectin RCA120 there are no differential glycosylation 
differences, though the OA patient sample in lane 5 appears to exhibit overall reduced 
glycosylation relative to the other OA patients.   
 
Figure 4.15: WB images of whole SF samples incubated with the lectins ConA, WGA and 
succinylated WGA. 
As the WB image of WGA in Figure 4.15 displayed a high background noise, no 
glycosylation differences between the various arthritic pathologies could be ascertained.  
This background noise was consistently found to be a feature with this particular lectin 
over repeated experiments.   Succinylated WGA on the other hand did not exhibit this 
limitation.  Succinylation is a protein post-translational modification in which a –CO-
(CH2)2-CO- group is attached to the amino acid, lysine.  The charge on lysine changes 
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Lectin Common Abbreviation Preferred Sugar Specificity
Canavalia ensiforms ConA ?-Man; ?-Glc  
Triticum vulgaris WGA Terminal N-acetylglucosamine or chitobiose; NeuNAc  
Triticum vulgaris succinylated WGA Terminal N-acetylglucosamine or chitobiose  
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from +1 to -1 and this is believed to change the structure and function of the protein, 
possibly because of an alteration in electrostatic interactions.  The differences in the 50-
75kDa molecular range for lanes 2, 3 and 4 were believed to be artifacts associated with 
the experiment.  Therefore, it was concluded that differences in terminal GlcNAc or 
chitobiose (a dimer of β1-4 linked GlcNAc units) were not a feature that could 
distinguish disease types.  On the other hand ConA was deemed interesting as 
glycosylation differences were evident between patient pathologies.  What is also 
noteworthy is that ConA and LCA share sugar-binding specificities (Table 4.1).  In order 
to aid discussion the ConA WB is enlarged and displayed in Figure 4.16. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: Enlarged image of WB showing whole SF from patients with different 
arthritic pathologies incubated with the lectin ConA.  This is the same image that was 
shown in Figure 4.14.  Differentially expressed bands are highlighted by arrows.  
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As with LCA ConA exhibited interesting differences between OA and the other 
pathologies i.e. PSA, IA and gout.  In particular, there were double bands present in the 
latter that are absent in OA and these are highlighted with coloured arrows (pink and 
blue) in the figure.  At this point it is not possible to ascertain if these are differences due 
to extra glycoproteins or differences in glycosylation of the same glycoprotein or even 
differences in amount of each protein.  An extra band (~ 80kDa) in the gout sample was 
evident in both Figure 4.13 (yellow arrow) and Figure 4.16 (yellow arrow).  The 
commonality between LCA and ConA is that both of these lectins bind to α-mannose and 
α-glucose monosaccharides.  It was therefore concluded that there may be a glycoprotein 
at ~ 80kDa that is unique to gout, though only a larger patient cohort could establish this 
claim.  The differences in glycosylation revealed by LCA and ConA were not the same 
however.  In LCA differences were found to occur in the 75-100kDa range, while those 
found in ConA were manifest in the 50-75kDa interval.  Therefore, these highlighted 
bands could not be the same species.  As mentioned above, it is not possible to establish 
the nature of these bands, i.e. whether they represent different glycans or the same protein 
with different glycosylation attachments.  Another point worthy of note concerns the 
OA/CPPD sample (Lane 8).  As indicated with the blue arrow in Figure 4.16, this patient 
possess the same glycosylation difference as PSA, IA and gout, and is absent in OA.  
This may be an inflammatory-related species attributed to CPPD where the build up of 
calcium crystals in the joint may have triggered an inflammatory response.                
PNA and jacalin both specifically bind to O-glycans 37.  The WBs following incubation 
with these lectins is displayed as Figure 4.17.  The PNA and jacalin glycosylation 
patterns are very similar especially in the high molecular weight region, where the signal 
appeared as a smear.  A possible source of these high molecular weight species might be 
proteoglycans (polymers consisting of repeating disaccharide units).  As mentioned in the 
introduction to this chapter, chondroitin sulphate (a glycosaminoglycan) is O-linked to 
aggrecan and constitutes a major component in cartilage 6.  This species may bind to 
PNA and jacalin and so account for the species detected at a molecular weight >250kDa.  
The fact that the band appeared as a smear could be accounted for by polymers of 
different lengths bound to the lectins.  With jacalin there is a differentially expressed 
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glycoprotein at ~90kDa in the PSA, IA and gout samples that is not represented in the 
OA patients.  In addition, these bands are not present in the PNA WB and may be 
explained by the fact that these species may be end-capped with sialic acid.  From Table 
4.1, it is known that jacalin also recognises a sialic acid residue, while PNA does not.  
Examination of the SNA blot in Figure 4.10 reveals a band at approximately 90kDa.  As 
before, it was noticed that the OA patient sample in lane 5 is very different in the jacalin 
blot relative to that of PNA.  This difference was already encountered with ConA and 
RCA120 and it was established that none of these three lectins share the same binding 
specificities.  The fact that this occurred in the same patient sample with three different 
lectins, analysed on three different days, leads one to suspect that this feature is not one 
of incorrect sample loading and is instead a genuine feature of the SF from this particular 
individual.        
 
Figure 4.17: WB images of whole SF samples incubated with the lectins PN and, Jacalin. 
 
Incubation with the mainly GalNAc-binding lectins GSI, DBA, SBA and SJA (Figure 
4.18), did not highlight glycosylation changes between patient samples.  However, with 
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SBA there was a clear difference in the intensities of some bands e.g. at ~ 200kDa there 
were increased band intensities for one OA patient (Lane 4), the OA/CPPD patient (Lane 
8) and the gout sample (Lane 9).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18: WB images of whole SF samples incubated with the GalNAc-binding lectins 
GSI, DBA, SJA and SBA. 
 
Of the 18 lectins employed in the screening process, three (LCA, ConA and jaclin) 
featured potentially interesting glycosylation differences between OA and other arthritic 
pathologies (PSA, IA and gout) i.e. bands present in that latter that are absent in the 
former.  It may be the case that these specific glycoproteins are indicative of a specific 
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pathology, as in for example, the band highlighted in yellow in gout (Figures 4.13 & 
4.16).  This is absent in all other pathologies.  Another hypothesis is that the other “extra” 
bands in PSA, IA and gout are endogenous to SF, but are down-regulated in OA or the 
glycosylation is significantly altered in OA. 
It was then decided to explore this hypothesis further by employing lectin-affinity 
chromatography to further elucidate any glycan changes – either in terms of protein 
changes and/or glycosylation changes – with a new cohort of patient samples using LCA. 
As mentioned previously and indicated in Table 4.1, LCA and ConA are very similar in 
terms of their sugar-binding specificities.  Both bind α-Man and α-Glc.  ConA binds non-
specifically to glucose and mannose 38.   LCA however, also has a preferred specificity 
for a Fucα1-6GlcNAc motif at the core oligosaccharide (Figure 4.6), and the presence of 
this feature markedly enhances the affinity of this lectin.   
Sobiesiak 39 studied the glycosylation of human serum transferrin with LCA and ConA 
and concluded that both can be used as diagnostic tools of the acute phase response, 
although variants produced using LCA were much more apparent.  Ferens-Sieczkowska 
et al. 40 studied fucosylation in SF and found that the density of fucosylated epitopes 
differs significantly in particular glycoproteins.  As LCA has a binding specificity for 
core fucosylation in addition to mannose and glucose, it was believed that employing 
lectin-affinity chromatography experiment with LCA in the stationary phase could be 
interesting.  As mentioned in section 4.0.7 above, fucosylation of fibronectin was found 
to be related to RA disease activity, while increased fucosylation of IgG heavy chains 
distinguished between acute and remission phases of juvenile chronic arthritis 41.         
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4.2.4 Analysis of whole SF employing lectin-affinity chromatography with LCA as 
the stationary phase 
Lectin-affinity chromatography was carried out as outlined in 4.1.9 and a Coomassie 
stained gel was prepared for each fraction (whole SF, unbound and bound).  This is 
shown in Figure 4.19.  
  
 
 
 
 
 
 
 
 
 
 
Figure 4.19: Coomassie-stained gel of all fractions following lectin affinity 
chromatography with LCA lectin.  The targeted bound fractions are highlighted with a 
yellow box.  The blue line is serves as a reference to aid a comparison between the two 
gels A and B.   
Gel A (Lane 8) is a LCA positive control to ensure that none of the bands in the samples 
are due to the lectin itself.  LCA is a 49kDa protein composed of four subunits – two ~ 
17kDa and two ~ 8kDa 37.  That the samples were dissolved in sample buffer containing 
under reducing conditions and then boiled ensured that the lectin dissociated into its 
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component subunits.  From Figure 4.18, it may be seen that there are no bands due to 
LCA.  As LCA is composed of four subunits (two of 17kDa and two of 8kDa), under 
reducing conditions these subunits would have exited the bottom of the gel.  The lanes 
highlighted with a yellow box are the targeted, LCA-bound fractions i.e. those 
glycoproteins that bind to LCA.  Comparing the bound fractions in the Coomassie-
stained gels in Figure 4.19 with the WB of LCA in Figure 4.13, it may be expected that 
both should reveal identical banding patterns.  However, this is not the case.  This is 
readily explained by consideration of the conditions under which each experiment was 
performed. 
The initial lectin screening process was carried out under reducing conditions i.e. the 
glycoproteins were treated with β-mercaptoethanol and boiled prior to incubation with 
the lectins.  By contrast in the lectin affinity chromatography study, all glycoproteins 
were in their native condition when captured by the stationary LCA.  This is important 
(as already outlined in the introduction to this chapter) considering lectin binding depends 
on the stereochemistry of the glycan-binding region. Sample conditions (i.e. reducing 
versus non-reducing) greatly influence the conformational structure of proteins and 
therefore the lectin binding region environment.  Further, in lectin affinity 
chromatography, divalent cations (Ca2+ and Mn2+) were required to ensure successful 
lectin-glycan binding.  It was not possible to employ these cations in the lectin screening 
process as incubation with the phosphate buffer would result in the formation of insoluble 
phosphate salts which precipitate on the surface of the membrane during incubation of 
the lectin.  This increases the background noise in both channels (emission wavelengths 
λ=700nm and λ=800nm).   Also, the commonly used tris buffer could not be used either 
as this would render image acquisition with the Odyssey scanner difficult due to high 
background noise.   
A band in the OA sample (Gel B, Lane 3) was found to have a band that was either 
absent from or at a slightly higher molecular weight relative to the other pathologies and 
this is indicated in Figure 4.18 with a red asterisk.  For example, this band is completely 
absent in the gout sample (Gel B, Lane 5) and at a higher molecular weight than 
comparable bands in IA, PSA and RA.  This is demonstrated by using a reference visual 
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aid (blue line).  It may be the case that this is a glycoprotein unique to OA, or a species 
common to each pathology but possessing a different glycosylation signature in OA.  
Indeed, the perceived difference may not exist.  It was not possible to speculate which is 
the case without further investigation. 
The corresponding whole SF and unbound fractions from each of the pathologies do not 
seem to exhibit notable differences.  Other studies in the literature (see introduction) have 
already characterized the proteome of whole SF and therefore, it is outside the scope of 
this project to explore these fractions any further. 
The band marked with a red asterisk was excised for characterisation by MS.  In addition, 
bands on the blue line from the other patient samples were also cut out for 
characterisation and comparison.  As the gout sample did not possess a band at this 
molecular weigh, no band from this sample was sent for MS analysis. 
A full list of proteins identified for each band is displayed in Appendix F.  The list was 
studied and a screening process was adopted in order to remove unlikely redundant 
candidates.  For example, all contaminating keratin species (possibly due to skin, hair 
etc.) were removed, all non-glycosylated proteins were removed (e.g. albumin) and 
finally as the excised band is ~150kDa, all species less than 80kDa were ignored.  This 
modified list of proteins is given in Table 4.2.  
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Reference P (pro) Score Coverage MW Accession Peptide (Hits)
Scan(s) P (pep) XC DeltaCn Sp RSp Ions
Alpha-2-macroglobulin 1.00E-30 1148.35 67.60 163187.4 308153640 115
Ceruloplasmin 7.77E-15 350.33 38.30 122127.6 116117 35
Attractin 1.48E-12 150.25 12.50 158431.7 13431311 15
Fibronectin 4.17E-12 140.23 8.30 262457.6 300669710 14
Pregnancy zone protein 3.34E-12 150.28 6.70 163759.1 281185515 15
Lactotransferrin 4.79E-09 30.21 5.40 78132.0 85700158 3
Complement factor H 3.98E-07 30.18 2.80 139004.4 158517847 3
Complement C4-B 2.27E-10 30.23 2.10 192671.6 81175167 3
Complement C4-A 2.27E-10 30.23 2.10 192649.5 81175238 3
Apolipoprotein B-100 6.06E-06 20.14 0.50 515283.6 300669605 2
Reference P (pro) Score Coverage MW Accession Peptide 
Scan(s) P (pep) XC DeltaCn Sp RSp Ions
Alpha-2-macroglobulin 4.44E-16 1648.36 79.00 163187.4 308153640 165
Ceruloplasmin 9.99E-15 310.38 43.50 122127.6 116117 31
Attractin 1.11E-15 230.31 17.70 158431.7 13431311 23
Pregnancy zone protein 1.48E-12 220.29 13.00 163759.1 281185515 22
Fibronectin 5.53E-13 160.26 9.30 262457.6 300669710 16
Hornerin 3.54E-09 30.21 5.20 282225.7 45476906 3
Complement factor H 3.24E-05 30.15 3.10 139004.4 158517847 3
Apolipoprotein B-100 5.32E-09 30.19 0.80 515283.6 300669605 3
Reference P (pro) Score Coverage MW Accession Peptide 
Scan(s) P (pep) XC DeltaCn Sp RSp Ions
Alpha-2-macroglobulin 1.00E-30 1408.36 72.90 163187.4 308153640 141
Ceruloplasmin 8.88E-15 170.35 25.60 122127.6 116117 17
Attractin 3.79E-11 230.27 18.00 158431.7 13431311 23
Pregnancy zone protein 5.01E-12 190.27 10.70 163759.1 281185515 19
Fibronectin 3.17E-11 80.27 4.70 262457.6 300669710 8
Reference P (pro) Sf Score Coverage MW Accession
Scan(s) P (pep) Sf XC DeltaCn Sp RSp
Alpha-2-macroglobulin 1.00E-30 119.01 1338.36 72.60 163187.4 308153640
Ceruloplasmin 4.44E-16 38.42 420.38 47.50 122127.6 116117
Fibronectin 2.22E-16 57.13 622.34 36.80 262457.6 300669710
Pregnancy zone protein 2.11E-14 27.16 300.31 22.50 163759.1 281185515
Complement factor H 5.21E-10 10.59 120.27 13.00 139004.4 158517847
Attractin 3.77E-07 10.75 130.26 11.30 158431.7 13431311
Fibrinogen alpha chain 4.14E-06 1.78 20.18 2.90 94914.3 1706799
Apolipoprotein B-100 4.75E-11 2.32 30.24 0.80 515283.6 300669605
Rheumatoid Arthritis
Inflammatory Arthritis
Psoriatic Arthritis (PSA)
Osteoarthritis
 
Table 4.2:  Modified list of proteins identified following excision of ~150kDa band from 
SDS-PAGE gel in Figure 4.18.   The bands were taken from the bound fraction after 
analysis of whole SF by lectin affinity chromatography employing LCA lectin.  This list is 
a subset of that given in Appendix 9 following a screening process to remove unlikely 
candidates.     
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From Table 4.2 it can be seen that, on the basis of total protein coverage and the number 
of peptide hits, a strong degree of confidence may be had in identifying alpha-2-
macroglobulin (α-2-M) as the major species present in all the bands excised at ~150kDa.  
It was therefore decided to pursue a study of the glycosylation of this protein with a 
larger cohort of patient samples. Incubation with both anti-α-2-M and LCA, and then 
measuring the intensity of for each species at ~ 150kDa, would yield a ratio of intensities.  
These ratios would then be compared in order to ascertain if there are changes in the 
protein moiety or the sugar attachments.   Other potentially interesting species present are 
ceruloplasmin, attractin and pregnancy zone protein.  UniProt describe the latter as a 
relative to α-2-M and indeed the functionality description given for both species is 
identical.  Knowing its known role as a proteinase inhibitor and a regulator of cytokine 
and growth factor activities (by binding and inhibiting these signaling molecules from 
interacting with their cell-surface receptors) 42, α-2-M offered an interesting line of study.  
Confirmation as to whether there is a change in the protein entity and/or the glycosylation 
decoration (these changes may be manifest by changes in molecular weight) of the 
protein was the aim of the next phase of the experiment.  For this, a larger cohort of 
patient samples was gathered and analysed by SDS-PAGE (under reducing conditions) 
followed by incubation with LCA (λem800nm) and anti-α-2-M (λem700nm).  The samples 
set consisted of; 8 OA samples, 5 RA samples; 2 IA samples; 2 CPPD samples; 4 PSA 
samples and finally 2 Gout samples.  The band intensity ratio (LCA: anti-α-2-M) was 
calculated for each sample using the Odyssey scanner.  The result of this study can be 
seen in Figure 4.20.  
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Figure 4.20: WB image sets (A, B, and C) of various arthritic patient pathologies 
incubated with anti-α-2-Macroglobulin (λem800) and LCA lectin (λem700).  Also included 
is the image which displays both channels simultaneously.  Regions in which both red 
and green channels overlap, show up as yellow.  A table showing the band intensities of 
monomeric α-2-M in both the red and green channels is displayed with each image set.  
The final column is ratio of LCA intensity to α-2-M intensity.   
       
Comparison of the whole synovial fluid WB image for LCA in Figure 4.13 with those in 
Figure 4.20 highlights remarkable difference in terms of band patterns.  Though there are 
differences in terms of individual patients, the principal reason for this phenomenon 
could be due to differences in methodology.  In the initial lectin screening process, 
electrophoresis was performed using commercial pre-cast gradient gels with a HEPES 
buffer, while in the study performed in Figure 4.20, electrophoresis was carried out 
employing home-made gradient gels with a tris-glycine buffer system.  A further 
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difference between the two studies concerned the mode of protein transfer from gel to 
membrane.  In the lectin screening experiment the “dry” method was adopted while in the 
study of α-2-M the “wet” method was used.  An important distinction between these 
modes of transfer concerned the amount of heat generated.  With the “dry” method the 
amount of heat was appreciable while with the “wet” method transfer took place under 
ice.  It may be appreciated by comparing the WBs that the latter method generated much 
more information and better resolved bands than the former.  Thus the choice of method 
employed, greatly influences the experimental result.   
The mean and standard deviation LCA:α-2-M intensity ratios representing each of the 
pathologies were calculated and a histogram was produced.  This is shown in Figure 4.21. 
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Figure 4.21:  Histogram displaying the mean and standard deviation of LCA:α-2-M 
intensity ratios obtained from the raw data in Figure 4.20.    
Figure 4.21 suggests that there some slight differences in the LCA:α-2-M intensity ratios 
between the various arthritic pathologies with this larger cohort of samples.  The peak for 
gout may be somewhat misleading as it is based on two patient samples with a very large 
standard deviation.  OA (n=8) has a slightly lower ratio relative to the other pathologies.  
However, a larger sample size for each of the pathologies would be required in order to 
acquire meaningful statistical information and conclude a valid inference.  
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4.2.5 The analysis of the glycosylation of α-2-M in SF MV 
However, at this point it was decided to engage in a further study of α-2-M glycosylation, 
only this time in relation to MVs.  That continued interest in this protein was maintained, 
is in part due to a publication 43 that was found citing α-2-M as a substrate for ADAMTS-
4 and ADAMTS-5 (putative OA markers) and thereby inhibiting their activity.  Mass 
spectrometry found α-2-M to be associated with MV and this was confirmed by WB 
(Figure 3.33).  The current work is aimed at establishing if any differences exists between 
soluble α-2-M and vesicle-associated α-2-M in terms of glycosylation and/or protein 
band patterns.  The approach taken was to analyse all differentially centrifuged fractions 
of several patient samples with LCA and anti-α-2-M, and ascertain if any notable 
differences are evident.  The WB images of the pellet fractions (i.e. 18,000g crude and 
200,000g CHAPS) are displayed in Figure 4.22, while the SN fraction (i.e. 200,000g 
crude and 200,000g CHAPS) are shown in Figure 4.23. 
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Figure 4.22: WB images of the pellet fractions resulting from the differential 
centrifugation process developed to isolate MV from SF.  Incubation with LCA lectin was 
carried out in the λem800nm (lower left), incubation with anti-α-2-M was in the 
λem700nm (lower right).  The upper blot is a compound image of both LCA and anti-α-2-
M.  The orange/yellow bands are where there is an overlap of both images.  The bands 
enclosed within the coloured boxes are discussion aids    
 
 
 
 
LCA Lectin +
Anti-α-2-M
Lane 1: MWM
Lane 2: OA 18,000g Crude Pellet
Lane 3: RA 18,000g Crude Pellet
Lane 4: IA 18,000g Crude Pellet
Lane 5: PSA 18,000g Crude Pellet
Lane 6: Gout 18,000g Crude Pellet
Lane 7: OA 200,000g CHAPS Pellet
Lane 8: RA 200,000g CHAPS Pellet
Lane 9: IA 200,000g CHAPS Pellet
Lane 10: PSA 200,000g CHAPS Pellet
Lane 11: Gout 200,000g CHAPS Pellet
1     2      3      4       5     6      7     8      9      10 11
250
150
100
75
50
37
25
20
250
150
100
75
50
37
25
20
1     2       3      4      5      6     7      8      9     10 11                       1      2      3      4      5     6      7     8      9     10     11
LCA Lectin Anti- α-2-macroglobulin
250
150
100
75
50
37
25
20
  246 
 
 
 
 
 
 
 
 
 
 
Figure 4.23: WB images of the SN fractions resulting from the differential centrifugation 
process developed to isolate MV from SF.  Incubation with LCA lectin was carried out in 
the λem800nm (lower left), incubation with anti-α-2-M was in the λem700nm (lower 
right).  The upper blot is a compound image of both LCA and anti-α-2-M.  The 
orange/yellow bands are where there is an overlap of both images.  The bands enclosed 
within the coloured boxes are discussion aids.    
In Figure 4.22 there is a striking difference in the band patterns between the 18,000g 
crude and 200,000g CHAPS pellets.  Relative to the 18,000g pellet (Lanes 2-6), there is 
extensive fragmentation of α-2-M in the 200,000g pellets (Lanes 7-11) of all patient 
samples (red channel).  All samples in both 18,000g and 200,000g pellets indicate that 
the monomeric form of α-2-M is present at ~ 180kDa (highlighted with a purple box).  
Hypothetical reasons for this fragmentation unique to the 200,000g CHAPS pellet will be 
explored in the discussion section. 
This same fragmentation of α-2-M is mirrored in the SN fractions (Figure 4.23, red 
channel).  Here it may be seen that the 200,000g CHAPS SN possesses the same 
fragmentation as the 200,000g CHAPS pellet, while this feature is absent in the 200,000g 
crude SN.  In light of the discussion in the previous chapter, this is not a surprise.  There, 
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a discussion was had concerning the likelihood of MVs remaining in the 200,000g 
CHAPS SN i.e. a 100% recovery of MVs in the pellet fraction does not occur.  But why 
is fragmentation of α-2-M not evident in the crude SN (Figure 4.23, λem700nm, Lanes 2-
6) bearing in mind that both the crude and CHAPS fractions are analysed under reducing 
conditions?  Here it needs to be appreciated that the crude SN represents the entire SF 
proteome minus the isolated MV proteome, whereas the CHAPS SN is a combination of 
proteins from any entrapped MVs plus proteins removed by CHAPS from the 200,000g 
CHAPS pellet surface.  Comparing Figures 4.22 and 4.23 with Figure 4.19 it can be seen 
that the crude SN is an almost whole SF proteome, whereas the CHAPS SN represents a 
unique sub-proteome i.e. the band profile between the crude SN and whole SF is very 
similar.  Thus this study uncovered for the first time that the nature of α-2-M 
fragmentation in the 200,000g CHAPS pellet is a characteristic feature not evident in 
whole SF and may indicate that other proteins may exhibit such alterations.  This would 
warrant further study in the future.     
In addition to α-2-M fragmentation, there are also noted differences in glycoproteins 
between various fractions.  For example, both the 200,000g CHAPS pellets and CHAPS 
SN lack the strong band intensities that are present in the 18,000g pellet and 200,000g 
crude SN at ~23kDa (enclosed in a red box in both Figure 4.22 and 4.23, λem800nm).  
There are also differences between pathologies within the same fraction.  The bands 
enclosed in the blue boxes at ~37kDa (Lanes 8, 9 and 10) in each figure are more 
strongly represented in RA, IA and PSA, than in OA or gout.  This may be a difference in 
glycosylation rather than a protein difference. 
As noted, the study that was performed on the MV sub-proteome revealed interesting 
differences that were masked in the analysis of whole SF.  It may be the case that future 
screening of MVs rather than whole SF with the same 18 lectins that were used in this 
project would be interesting and worthwhile.       
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4.3 Discussion 
The role which protein glycosylation plays in the human body was previously discussed 
in the introduction and a summary is outlined in Figure 4.9.  There, diverse 
functionalities were mentioned e.g. modifications in protein solubility and stability, 
alterations in protein folding, mediators for targeting and receptor recognition, resistance 
to protein lysis and prevention to inflammation and autoimmune disease.   
A panel of plant lectins with a diverse range of sugar specificities was employed to probe 
any glycan differences between OA and other arthritic pathologies.  It was hypothesised 
that differentially expressed bands would signify the presence/absence of glycans and/or 
changes to glycosylation between disease states.  Lectins that exhibited disease marker 
potential would then be used in lectin-affinity chromatography to further aid in 
characterising potentially interesting glycoproteins. 
Sialic acid-binding lectins i.e. SNA, MAL I and MAL II (Figure 4.11) yielded interesting 
intensity differences between OA and the other disease states.  Previously, Przybysz et al. 
32
 used the same three lectins to probe fibronectin in order to classify the different stages 
of RA (early, middle or late-stage) and concluded that the degree of sialylation increased 
with disease duration.  Though RA was not one of the pathologies explored in this stage 
of the project, there is stronger band intensity at ~90kDa for SNA and MAL I in IA, PSA 
and gout relative to OA. 
The same author also found that the expression of α1-6-linked fucose in fibronectin was 
found to be related to disease activity.  Again, three lectins were used in fucosylation 
analysis by the authors of which only one (UEA) was common to the three lectins in this 
project (which were LCA, PSA and UEA-1, Figure 4.12.  Of the three fucose-specific 
lectins used, LCA was found to show the most interesting band differences between 
disease types (Figure 4.13).  However, the choice of conditions under which the 
experiment was performed greatly influenced the result.  In Figure 4.13 the entire glycan 
population was denaturated prior to lectin incubation while in Figure 4.20 the converse 
was the case where all glycoproteins were in their native conformation at the time of 
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lectin binding.  Alterations in the binding site were believed to be the primary reason for 
the marked differences in band profiles in denaturing versus non-denaturing conditions.        
ConA and jacalin also featured differential band patterns between patient pathologies.  
However, due to additional affinity for core fucose and encouraged by other studies in the 
literature 32, 33, 40 , LCA was the candidate lectin for further analysis employing lectin-
affinity chromatography. 
Following lectin affinity chromatography it was found that one band, at a molecular 
weight just above 150kDa, was unique to OA.  Other pathologies had bands in the same 
region, but at a lower molecular weight.  It was hypothesised that this was either a glycan 
unique to OA or else a protein(s) that is common to all pathologies, though possessing a 
different glycosylation signature in OA.  MS analysis indentified a number potential 
candidates this band and based on the number of peptide hits, the protein coverage and 
the closeness of the molecular weight to the monomeric form of α-2-M, this was the 
protein that received priority for further study.       
A larger cohort of patient samples was obtained and the whole SF of each was analysed 
by SDS-PAGE followed by incubation with both anti-α-2-M and LCA lectin.  However, 
when the ratio of the intensity of the lectin to the intensity of α-2-M was compared for 
each sample, no significant difference presented itself between different patient 
pathologies.  Gout and OA appeared to exhibit a different ratio, but a larger patient cohort 
would be required to confirm this result before anything definitive can be hypothesised.  
It was recognised that this study was on a patient sample set of whole SF, and not on an 
LCA-separated sub-set.  However, the principal aim of this particular study was to be 
able to establish biomarker differences in whole SF after having first identified that 
marker using more extensive methodologies.  The next logical step would have been to 
repeat the lectin-affinity experiment with this larger cohort of samples, but a potentially 
more interesting side-study of α-2-M presented itself following a further literature 
research into this protein. 
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α-2-M is a 720kDa homotetrameric species and is the third most abundant glycoprotein 
in human plasma 44.  The tetramer structure itself is composed of two 370kDa disulphide-
linked homodimers.  This protein has eight N-linked glycosylation sites and 13 disulphide 
bridges (11 of which are intra-chain and two are inter-chain) to form the final tertiary 
structure 45, 46.  From the UniProt database α-2-M is able to inhibit all four classes of 
proteinases (serine, aspartic, cysteine and MMPs) by a unique “trapping” mechanism.  
Each α-2-M monomer possesses a “bait region” (a short stretch of amino acids beginning 
at Pro667 and ending at Thr705)43 and it is this region which is susceptible to proteolytic 
cleavage.  When cleaved by an enzyme, α-2-M undergoes a conformational change 
which “traps” the proteinase.  This resulting change in α-2-M morphology, results in the 
inhibition of protease activity through the prevention of substrate access by means of 
steric hindrance.  It may be possible that α-2-M itself may become a substrate for the 
entrapped enzyme.  As proteases were confirmed to be associated with MVs by MS and 
zymography (chapter 3), this theory is a distinct possibility.  This would offer a plausible 
explanation for the observed fragmentation especially in light of a recent paper by Paiva 
et al. 44 who found that covalently-linked proteinases to the bait region converted “the 
native or electrophoretically slow S-α2M into the electrophoretically fast form or F-
α2M”.  The terms “fast” and “slow” may relate to the relative sizes of α-2-M fragments 
or indeed any induced changes in charge.  Extensive fragmentation of α-2-M experienced 
in the 200,000g CHAPS pellet suggested the activated form of this inhibitor was en route 
to some as yet, unknown destination.  
A very interesting study by Tortorella et al. 43 into cleavage of α-2-M by ADAMTS-4 
and ADAMTS-5 found that these species cleave α-2-M at a specific and unique amino 
acid residue in the bait region i.e. Met690.  Moreover, they found that this cleavage 
produces a 98kDa α-2-M fragment plus “higher molecular weight fragments 
representing an SDS-stable complex between α-2-M and ADAMTS-4”.   Figures 4.22 and 
4.23 clearly show intense bands in the 100kDa region for the 200,000g CHAPS pellet and 
SN for each patient sample.  This was also found in the anti-α-2-M WB under reducing 
conditions in Figure 3.33 in the previous chapter.  Bands in this regions are absent in the 
18,000g pellet and 200,000g crude SN.  This result leads to the hypothesis that cleaved 
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α-2-M residues are solely vesicle associated.  Further, the authors identified α-2-M 
fragments containing the N-terminal 691GRGHAR and C-terminal YESDVM690 generated 
by cleavage of the α-2-M subunit by both ADAMTS species, as potential markers of 
aggrecanase activity, which in turn by means of aggrecan degradation, reduces the ability 
of cartilage to resist compressive forces.  The authors regret that they were unable to find 
these neoepitopes in OA synovial fluid and they conclude, “That we were unable to 
detect the α-2-M:ADAMTS-4/-5 complex in OA synovial fluid suggests the complex is 
rapidly cleared through the vascular and lymph systems.  It is well known that 
conformational change of α-2-M leads to exposure of recognition sites that bind 
receptors such as lipoprotein receptor-related protein on a variety of cells, including 
macrophages, resulting in clearance”.  The afore-mentioned receptor, also known as 
alpha-2-macroglobulin receptor (UniProt), was one of the species characterized by MS in 
the OA 200,000g CHAPS pellet (Table 3.7, Q07954).  One of the functionalities listed by 
the UniProt database for this receptor is the clearance of activated α-2-M.  Based on the 
results of the current project displayed in Figures 4.22 and 4.23 and above discussion, 
also in light of the above quotation by Tortorella et al. 43, there is sufficient evidence to 
hypothesise  that proteinase-activated α-2-M, is associated with MVs and ferried thus out 
of the joint cavity.  
An earlier study by Wu et al. 47 focused on the effects of oxidation on α-2-M in terms of 
proteinase-inhibitory function.  They concluded that α-2-M from RA SF is significantly 
more oxidized than that in OA SF, hence the proportion of α-2-M capable of inhibiting 
proteases is reduced in RA relative to OA.  However, they did state that the degree of 
oxidation correlates with the number of bands in WB, and it was concluded that oxidation 
correlates with α-2-M susceptibility to proteolytic degradation.  Applying this criterion to 
the current study was the case that the IA, PSA and gout 200,000g CHAPS pellet samples 
exhibited greater fragmentation (Figure 4.22, λem700nm) than OA and RA suggesting 
that the former samples have been subject to a greater degree of α-2-M oxidation.  
Comparing Figure 4.22 of this thesis with Figure 5 in Wu’s paper revealed that there are 
many bands in common.  This evidence indirectly implies that an oxidation event could 
be the origin of the fragmentation detected by WB.  Another interesting insight offered 
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by the group concerned the association of α-2-M with the regulation of the pro-
inflammatory cytokine, TNF-α.  Here it was found that increased oxidation of α-2-M 
resulted in increased binding to TNF-α and the authors attributed this phenomenon to the 
fact that oxidised α-2-M has impaired tissue clearance through the already mentioned 
lipoprotein receptor-related protein.  Consequently, oxidised α-2-M may remain in the 
inflammatory fluid for a great period of time and so inhibit TNF-α .  Thus, it may be 
possible MVs bearing activated α-2-M via the lipoprotein receptor-related protein, could 
in principle, aid in trafficking harmful TNF-α out of the joint.  Finally, the authors 
recognised an apparent contradiction in their results.  They ask how proteinases are able 
to function given that some proteinase inhibitory activity is present in all of the SF 
samples that they studied.  They offer three possible solutions to this question; 
1. Concentrations of oxidants and proteinases may rise and fall transiently.  During 
“each oxidative burst” the amount of these species released overwhelms the 
protective effects of α-2-M.  The result is inflammation which in turn increases the 
vascular permeability allowing a replenishment of functional α-2-M which completes 
the inactivation of proteinases. 
2. Large proteinases with molecular weights > 90kDa and lysine-specific proteinases 
that cannot be inhibited by α-2-M are released into SF to mediate α-2-M proteolysis. 
3. Proteinases and oxidants are released in “sequestered pockets” such that α-2-M 
localized within these pockets is for the most part oxidised and proteolysed. 
The authors hypothesised that the first explanation, based on their results, was the more 
likely.  Not surprisingly, the third option is the one that fits with the result obtained in this 
project.  Again, Figures 4.22 and 4.23 indicate that proteolysed α-2-M is strongly 
associated with MVs, the “sequestered pockets” referred to by Wu et al. 47.  Another 
protein that was identified by MS in the previous chapter was myeloperoxidase.  This 
protein produces hypochlorous acid (HOCl) which is a powerful protein oxidizing agent 
48
 and may lead to α-2-M oxidation which in turn leads to greater susceptibility to 
proteases activity.  From the previous chapter proteases were found to be vesicle-
associated by MS and zymography.  It may be that oxidation of α-2-M by HOCl is 
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indirectly responsible for the fragmentation in MVs.  In reality, the possibility of all three 
proposals being the case exists.  
A very interesting link between the previous chapter of this thesis and the current chapter 
is a study carried out by Luan et al. 49.  The link to the previous chapter lies in the fact 
that they found that ADAMTS-7 and -12 were induced from the cartilage and synovium 
of arthritic patients, which then bound to and degraded COMP.  The molecular mass of 
the COMP fragments produced by either ADAMTS-7 or -12 were stated to be similar to 
those observed in OA patients.   The connection to the present chapter is their conclusion 
that both ADAMTS-7 and ADAMTS-12 were able to cleave α-2-M, giving rise to 180- 
and 105-kDa cleavage products, respectively. Furthermore, they found that α-2-M 
inhibited both ADAMTS-7- and ADAMTS-12-mediated COMP degradation in a 
concentration (or dose)-dependent manner.  Figures 4.22 and 4.23 clearly show bands at 
these molecular weights in the 200,000g CHAPS pellets.  The authors stated that “α-2-M 
represents the first endogenous inhibitor of ADAMTS-7 and ADAMTS-12”.                 
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4.4 Conclusion 
The initial aim of this study was to ascertain if there were differences in glycosylation 
and/or glycoprotein moieties in whole SF between different arthritic patient pathologies, 
employing a panel of 18 available plant lectins.  Two lectins (LCA and ConA) 
highlighted some potentially interesting differences between OA and the other diseases.  
LCA was selected for use in the employment of immunoaffinity chromatography.  A 
band that appeared to be unique to OA was characterised by MS and a number of 
candidate proteins were identified.  Based on protein coverage and the number of 
peptides identified, alpha-2-macroglobulin (α-2-M) was pursued for further study.  A 
slightly larger cohort of patient samples was screened in order to establish if there was a 
change in glycosylation of α-2-M or that the α-2-M itself manifestly changed.  This pilot 
experiment indicated that there maybe a slight decrease in the glycosylation of α-2-M in 
OA and an increase in this proteins glycosylation in gout, relative to the other 
pathologies.  Only with a much larger sample set from each disease-type, can this 
preliminary finding be ascertained.    
However, α-2-M became the object of further study - this time in MVs.  It was found that 
α-2-M (under reducing conditions) present in vesicles displayed extensive fragmentation 
relative to that in whole SF.  A hypothesis for this phenomenon was suggested, whereby 
MVs may be carriers of activated α-2-M i.e. α-2-M that trapped proteinases, thus 
rendering them inactive. 
Wu et al. 47 stated that oxidised α-2-M has decreased ability to entrap proteases and 
hypochlorite is a potent α-2-M modifier in vivo.  Further, hypochlorite oxidation is 
evident in RA but not OA.  A recent study by Kahn et al. 50 also noted that hypochlorite 
significantly reduced the anti-proteolytic potential of α-2-M.  Their study examined the 
role of nitrite as an anti-oxidant by removing hypochlorite. 
In the next chapter it is proposed to establish if nitrite is present in MV. 
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Determination of the presence of nitrite in synovial fluid 
microvesicles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  261 
5.0 Introduction 
5.0.1 Nitric Oxide 
 
Prior to the 1980’s Nitric Oxide (NO) was believed to be a free radical gas that 
contributed to atmospheric pollution 1.  In 1980 however, Furchgott and Zawadzki 
published their landmark paper in Nature 2 describing the endothelium-derived relaxing 
factor (EDRF) which is released by the endothelium upon stimulation with acetylcholine.  
In 1987 Ignarro and co-workers 3 discovered that the identity of this EDRF was in fact 
NO.  A year later Furchgott and Ignarro were awarded the Nobel Prize ‘for their 
discoveries concerning nitric oxide as a signalling molecule in the cardiovascular 
system’.  The synthesis of NO by vascular endothelium is responsible for the vasodilation 
essential for the regulation of blood pressure.   Today, NO is known to act as a mediator 
and a signalling molecule in both physiological and pathophysiological processes in the 
body.  The critical functions of NO in the human body include (i) its role as a 
neurotransmitter in the central nervous system, (ii) its mediating roles in mechanisms that 
regulate various gastrointestinal, respiratory and genitourinary tract functions, (iii) the 
control of platelet aggregation, (iv) regulation of cardiac contractility and finally (v) its 
production in large quantities during host defence and immunologic reactions 1 .   
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5.0.2 Biosynthesis of NO 
 
NO is synthesised by a family of enzymes termed nitric oxide synthases (NOS) which use 
the amino acid L-Arginine as a substrate 4.  There are three forms of NOS known to exist 
– neuronal (nNOS, NOS-I) 5, inducible (iNOS, NOS-II) 6 and endothelial (eNOS, NOS-
III) 7.  Generally speaking nNOS and eNOS are thought to be constitutively expressed 
and expression depends on the concentration of intercellular free calcium and calmodulin.  
These enzymes produce picomolar to nanomolar concentrations of NO for short periods 
of time – “NO puffs” 8.  By contrast, iNOS is expressed in response to cytokines e.g. 
interleukin 1β (Il-1β), tumour necrosis factor-α (TNF-α), lipopolysaccharide (LPS) or γ-
interferon (IFN-γ).  It is produced by some cell types e.g. macrophages, neutrophils, 
hepatocytes, smooth muscle cells and importantly for the various arthritic diseases, 
chondrocytes.  The iNOS isoform can generate higher quantities of NO (micromolar 
quantities) for a greater amount of time (up to 72 hours in vitro) 4.  While the overall NO 
synthesis pathway is quite complex and the end result can be simplified to: 
 
 
 
 
A schematic diagram outlining NO production from NOS and L-arginine can be seen in 
Figure 5.1 9.  The overall active NOS enzyme is a tetramer composed of a NOS dimer 
and two molecules of calmodulin.  In addition, a number of cofactors are required for  
enzyme activation in order to effect NO production – flavin mononucleotide (FMN), 
flavin adenine dinucleotide (FAD), tetra hydrobiopterin (BH4) and haem (Fe).  The BH4 
cofactor is bound to the C-terminal reductase domain and is known to be critical for the 
overall dimerisation of iNOS.  Indeed, in BH4-deficient cells the iNOS is in a monomeric 
form and is proven to be inactive 10.  Ellis et al.11 state that as much as 90% of circulating 
NO2- is derived from the L-arginine : NO pathway.   
 
 
Arginine + O2 Citrulline + NO
NOS
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Figure 5.1: Schematic diagram outlining the production of NO and citrulline from 
arginine and O2 by means of a catalytic reaction with the Nitric Oxide Synthase (NOS) 
enzyme. Diagram taken from Vuolteenaho et al. 9 
 
All three isoforms of NOS require calmodulin as a cofactor in order to facilitate the 
essential flow of electrons from the reductase domain to the oxygenase domain.  
However, in the eNOS and nNOS constitutive isoforms, calmodulin binding and 
activation is modulated by changes in [Ca2+].  By contrast, in the iNOS isoform the 
calmodulin is so tightly bound that even at low [Ca2+], the enzyme is active.  Therefore, 
once the iNOS isoform is expressed, it can continue to synthesise NO until the substrate 
and or cofactors are depleted 12. 
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5.0.3 Biochemical reactions of NO 
 
From the discussion above it recognised that NO acts as a signalling and mediator 
molecule in the human body e.g. in the cardiovascular system (maintains blood pressure), 
immune system and neurotransmission.  The biological activity of NO is dependant on 
the micro-environmental conditions (e.g. pH and oxygen levels) at the site of production 
and also the quantity of NO produced.  Concomitantly, the quantity produced depends on 
the particular NOS isomer involved in the synthesis.  NO levels also determine whether a 
regulatory or proinflammatory/destructive role is produced 13.       
NO is a free radical with a half life in the order of seconds 4.  It has a high affinity for and 
readily reacts with heme iron, sulfhdryl or thiol groups, superoxide anion O2.-, and 
molecular oxygen.  The decomposition products of NO in the presence of oxygen are 
NO2- and NO3-.  The conversion of NO to NO2- is given by: 
 
                                  4NO. + O2 +2H2O  4 NO2- +4H+ ……..(i)  
  
However in blood, NO2- is oxidised to NO3- by the presence of oxyhaemoglobin.  The 
overall reaction is: 
 
4HbO2 + 4NO2- + 4H+  4Hb+ + 4NO3- + O2 + 2H2O  14……….(ii) 
 
The biochemical effects of NO are in part governed by the concentration of NO in the 
micro-vicinity.  At low concentrations (< 0.5µM) 15, the biological action of NO said to 
be direct i.e. NO itself mediates with various species.  These interactions account for the 
normal regulatory effects of NO in the body.  Examples of these effects include 
interactions with metals, metalloproteins and free radical scavenging.  Some examples of 
interactions with metals and metalloproteins include binding of NO to the heme group of 
soluble guanylyl cyclise (involved in the relaxation of smooth muscle) 16, cytochrome P-
450 and cyclooxygenase (COX).  Direct scavenging of free radicals include superoxide, 
O2- (forming peroxynitrite, ONOO-), hydroxyl radicals (forming nitrous acid, HNO2) and 
lipid peroxides (which prevent lipid peroxidation) 15.   
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At higher concentrations of NO (> 0.5µM), the biological effects are said to be indirect.  
Instead, the effects of NO are mediated through reactive nitrogen species (RNS) 15.  One 
such RNS is formed by the auto oxidation of NO 17: 
 
                                      2NO + O2  2NO2 ……………(i) 
                                      NO2 + NO  N2O3 ……………(ii) 
                                      N2O3 +RS-  RSNO + NO2- ….(iii) 
 
Dinitrogen trioxide is produced which is readily hydrolysed to NO2- and NO+.  The 
nitrosonium ion NO+ interacts with cysteine and tyrosine residues of proteins and so 
changes the activity of the protein 18 .  Some consequences of this include modification of 
several transcription factors, kinases involved in signaling cascades, ion channels and the 
activation of matrix metalloproteinases (MMPs) 19. 
When NO and O2- (produced by mitochondria, macrophages and granulocytes) are 
present in equal amounts, ONOO- is produced.  This is a highly reactive oxidant and 
nitrating agent.  When produced in excess, it has been identified as a major factor of 
cellular toxicity 17.  In particular ONOO- is known to cause the mis-pairing and 
separating of DNA strands, oxidation and nitration of proteins 20, oxidation of lipids, the 
inhibition of mitochondrial respiration 21 and finally cellular death and apoptosis 22.  At 
neutral pH ONOO- rapidly decomposes to peroxynitrous acid (ONOOH).  This is an 
unstable molecule and rapidly decomposes to NO3-.  Both ONOO- and HONOOH are 
strong oxidizing agents and produce NO2-: 
 
ONOO- +2H+ + e-  NO2- (aq) + H2O……..(iv) 
 
Therefore it can be seen that NO2- and NO3- are also metabolites of ONOO-. 
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5.0.4 NO synthesis: an alternative pathway  
 
However the L-arginine/NOS pathway is not the sole pathway leading to the production 
of NO.  An alternative theory for NO synthesis was recently published 15 .  In hypoxic 
conditions, NO is produced by the reduction of NO2-.  It was hypothesised that the 
reduction of NO2- may serve to prevent a drop in NO when oxygen levels fall and 
production from NOS becomes insufficient.  The author therefore concluded that NO2- is 
not merely an oxygenised product of NO, but also has a significant biological role.  In 
short, NO2- is not a metabolic end product of NOS activity, but must also be considered 
as a precursor of NO production under hypoxic conditions. In their recent review paper 
Vitturi et al.23 acknowledged that the recent interest in NO2- biology stems from the 
realisation that the generation of NO from NO2- reduction can occur “under conditions 
that span a range of oxygen tensions and pH observed over the pathophysiological 
spectrum”.  Ford 24 concurred and stated that the nitrite ion has received renewed 
attention and that much of mammalian biology of both NO and NO2- involves heme 
proteins.  Feelish 15 however, cautions that “without understanding the relative 
contribution of local versus systemic factors, knowing what the concentration of 
nitrite/nitrate is in synovial fluid or blood is of limited value”.  He believed this was 
relevant to the study of OA as oxygen availability in the joint is somewhat intermittent 
and usually significantly lower than other tissues.  In addition, during inflammation the 
concentration of O2 is further reduced.  However it is interesting to note that in the same 
year as Feelisch’s paper, Vuolteenaho et al. 9 stated that “Increased concentrations of 
nitrite in synovial fluid from OA patients indicate local NO production in the joint”.  It 
would appear then that the clinical importance of NO2- levels in the joint remains to be 
elucidated.   
 
5.0.5 The role of NO in the destruction of articular cartilage 
 
It has been shown by a number of groups that iNOS is expressed by the chondrocyte and 
that the chondrocyte is the major source of NO in the joint 4, 9, 25, 26.  Other sources of 
iNOS are the synovium and infiltrating inflammatory cells e.g. neutrophils and 
  267 
macrophages.  Vuolteenaho et al. 9 list a number of cytokines and other factors which if 
unregulated, promote the synthesis of iNOS by the chondrocyte and by extension, the up- 
regulation of NO.  These include Il-1, TNF-α, Il-17, IFN-γ, bacterial LPS, fibronectin 
fragment (FN-f), shear stress, endothelin-1 (ET-1) and finally, leptin in synergy with Il-1 
or IFN-γ.  A brief summary of the effects of excessive NO production on cartilage may 
be seen in Figure 5.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Summary of the effects of excess NO on cartilage in the OA joint. 
 
As noted in the introduction, OA is a complex, multi-faceted and highly heterogeneous 
pathological condition.  Therefore, it is not suggested that NO production, its metabolites 
and their potential effects on cartilage, are the sole contributors to the onset of OA.  
Rather, it may be one of many causes for this disease or indeed it may have little to 
contribute to the initial triggering of OA.  Feelish 15 stated that we still do not know how 
NO functions, whether it is “friend or foe”, or even if in vitro studies mirror the in vivo 
hypoxic metabolism of the joint.  He finally concludes “Thus, the question as to whether 
MMPs ↑
e.g. MMPs-1,3,8,10,13
Cyclooxygenase-
2 (COX-2) ↑
Collagen and proteoglycan 
synthesis ↓
Chondrocyte death ↑
Cytokine imbalance 
TGFβ (anabolic mediator) ↑ and 
IL-1 -Ra (Il-1Receptor antagonist) 
production ↓
TNFα (catabolic mediator) ↑
Resistance to IGF-1 (anabolic 
mediator)↑
IL-10 ↓
Susceptibility to other oxidants ↑
Sustained NF-kB
activation ↑
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NO is of benefit or detriment in OA remains open.” More recently, Jedlickova 27 
proposed a renewed interest in plasma levels of NO2- as a marker of endothelial function 
in relation to ageing.  It was noted by the author that there are conflicting reports on NO 
levels with increasing age with some authors reporting decreasing levels with increasing 
age, while others have reported the converse.  Ford 24 remarks that although NO2- was 
once thought to be physiologically deleterious by contributing to amine nitrosation, 
recent research suggests that endogenous NO2- may play a role in vasodilation under 
hypoxic conditions and in organ protection during incidents of ischemia.  Indeed, Hines 
et al.28 proclaimed that therapeutic uses of NO or NO2- are currently underway in several 
different laboratories to treat a variety of ischemic disorders. 
 
 
5.0.6 Nitric Oxide in Microvesicles 
 
Vitturi et al. 23 studied the biochemical schemes for NO production and their findings led 
them to ask the question - how could NO signalling activity escape savaging by ferrous 
heme?  A number of hypothesis were explored, one of which is the possible 
compartmentalisation of NO2- reduction away from excess ferrous heme.  In particular, 
the authors argue the production of N2O3 in equation (iii) above, might under 
physiological conditions; require special spatial localisation conditions in red blood cells.  
Relatively little is known about how nitrite reductase proteins and their ability to reduce 
NO2- to NO are regulated by availability of cofactors and substrates, the level of 
expression, post translational modification, or cellular/tissue localization.  In a separate 
study 29 it was found that sub-cellular compartmentalization of distinct NO2- reducing 
activities have been reported in the liver. Figure 5.3 depicts a summary of the current 
perspectives on the regulation and function of NO2- as a mediator of NO signaling.  
Though this represents NO2- uptake into the cell, from the viewpoint of this project, what 
is interesting about this figure is the ability of NO2- to traverse bi-lipid membranes, 
whether by facilitated transport or passive diffusion.  Either of these transport modes may 
offer a route for NO2- into MVs. 
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Figure 5.3: Schematic diagram outlining current perspectives on the regulation and role 
of nitrite as a mediator of NO signaling.  The blue boxes show known and potential 
mechanisms for nitrite transport and reduction to NO.  The red boxes summarise known 
and potential targets for NO and other RNS.  Diagram taken from Vitturi et al. 23        
 
 
5.0.7 Aim of project 
  
Due to the relatively recent resurge of interest in the biology of NO2-, and in particular, its 
probable role as a precursor to the formation of NO, the aim of this project is to ascertain 
if this anion is present in microvesicles which may offer a “safe” environment for 
reduction of NO2- to NO and subsequent delivery to a specific target, thus avoiding NO 
scavenging.  As outlined above, the detection of NO2- in whole synovial fluid has been 
studied before, but no literature has been discovered pertaining to the presence of NO2- in 
microvesicles. This is important especially in light of Vitturi’s 23 comment, “The major 
challenges remain theoretical in trying to rationalize NO formation and bioactivity in the 
presence of ferrous heme………it is (NO2-) still biologically and therapeutically 
important, which could simply reflect the fact that activation of NO-dependant signaling 
pathways requires relatively low concentrations of this mediator”.  It is envisioned that 
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should NO2- prove to be present in MVs, it will be present in very low concentrations.  
Therefore a very sensitive and selective method of detection will be required.  In order to 
investigate if NO2- is present inside MVs, it will be necessary to solublise the vesicle 
membrane.  From a study of five different detergents Garner et al. 30 found β-
octlyglucopyranoside (OG) to be the most effective and efficient membrane-dissolving 
agent.  Therefore this is the detergent of choice for this project.  
  
5.0.8 Methodologies for measurement of nitrite in biological matrices 
 
The most commonly employed method for the analysis of NO2- is the Griess method 31. 
This is a colorimetric method based on a two-step diazotisation reaction in which 
acidified NO2- produces a nitrosating agent which in turn reacts with sulfanilic acid to 
produce the diazonium ion.  The second step in the assay is the coupling of the diazonium 
ion to N-(1-naphthyl)ethylene to form a chromophoric azo derivative.  One mole of NO2- 
yields one mole of the azo dye.  This method is used quite extensively in the literature.  
Though the Griess method is quick and simple, it does have limitations in terms of 
sensitivity when used to analyse biological samples.  It is said that measuring NO2- below 
the µM threshold is not possible with this assay 32, 33.  Therefore, other methods have 
been developed to overcome this limitation.   
Jobgen et al. 34 offer a very lucid and detailed critique of various HPLC modes of 
detection employed for the analysis of NO2-.  From their paper it can be seen that 
fluorescence detection is an extremely sensitive method, with detection limits in the pM 
range.   However, NO2- cannot be directly detected by fluorescence.  Derivitisation with 
an appropriate reagent that yields a stable fluorescent compound is required.   
Fortunately, such a derivatising reagent is available and involves a one step reaction 
between NO2- and 2,3-diaminonaphthalene (DAN) to yield 2,3-naphthotriazole (NAT).  
The reaction is carried out in acidic conditions and proceeds to completion as seen in 
Figure 5.4. 
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                                   2,3-diaminonapthalene                     2,3-naphthotraizole 
 
Figure 5.4: The reaction of nitrite with 2,3-diaminonapthalene (DAN) to form the 
fluorescent adduct 2,3-napthotraizole (NAT).  The reaction takes place under acidic 
conditions. 
 
The NAT product was found to be stable for 24 hours 32.  The author also found that at an 
emission wavelength of 415nm and an excitation wavelength of 375nm, the NAT 
product-complex exhibits relatively high fluorescence intensity while the DAN reactant 
does not.  This reaction offers high specificity for NO2-. 
Therefore, analysis by HPLC employing fluorescence detection will be used to detect 
NO2- in synovial fluid microvesicles. 
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5.1 Materials and Methods 
 
5.1.1 Reagents and Materials 
  
HPLC grade methanol (MeOH) was purchased from Sigma Aldrich. 
Phosphate buffer salts, NaH2PO4.H2O (>99%) and Na2HPO4.7H2O (98-102%) were 
purchased from Sigma. 
Phosphoric Acid (>85%) was obtained from Sigma.   
NaNO2 (99.99%) purchased from Sigma was used to prepare standard solutions.  
Amicon Ultra – 0.5mL, 3000MWCO centrifugal filters were obtained from Millipore. 
2,3-diaminonapthalene (DAN) was purchased from Sigma 
β-octlyglucopyranoside (OG) was purchased from Sigma 
 
5.1.2 Miscellaneous equipment  
    
A Hettich Mikro120 centrifuge was used for the immunoaffinity protocol. 
A Gilson GV Lab vortex mixer was used mix sample and standard solutions. 
A Mettler pH meter was used for mobile phase preparation 
 
 
5.1.3 HPLC Instrumentation 
 
A Waters HPLC modular system was used and comprised of the following: 
 1) 600E Powerline multisolvent delivery system with 100µL heads 
 2) 600E system controller 
 3) 717plus autosampler 
 4) 486 UV absorbance detector 
 5) 474 Fluorescence detector. 
 The instrument was controlled by Empower software. 
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5.1.4 HPLC Conditions 
 
Mobile phase consisted of 15mM phosphate buffer in 55% MeOH, pH7.5 
Excitation wavelength: 375nm 
Emission wavelength: 415nm 
Injection volume: 20µL 
Flow rate: 1mL/minute  
Column: Waters ACE 5 C18 250x4.6mm 
All mobile phases were vacumn filtered through 0.45µM filters and then sonicated in a 
water bath for 5 minutes before pumping through the system. 
 
5.1.5 Sample preparation 
 
Whole SF was diluted by a factor of five with Milli-Q water.  
For the isolation of MVs, please refer the method that was developed in chapter 3 (Figure 
3.23) 
MVs were burst by adding with 1% (w/v) β-octlyglucopyranoside (OG) and mixing end-
over-end overnight at 4ºC 
The lyased vesicles were passed through a “3kDa cut-off “centrifugal filter as per the 
manufacturer’s instructions in order to remove proteins and lipids which would interfere 
with the fluorescence derivitisation 31, 32 in addition to fouling the column. 
  
 
5.1.6 Preparation of Standards 
 
A 2mM (69mg/L) NO2- stock solution was prepared from the sodium salt.  From this a 
2µM working standard was prepared.  Using this working standard a series of standards 
were prepared by serial dilution – 0nM, 31.25nM, 62.5nM, 125nM, 250nM, 500nM, 
1000nM. 
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5.1.7 Reaction of NO2- with DAN to yield NAT 
 
A modified version of the method developed by Li et al. 32 was employed (details in the 
Discussion section). 
200µL of standard/ultrafiltered sample was incubated at room temperature with 20µL 
1µg/mL DAN followed by the addition of 10µL of 2.8M NaOH.  20µL of this solution 
was directly injected onto the HPLC column. 
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5.2 Results 
5.2.1 Establishment of linearity range and generation of a calibration curve 
The method employed was that developed by Li et al. 32 except a final concentration of 
0.1µg/mL DAN was used instead of 5µg/mL due to high blank values (see discussion).  A 
series of nitrite standards were run - 0nM, 31.25nM, 62.5nM, 125nM, 250nM, 500nM, 
1000nM.  Linearity was excellent up to 250nM.  Beyond that concentration, the linearity 
suffered adversely.  This was possibly due to the DAN reagent being completely used up.  
Therefore, all standard curves were prepared in the 0-250nM range.  Three injections for 
each standard were carried out and the mean and standard deviation were calculated.  An 
example of a calibration curve may be seen in Figure 5.5. 
Nitrite Calibration Curve
y = 3190.4x + 38176
R2 = 0.9966
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Figure 5.5:  A typical calibration curve generated from standard NO2- (0-250nM).  Three 
injections per standard were carried out and the mean and standard deviation were 
plotted.  Also included is the R2 value. The chromatography conditions were: Mobile 
phase: 15mM phosphate buffer in 55% MeOH, pH7.5; Excitation wavelength: 375nm; 
Emission wavelength: 415nm; Injection volume: 20µL; Flow rate: 1mL/minute; Column: 
Waters ACE 5 C18 250x4.6mm 
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5.2.2 Establishment if the Microcon ultracentrifugation filters are a source of NO2- 
Prior to performing a HPLC experiment on any biofluid, it is important to remove 
proteins and other high molecular weight species that may interfere with the analysis or 
as discovered in chapter 2, irreversibly bind to the stationary phase.  Initially, a C18 
Waters Sep-Pak filter was selected as the means to remove proteins etc.  However the 
formic acid present, which acts as an ion-pairing reagent in order to increase the 
hydrophobicity of the proteins, interfered with the subsequent fluorescent derivitisation 
of NO2-.   
Therefore these unwanted species were removed using an ultra-filtration device with a 
3kDa molecular weight “cut-off”.  However, centrifuge filters are known to be a source 
of nitrite.  This is due to the possible presence of azide which may be added to preserve 
the cellulose or other filter matrix 11.  Smith et al. 35 performed a study on ten 
commercially available filters from a number of manufacturers.  One of the filters studied 
was the 3kDa cut-off filter that was used in this experiment.  They pre-washed the filter 
three times prior to analysis and found that the [NO2-] was 0.7 ± 0.1µM.  Li et al. 32 also 
found that some filters may contain nitrite and/or nitrate and therefore the filters should 
be washed four times with distilled water prior to use.  A filter study was therefore 
performed in order to establish NO2- levels, and determine the amount of washing 
required.  Chromatograms from this study are displayed in Figure 5.6.  After the fourth 
wash, further washing did not reduce [NO2-] below ~15nM.  Therefore, all filter devices 
were washed four times before sample filtration.  
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Figure 5.6: Chromatograms resulting from a series of consecutive washes through a 
Microcon ultracentrifugation device.  The unreacted fluorescent DAN and the NAT 
complex (i.e. NO2-) are indicated.  The chromatography conditions were: Mobile phase: 
15mM phosphate buffer in 55% MeOH, pH7.5; Excitation wavelength: 375nm; Emission 
wavelength: 415nm; Injection volume: 20µL; Flow rate: 1mL/minute; Column: Waters 
ACE 5 C18 250x4.6mm 
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5.2.3 Establishment if β-octlyglucopyranoside (OG) releases further NO2- from the 
filtration device 
As 1% (w/v) OG is used to lyase the MVs, it was deemed this would be an appropriate 
blank.  Therefore, following four washes with Milli-Q water, a 1% (w/v) OG solution 
was filtered and the eluate was analysed employing the established method with three 
injections.  A chromatogram is shown in Figure 5.7. 
   
 
 
 
 
 
 
 
 
 
 
Figure 5.7: Chromatogram of 1% (w/v) OG which is used as a control blank. Unreacted 
fluorescent DAN, and the NAT complex (i.e. NO2-) are indicated.  The chromatography 
conditions were: Mobile phase: 15mM phosphate buffer in 55% MeOH, pH7.5; 
Excitation wavelength: 375nm; Emission wavelength: 415nm; Injection volume: 20µL; 
Flow rate: 1mL/minute; Column: Waters ACE 5 C18 250x4.6mm 
 
As the water only blank contained 15nM NO2- and the OG blank value was 19nM NO2-, 
it was concluded that OG does not contribute to further release of NO2- from the filtration 
devices. 
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5.2.4 Determination of [NO2-] in whole synovial fluid 
  
One OA and one RA synovial fluid sample were taken, diluted by a factor of five with 
Milli-Q water and filtered to remove proteinaceous material.  Dilution was necessary to 
ensure nitrite concentrations would fall within the calibration curve.  Following 
fluorescence derivitisation, the samples were analysed by HPLC.  Chromatograms from 
both patient samples are shown in Figure 5.8.  
 
   
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 5.8: Chromatogram of one OA and one RA whole synovial sample diluted in 
water by a factor of five. Unreacted fluorescent DAN, and the NAT complex (i.e. NO2-) 
are indicated.  The chromatography conditions were: Mobile phase: 15mM phosphate 
buffer in 55% MeOH, pH7.5; Excitation wavelength: 375nm; Emission wavelength: 
415nm; Injection volume: 20µL; Flow rate: 1mL/minute; Column: Waters ACE 5 C18 
250x4.6mm 
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From Figure 5.8 it can be seen that [NO2-] in the diluted OA sample is 54nM, while that 
in the RA sample is 144nM.  This means that [NO2-] in whole synovial fluid for the OA 
and RA patient sample is 270nM and 720nm respectively.  These concentrations are 
similar to those found in the literature (~ 100-4000nM 11).  The nitrite concentration in 
the RA sample is three times that of the OA sample.  
5.2.5 Determination of [NO2-] in 200,000g CHAPS Pellet 
Reconstituted 200,000g CHAPS pellets from one OA and one RA samples were treated 
with 1% (w/v) OG and mixed end-over-end overnight at 4ºC.  Following filtration, 
derivitisation with DAN took place, and each sample was analysed by HPLC.  
Chromatograms for this analysis are shown in Figure 5.9. 
     
    
 
 
 
 
 
 
 
 
Figure 5.9: Chromatogram of one OA and one RA 200,00g CHAPS pellets. Unreacted 
fluorescent DAN, and the NAT complex (i.e. NO2-) are indicated.  The chromatography 
conditions were: Mobile phase: 15mM phosphate buffer in 55% MeOH, pH7.5; 
Excitation wavelength: 375nm; Emission wavelength: 415nm; Injection volume: 20µL; 
Flow rate: 1mL/minute; Column: Waters ACE 5 C18 250x4.6mm 
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Analysis of the 200,000g CHAPS pellets clearly demonstrates that NO2- is present in both 
OA and RA microvesicles at concentrations of 225nM and 174nM respectively.     
Finally, the crude 200,000g supernatant samples, corresponding to the CHAPS pellets 
above, were also analysed, and yielded nitrite concentrations of 95nM for OA and 259nM 
for RA.  It was noted that the level of NO2- is higher in the MV fraction than in the SN 
fraction for the OA sample while the converse is true in the case of RA.  However, this is 
not offered as a hypothesis.  Clearly, a large cohort of patient samples would need to be 
analysed before making any quantitative claims relating to the distribution of NO2- 
between the pellet and the SN.  However, the analysis did accomplish the original 
qualitative aim of the study by establishing that NO2- is associated with SF MVs 
following vesicle solubilisation with OG.    
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5.3 Discussion 
As outlined in the introduction to this chapter, interest in the role that NO plays in the 
body has received considerable attention (Ford 24 quoted some 104 publications in the last 
two decades).  Previously believed to be a metabolite of NO activity, NO2- is now 
appreciated as a source of NO under hypoxic conditions 15.  However, given its short half 
life in the presence of heme proteins, many studies were undertaken to ascertain how the 
reduction of NO2- to NO might be realised before being scavenged by heme proteins.  
Also from the introduction, the hypothesis that SF MVs could harbour NO2- and thus act 
as possible NO-producing sites was ventured.  Therefore a novel study was undertaken to 
establish this possibility. 
It was believed that the concentration of nitrite ([NO2-]) in MV would be very low and so 
a sensitive method of analysis would therefore be needed.  A literature search established 
that a HPLC method based on fluorescence detection offered the greatest sensitivity.  One 
such method was developed by Li et al. 32  However, it was found in this project that the 
blank (water) yielded a high NO2- concentration.  It was established that the Millipore 
micron filtration device (employed to remove proteins, due to the fluorescence quenching 
effect they exert) was the source of this exogenous NO2-.  Therefore, prior washing with 
water was necessary to bring the blank value within acceptable levels.  However, when 
applied to the analysis of the 200,000g pellet, the magnitude of this black value became 
unacceptable i.e. the [NO2-] in the sample was less than three times the [NO2-] in the 
blank.  Further washing with water was ineffective, as was washing with 0.1M NaOH (as 
recommended by the supplier).  A publication by Gharavi et al. 36 also employed Li’s 
method, except a final concentration of 0.1µg/mL DAN was used instead of 5µg/mL.  
This was found to be successful in significantly reducing the blank value to 15nM (Figure 
5.6).  A linear range of 0-250nM NO2- was established with R2=0.9966.  Concentrations 
greater than 250nM, adversely affected the R2 value, most likely due to total consumption 
of the DAN fluorescent agent at higher concentrations.   
The detergent employed to rupture the MV membranes was 1% (w/v) OG, and therefore 
this was the blank used.  This did not contribute to further NO2- from the filtration device 
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(Figure 5.7) after washing with Milli-Q water.  One OA and one RA sample were 
analysed and the [NO2-] was measured in the whole SF (Figure 5.7) and the 200,000g 
pellet (Figure 5.8) of each.  As only one patient sample was analysed representing each 
pathology, it was not possible to infer a meaningful hypothesis based on the quantitative 
data obtained.  However, the aim of this study was to establish the presence of NO2- in 
MVs.  This was achieved and it was confirmed that NO2- is present in MVs.  Advancing a 
hypothesis concerning the implication of this on the other hand may ignite interest to 
further study. 
Studies by Feelish et al. 15, 29 have established that the presence of NO2- under hypoxic 
conditions lead to NO formation.  This is particularly pertinent in the joint environment 
where hypoxic conditions exist.  Under these conditions, the formation of NO by 
reduction of NO2- may be a more realistic model than the formation of NO by the classic 
iNOS pathway, (Figure 5.1) where O2 was seen to be a critical co-factor in this metabolic 
pathway.  A caveat to this suggestion was recognised by Ford 24 and Vitturi et al. 23 and 
related to the conundrum; how can NO be produced from NO2- and survive being rapidly 
scavenged by ferrous heme?  Various schemes were offered by the authors, but each 
encountered objections on kinetic grounds.  On three occasions in their publication 
Vitturi et al. 23 alluded a protective micro-environment; “Compartmentalization of nitrite 
reduction away from excess ferrous heme is one potential strategy by which the kinetic 
barriers discussed above are bypassed”……”..under physiological conditions might 
require special spatial localization conditions…”  and “Emerging data are shedding 
some insights…For example, subcellular compartmentalization of distinct nitrite-
reducing activities have been reported in the liver”.  However, there was no suggestion 
that MVs may offer this micro-environment.  Two factors support this proposition that 
MVs are plausible NO-producing sites.  The first is a result of this current study which 
established that NO2- is associated with MVs and the second is that there is a mode of 
entry for NO2- into the vesicle (Figure 5.3). 
The discussion thus far has centred on the tenet that NO2- which is present in SF MVs is a 
precursor to the formation of NO.  However, the converse may be true i.e. NO initially 
present in vesicles may have undergone oxidation to NO2-.  In light of the discussion thus 
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far, the presence of hemoglobin would ensure this.  From the MS data in chapter 3, 
hemoglobin subunits alpha and beta were found to be associated with MVs.  This 
possibility depends on the oxygen tension is the micro-locality i.e. the presence of 
deoxygenated versus oxygenated hemoglobin 23.  In deoxygenated conditions the 
reduction of NO2- to NO is favoured, while in an oxygenated environment, oxidation of 
NO to NO2- and finally to NO3- is the case.  That NO2- was found in MVs and these 
vesicles in turn were in a hypoxic setting, any hemoglobin present was likely to be 
deoxygenated.  Therefore, how is oxidation of NO to NO2- achieved?  Another protein 
species that was identified by MS was ceruloplasmin.  Shiva et al. 37 termed this protein 
“a NO oxidase and nitrite synthase”.  Ceruloplasmin is a 132 kDa protein containing six 
copper centres 38 and the redox reaction proceeds as follows; 
 
             
             
      
 
 
 
 
 
 
 
 
 
 
 
NO NO+ HNO2 H
+ + NO2-
Cu2+ Cu+ H2O H+ H+
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5.4 Conclusion 
This study established for the first time that NO2- is present in MVs.  It was not possible 
to determine the type of vesicle that harbour this anion, but some potentially interesting 
speculations have been proposed that may account for questions that were raised in the 
literature.  In particular, it may be that MVs afford a sub-cellular microenvironment that 
is compatible to the chemistry of NO and/or NO2-.  Potentially fruitful future work could 
establish if there are unique protein nitrosylation reactions taking place inside vesicles 
that may not occur in the cytoplasm of the cell or in the ECM.  The hypothesis that 
different vesicle types may possess unique biochemical sites is plausible and future study 
into MVs is needed.  A potentially useful starting point may be directed towards the 
isolation of homogeneous vesicle types.  In that way it would be easier to classify and 
establish the true purpose of MVs in the body.    
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